BioMedLib Search Engine
[ goto HOMEPAGE ]
Search the biomedical literature, for the most relevant articles.
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
801 804 epithelial neoplasms nos 2005:2010[pubdate] *count=100
1817 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
801 804 epithelial neoplasms nos
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 1817
1.
Meister M, Schirmacher P, Dienemann H, Mechtersheimer G, Schnabel PA, Kern MA, Herpel E, Xu EC, Muley T, Thomas M, Rieker RJ:
Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Cancer Lett
; 2007 Apr 18;248(2):186-91
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Epithelial
tumours
of the thymus (thymoma, thymic carcinoma) are rare
tumours
of the anterior mediastinum.
So far, EGFR mutational status of different subtypes of
epithelial
tumours
of the thymus has been analyzed only inappropriately.
Thus EGFR-expression in thymic
tumours
does not rely on mutations in critical functional (activation) domains of the EGFR-gene.
[MeSH-major]
Genes, erbB-1. Thymoma / genetics. Thymus
Neoplasms
/ genetics
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16919868.001).
[ISSN]
0304-3835
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
2.
Lin JP, Lu HF, Lee JH, Lin JG, Hsia TC, Wu LT, Chung JG:
(-)-Menthol inhibits DNA topoisomerases I, II alpha and beta and promotes NF-kappaB expression in human gastric cancer SNU-5 cells.
Anticancer Res
; 2005 May-Jun;25(3B):2069-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
It has been reported that (-)-Menthol can inhibit the growth of rat liver
epithelial
tumor
cells and is a potent chemopreventive agent.
[MeSH-major]
Menthol / pharmacology. NF-kappa B / biosynthesis. Stomach
Neoplasms
/ drug therapy. Topoisomerase Inhibitors
[MeSH-minor]
Antigens,
Neoplasm
/ biosynthesis. Antigens,
Neoplasm
/ genetics. Cell Death / drug effects. Cell Line,
Tumor
. Cell Survival / drug effects. DNA Damage. DNA Topoisomerases / biosynthesis. DNA Topoisomerases / genetics. DNA Topoisomerases, Type I / biosynthesis. DNA Topoisomerases, Type I / genetics. DNA Topoisomerases, Type II / biosynthesis. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / antagonists & inhibitors. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Gene Expression. Humans. Stereoisomerism. Topoisomerase I Inhibitors. Topoisomerase II Inhibitors
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
Hazardous Substances Data Bank.
MENTHOL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16158947.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / NF-kappa B; 0 / Topoisomerase I Inhibitors; 0 / Topoisomerase II Inhibitors; 0 / Topoisomerase Inhibitors; 1490-04-6 / Menthol; EC 5.99.1.- / DNA Topoisomerases; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; EC 5.99.1.3 / DNA topoisomerase II beta
3.
Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, Yamamichi N, Tateishi A, Oka M, Ogura K, Kawabe T, Ichinose M, Omata M:
Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases.
Clin Gastroenterol Hepatol
; 2007 Jun;5(6):678-83; quiz 645
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcomes of endoscopic submucosal dissection for colorectal
epithelial neoplasms
in 200 consecutive cases.
BACKGROUND & AIMS: The clinical outcomes for endoscopic submucosal dissection (ESD), a novel endoluminal surgery for gastrointestinal
neoplasm
in the colorectum, are reported.
METHODS: ESD was performed on 186 consecutive patients with 200 colorectal
epithelial neoplasms
who had preoperative diagnoses of mucosal or slight submucosally invasive
neoplasms
.
The rate of en bloc resection was 91.5% (183/200), and en bloc resection with
tumor
-free lateral/basal margins (R0 resection) was 70.5% (141/200).
Two multiple-piece resections of 111
tumors
(1.8%), which were successfully followed by colonoscopy (median follow-up, 18 months; range, 12-60 months), were found as locally recurrent
tumors
2 and 21 months after ESD.
However, when considering the risks and benefits, piecemeal endoscopic resection or colorectal resection might be more appropriate for some subgroups of large flat
neoplasms
or those with submucosal fibrosis.
[MeSH-major]
Colonoscopy. Colorectal
Neoplasms
/ surgery
MedlinePlus Health Information.
consumer health - Colonoscopy
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Clin Gastroenterol Hepatol. 2007 Jun;5(6):674-7
[
17544994.001
]
(PMID = 17466600.001).
[ISSN]
1542-7714
[Journal-full-title]
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
[ISO-abbreviation]
Clin. Gastroenterol. Hepatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
Advertisement
4.
Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, Luthringer D, Paner GP, Amin MB:
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
Am J Surg Pathol
; 2009 Feb;33(2):241-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal
epithelial neoplasms
.
Data regarding expression in renal
epithelial
tumors
other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants.
Conventional sections from 200 renal
tumors
comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal
tumors
with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX.
Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal
tumors
with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive.
This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal
tumors
with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative).
[MeSH-major]
Antigens,
Neoplasm
/ metabolism. Biomarkers,
Tumor
/ analysis. Carbonic Anhydrases / metabolism. Kidney
Neoplasms
/ diagnosis.
Neoplasms
, Glandular and
Epithelial
/ pathology. PAX2 Transcription Factor / metabolism
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18941400.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
5.
Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E:
Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe.
J S Afr Vet Assoc
; 2005 Jun;76(2):59-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Canine cutaneous
neoplasms
: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous
neoplasms
in dogs from Zimbabwe.
Sixty per cent (540/900) of the cases were
tumours
and 40% (360/900) were non-neoplastic inflammatory or degenerative diseases.
Thirty different histological types of
tumour
were diagnosed.
The prevalence of
epithelial
, mesenchymal, lymphohistiocytic and melanocytic
tumours
was 39.4%, 44.4%, 7.4% and 8.7%, respectively.
The 10 most common
tumours
, comprising 73.7% of all cutaneous
neoplasms
, were mast cell
tumours
, squamous cell carcinomas, perianal gland adenomas, lymphomas, benign melanomas, haemangiosarcomas, sebaceous gland adenomas, fibrosarcomas, lipomas and malignant melanomas.
The prevalence of various
neoplasms
, age of affected dogs and sites of occurrence were similar to surveys in other countries, except that in Zimbabwe there was a greater prevalence of lymphomas and of
tumours
associated with increased exposure to ultraviolet light (squamous cell carcinomas, haemangiosarcomas and melanomas).
For all classes of
tumours
the sex of the dog did not have any significant influence on the likelihood of developing
a tumour
.
For a dog diagnosed with
a tumour
located on the trunk, the
tumour
was significantly more likely to be an
epithelial
tumour
than a non-
epithelial
tumour
The occurrence of melanocytic
tumours
on the trunk was significantly lower than at other sites.
Lymphohistiocytic
tumours
were 10 times more likely to occur at multiple locations as opposed to single locations.
[MeSH-major]
Dog Diseases / epidemiology. Dog Diseases / pathology. Skin
Neoplasms
/ veterinary
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16108522.001).
[ISSN]
1019-9128
[Journal-full-title]
Journal of the South African Veterinary Association
[ISO-abbreviation]
J S Afr Vet Assoc
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
South Africa
6.
Ziuganov VV, Popkovich EG:
[Arctic teleost fishes with canceled accelerated senescence program are a potential source of stress protectors and cancer drugs].
Izv Akad Nauk Ser Biol
; 2005 Sep-Oct;(5):578-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Trials of the biologic prepared from this secretion in salmons with
epithelioma
, guinea pigs with affected skin, and mice with transplantable
tumors
demonstrated a good therapeutic effect of the biologic.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16240755.001).
[ISSN]
1026-3470
[Journal-full-title]
Izvestiia Akademii nauk. Seriia biologicheskaia
[ISO-abbreviation]
Izv. Akad. Nauk. Ser. Biol.
[Language]
RUS
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Proteins
7.
Noskova V, Ahmadi S, Asander E, Casslén B:
Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms.
Gynecol Oncol
; 2009 Oct;115(1):121-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: Expression of uPA mRNA is massively up-regulated in the stroma of poorly differentiated ovarian
tumors
.
We hypothesized that this expression was induced by paracrine signals from the
epithelial
tumor
cells, and established an in vitro model of ovarian cancer microenvironment to study intercellular cross-talk.
[MeSH-major]
Adenocarcinoma / pathology. Cell Communication / physiology. Fibroblasts / cytology. Ovarian
Neoplasms
/ pathology. RNA, Messenger / biosynthesis. Stromal Cells / cytology. Urokinase-Type Plasminogen Activator / genetics
[MeSH-minor]
Cell Line,
Tumor
. Coculture Techniques. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Up-Regulation
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19631971.001).
[ISSN]
1095-6859
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
8.
de Souza A, Gibson LE, Wada DA, Yi ES, Medeiros F, Camilleri MJ, el-Azhary R, Micallef IN:
Resolution of CD8+ lymphomatoid papulosis after surgical excision of the type AB-thymoma.
Am J Dermatopathol
; 2009 Jul;31(5):475-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The type AB thymoma is an
epithelial
neoplasm
composed of both type A (lymphocyte-poor) and type B (lymphocyte-rich) areas.
[MeSH-major]
Lymphomatoid Papulosis / pathology.
Neoplasms
, Multiple Primary / pathology. Skin
Neoplasms
/ pathology. Thymoma / pathology. Thymus
Neoplasms
/ pathology
[MeSH-minor]
Aged, 80 and over. Antigens, CD / metabolism. Biomarkers,
Tumor
/ analysis. Blotting, Southern. CD8-Positive T-Lymphocytes / immunology. Chemokines / metabolism. Humans. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Chemokine / metabolism
Genetic Alliance.
consumer health - Lymphomatoid papulosis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19542925.001).
[ISSN]
1533-0311
[Journal-full-title]
The American Journal of dermatopathology
[ISO-abbreviation]
Am J Dermatopathol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokines; 0 / Receptors, Chemokine
9.
Kim DJ, Yang WI, Kim SH, Park IK, Chung KY:
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
Eur J Cardiothorac Surg
; 2005 Oct;28(4):611-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of neurotrophin receptors in surgically resected thymic
epithelial
tumors
.
OBJECTIVE: Neurotrophins are known to exert a variety of pleiotropic responses in different target tissues, but little is known about their effect on thymic
epithelial
tumors
.
Therefore, we analyzed the expression of neurotrophin receptors in surgically resected thymic
epithelial
tumors
and evaluated their clinical relevance.
METHODS: The expression of neurotrophin receptors (Trk-A, Trk-B, Trk-C and p75(NTR)) in thymic
epithelial
tumors
was evaluated in 99 consecutive patients based on immunohistochemical staining.
RESULTS: Thymic
tumors
were classified as type A (n=6), AB (n=21), B1 (n=15), B2 (n=24), B3 (n=22) or C (n=11).
All
tumors
, except one type C thymoma, demonstrated cytoplasmic Trk-A immunostaining, and no thymic
tumors
showed Trk-B or Trk-C immunoreactivity. p75(NTR) immunostaining demonstrated characteristic patterns according to the WHO subtypes of thymomas.
All type A and type AB thymomas showed p75(NTR) immunoreactivity, except one type
A tumor
.
Tumor
-related survival at 5 and 10 years was 95.5 and 89.5%, respectively, in p75(NTR)-positive thymomas and 82.8 and 77.2%, respectively, in p75(NTR)-negative thymomas; however, the differences were not statistically significant (P=0.14).
Further study of p75(NTR) expression may aid in understanding the biology of thymic
epithelial
tumors
.
[MeSH-major]
Receptors, Nerve Growth Factor / analysis. Thymoma / chemistry. Thymus
Neoplasms
/ chemistry
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged.
Neoplasm
Proteins / analysis. Nerve Tissue Proteins / analysis. Prognosis. Receptor, trkA / analysis. Receptor, trkB / analysis. Receptor, trkC / analysis. Receptors, Growth Factor / analysis. Survival Analysis. Thymus Gland / metabolism. Thymus Gland / pathology
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16125946.001).
[ISSN]
1010-7940
[Journal-full-title]
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
[ISO-abbreviation]
Eur J Cardiothorac Surg
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC
10.
Choi YD, Lee JS, Choi C, Park CS, Nam JH:
Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinoma.
Gynecol Oncol
; 2007 Mar;104(3):747-52
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Neuroendocrine carcinoma of the non-small cell type of the ovary is a rare aggressive
tumor
, interestingly associated with either a surface
epithelial
tumor
or teratoma.
Pathology examination showed a 6.5 cm in greatest dimension ovarian
tumor
composed of neuroendocrine carcinoma of the non-small cell type and serous carcinoma.
[MeSH-major]
Carcinoma, Neuroendocrine / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian
Neoplasms
/ pathology
Genetic Alliance.
consumer health - Ovarian small cell carcinoma
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17229461.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
11.
Grapsa D, Kairi-Vassilatou E, Hasiakos D, Kondi-Pafiti A:
Ovarian mucinous cystadenoma with extended calcification in an 11-year-old girl: case report and review of the literature.
Clin Exp Obstet Gynecol
; 2006;33(3):181-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The majority of ovarian masses in childhood and adolescence are non-
epithelial
in origin, with a predominance of germ cell
tumors
, while
epithelial neoplasms
comprise a small proportion of the total (approximately 15-20%).
Careful evaluation of the remaining pathological features of the
tumor
is needed in order to avoid misinterpreting this relatively non-specific finding as a feature of malignancy.
[MeSH-major]
Cystadenoma, Mucinous / diagnosis. Ovarian
Neoplasms
/ diagnosis
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17089585.001).
[ISSN]
0390-6663
[Journal-full-title]
Clinical and experimental obstetrics & gynecology
[ISO-abbreviation]
Clin Exp Obstet Gynecol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Italy
[Number-of-references]
11
12.
Gurevich LE, Kazantseva IA, Korsakova NA, Tsar'kov PV, Polishchuk LO:
[Expression of type 1 and type 2 mucins in colonic epithelial tumors].
Arkh Patol
; 2007 Mar-Apr;69(2):12-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Expression of type 1 and type 2 mucins in colonic
epithelial
tumors
].
[MeSH-major]
Adenocarcinoma. Antigens,
Neoplasm
/ biosynthesis. Colonic
Neoplasms
. Intestinal Mucosa. Mucins / biosynthesis
[MeSH-minor]
Adult. Aged. Biomarkers,
Tumor
/ analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin-1. Mucin-2. Prognosis
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17642184.001).
[ISSN]
0004-1955
[Journal-full-title]
Arkhiv patologii
[ISO-abbreviation]
Arkh. Patol.
[Language]
rus
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
13.
Arab M, Khayamzadeh M, Hashemi M, Hosseini M, Tabatabaeefar M, Anbiaee R, Anvari N, Ebrahimi M, Akbari ME:
Crude and age-specific incidence rate patterns for histopathologic subtypes of ovarian cancer in Iran.
Arch Iran Med
; 2010 May;13(3):203-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Epithelial
tumors
displayed the highest age specific incidence rate, followed by germ cell
tumors
.
Serous
epithelial
tumors
were the most common in the
epithelial
group.
[MeSH-major]
Ovarian
Neoplasms
/ epidemiology. Ovarian
Neoplasms
/ pathology
[MeSH-minor]
Adult. Age Distribution. Age of Onset. Aged. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Iran / epidemiology. Middle Aged.
Neoplasm
Invasiveness / pathology.
Neoplasm
Staging.
Neoplasms
, Germ Cell and Embryonal / epidemiology.
Neoplasms
, Germ Cell and Embryonal / pathology. Prognosis. Registries. Survival Analysis
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20433224.001).
[ISSN]
1735-3947
[Journal-full-title]
Archives of Iranian medicine
[ISO-abbreviation]
Arch Iran Med
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Iran
14.
Civit T, Klein O, Baylac F:
[Lacrimal gland epithelial tumors].
Neurochirurgie
; 2010 Apr-Jun;56(2-3):152-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Lacrimal gland
epithelial
tumors
].
[Transliterated title]
Tumeurs
épithéliales
de
la glande lacrymale.
Epithelial
tumors
of the lacrimal gland account for 50% of the expansive lesions of the lacrimal fossa.
[MeSH-major]
Eye
Neoplasms
/ surgery. Lacrimal Apparatus / surgery.
Neoplasms
, Glandular and
Epithelial
/ pathology
MedlinePlus Health Information.
consumer health - Eye Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Masson SAS. All rights reserved.
(PMID = 20303130.001).
[ISSN]
1773-0619
[Journal-full-title]
Neuro-Chirurgie
[ISO-abbreviation]
Neurochirurgie
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
15.
Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP:
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.
Cell Cycle
; 2009 Dec;8(23):3984-4001
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the
tumor
stroma.
Here, we propose a new model for understanding the Warburg effect in
tumor
metabolism.
Our hypothesis is that
epithelial
cancer cells induce the Warburg effect (aerobic glycolysis) in neighboring stromal fibroblasts.
Epithelial
cancer cells could then take up these energy-rich metabolites and use them in the mitochondrial TCA cycle, thereby promoting efficient energy production (ATP generation via oxidative phosphorylation), resulting in a higher proliferative capacity.
In this alternative model of tumorigenesis, the
epithelial
cancer cells instruct the normal stroma to transform into a wound-healing stroma, providing the necessary energy-rich micro-environment for facilitating
tumor
growth and angiogenesis.
In essence, the fibroblastic
tumor
stroma would directly feed the
epithelial
cancer cells, in a type of host-parasite relationship.
In this scenario, the
epithelial
tumor
cells "corrupt" the normal stroma, turning it into a factory for the production of energy-rich metabolites.
This alternative model is still consistent with Warburg's original observation that
tumors
show a metabolic shift towards aerobic glycolysis.
Importantly, a loss of stromal Cav-1 in human breast cancers is associated with
tumor
recurrence, metastasis, and poor clinical outcome.
Thus, an absence of stromal Cav-1 may be a biomarker for the "Reverse Warburg Effect," explaining its powerful predictive
value
.
[MeSH-major]
Breast
Neoplasms
/ metabolism. Fibroblasts / metabolism. Glycolysis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19923890.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P30-CA-56036; United States / NIAMS NIH HHS / AR / R01-AR-055660; United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-107382; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-70896; United States / NCI NIH HHS / CA / R01-CA-75503; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NCI NIH HHS / CA / R01-CA-86072
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Annexins; 0 / Caveolin 1; 0 / Tenascin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.1.40 / Pyruvate Kinase
16.
Fishman A, Shalom-Paz E, Fejgin M, Gaber E, Altaras M, Amiel A:
Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization.
Int J Gynecol Cancer
; 2005 Mar-Apr;15(2):261-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparing the genetic changes detected in the primary and secondary
tumor
sites of ovarian cancer using comparative genomic hybridization.
Our objective was to compare the genetic abnormalities in the primary
tumors
of
epithelial
ovarian cancer and their associated secondary peritoneal implants using comparative genomic hybridization (CGH).
Dissected tissue samples from the primary
tumor
and from the metastatic peritoneal implant were obtained at initial surgical staging and analyzed in each case.
We used CGH as this technique allows the entire genome of the
tumor
to be examined simultaneously for chromosomal imbalances without the need for tissue culture or targeting of specific loci.
Comparing the genomes of the primary
tumors
with the metastatic samples showed four cases with a balanced metastatic CGH profile while the primary site was aberrant.
The cytogenetic patterns in six of the seven primary
tumors
showed complex karyotypic changes, unlike the inconsistent findings that were associated with the secondary sites.
Such genomic heterogeneity between the primary and secondary sites may indicate that the secondary peritoneal implants are
de
novo carcinogenesis occurrences.
[MeSH-major]
Chromosome Aberrations. DNA Damage. DNA,
Neoplasm
/ genetics.
Neoplasm
Metastasis / genetics. Nucleic Acid Hybridization. Ovarian
Neoplasms
/ genetics. Ovarian
Neoplasms
/ pathology
[MeSH-minor]
Female. Humans. Karyotyping. Peritoneal
Neoplasms
/ genetics. Peritoneal
Neoplasms
/ secondary
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15823109.001).
[ISSN]
1048-891X
[Journal-full-title]
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
[ISO-abbreviation]
Int. J. Gynecol. Cancer
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA, Neoplasm
17.
Akbulut M, Zekioglu O, Terek MC, Ozdemir N:
Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
Arch Gynecol Obstet
; 2008 Sep;278(3):283-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed
tumor
.
OBJECTIVE: Adenofibroma is a form of mixed mesodermal
tumor
in which
epithelial
and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed
tumor
of Mullerian origin.
[MeSH-major]
Adenofibroma / pathology. Endometrial
Neoplasms
/ pathology. Mixed
Tumor
, Mullerian / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18236054.001).
[ISSN]
1432-0711
[Journal-full-title]
Archives of gynecology and obstetrics
[ISO-abbreviation]
Arch. Gynecol. Obstet.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
18.
Kellar KA, Lorenzi MV, Ho CP, You D, Wen ML, Ryseck RP, Oppenheimer S, Fink BE, Vite GD, Rowley BR, Yu C, Bol DK, Lee FY, Wong TW:
Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics.
Mol Cancer Ther
; 2006 Jun;5(6):1571-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Receptor tyrosine kinases (RTK) remain an area of therapeutic interest because of their role in
epithelial
tumors
, and experimental models specific to these targets are highly desirable.
A CD8HER2 fusion protein was shown to form disulfide-mediated homodimers and to transform fibroblasts and
epithelial
cells.
CD8RTK fusion proteins transform rat kidney
epithelial
cells and impart phenotypes that may reflect signaling specificity inherent in the native receptors.
Transgenic expression of CD8HER2 and CD8Met in mice resulted in the formation of salivary and mammary gland
tumors
.
The transgenic
tumors
allow the derivation of allograft
tumors
and cell lines that are sensitive to inhibition by small molecule kinase inhibitors.
This approach provides excellent cell and
tumor
models for the characterization of signaling properties of diverse RTKs and for the evaluation of rationally designed antagonists targeting these kinases.
[MeSH-major]
Antigens, CD8 / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary
Neoplasms
, Animal / genetics. Receptor, ErbB-2 / metabolism. Recombinant Fusion Proteins / genetics. Salivary Gland
Neoplasms
/ genetics
[MeSH-minor]
Animals. Blotting, Western. Cell Transformation, Neoplastic / genetics. Dimerization. Disease Models, Animal. Disulfides / pharmacology.
Epithelial
Cells / cytology.
Epithelial
Cells / metabolism. Female. Fibroblasts / cytology. Fibroblasts / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. Peptide Fragments / immunology. Plasmids. Proto-Oncogene Proteins c-met / genetics. Proto-Oncogene Proteins c-met / metabolism. Rats. Receptor Protein-Tyrosine Kinases / metabolism. Transfection
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16818516.001).
[ISSN]
1535-7163
[Journal-full-title]
Molecular cancer therapeutics
[ISO-abbreviation]
Mol. Cancer Ther.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD8; 0 / CD8 antigen, alpha chain; 0 / Disulfides; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
19.
Parajuli N, Doppler W:
Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.
In Vitro Cell Dev Biol Anim
; 2009 Sep;45(8):442-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Precision-cut slice cultures of
tumors
from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.
Ex vivo analysis of signaling pathways operating in
tumor
tissue is complicated by the three-dimensional structure, in particular by stroma-
epithelial
interactions.
Studies performed with pure populations of
tumor
cells usually do not take into account this issue.
One possibility to preserve the tissue architecture is the use of
tumor
slices.
By using precision cut slices of defined thickness, we were able to establish culture conditions for
tumor
material obtained from MMTV-neu transgenic mice, which allow the study of the action of cytokines and cytotoxic drugs for up to 24 h.
The slices were also a convenient source for the establishment of explant cultures of
tumor
epithelial
cells.
It is concluded that cultivation of precision-cut
tumor
slices provides a convenient way for the ex vivo molecular analysis of MMTV-neu
tumor
tissue under conditions which closely simulate the situation in vivo and can provide an alternative to in vivo experiments.
[MeSH-major]
Cytokines / pharmacology. Cytostatic Agents / pharmacology. Mammary
Neoplasms
, Animal / metabolism. Mammary
Neoplasms
, Animal / pathology. Tissue Culture Techniques
[MeSH-minor]
Animals. Doxorubicin / pharmacology.
Epithelial
Cells / drug effects.
Epithelial
Cells / pathology. Interferon Regulatory Factor-1 / drug effects. Interferon Regulatory Factor-1 / metabolism. Mammary
Tumor
Virus, Mouse. Mice. Mice, Transgenic. Receptor, ErbB-2 / metabolism. STAT1 Transcription Factor / drug effects. STAT1 Transcription Factor / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Suppressor of Cytokine Signaling 1 Protein. Suppressor of Cytokine Signaling Proteins / drug effects. Suppressor of Cytokine Signaling Proteins / metabolism.
Tumor
Cells, Cultured
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
DOXORUBICIN
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell Biol Toxicol. 2002;18(3):205-19
[
12083426.001
]
[Cites]
Life Sci. 1995;57(21):1887-901
[
7475939.001
]
[Cites]
J Biol Chem. 2008 Aug 8;283(32):22089-96
[
18524780.001
]
[Cites]
Clin Cancer Res. 2004 Dec 15;10(24):8697-703
[
15623655.001
]
[Cites]
Int J Biochem Cell Biol. 2007;39(11):1987-94
[
17719831.001
]
[Cites]
Liver Int. 2006 Jun;26(5):604-12
[
16762006.001
]
[Cites]
J Virol. 2008 Jan;82(2):999-1010
[
17977977.001
]
[Cites]
Eur J Biochem. 1999 Jan;259(1-2):25-31
[
9914471.001
]
[Cites]
J Pharmacol Toxicol Methods. 1997 Oct;38(2):59-69
[
9403776.001
]
[Cites]
Gynecol Oncol. 2007 Sep;106(3):614-21
[
17602728.001
]
[Cites]
Nat Rev Cancer. 2006 Mar;6(3):204-16
[
16498443.001
]
[Cites]
Respir Res. 2007 Jun 14;8:43
[
17567922.001
]
[Cites]
Toxicology. 2000 Nov 16;153(1-3):221-53
[
11090959.001
]
[Cites]
BMC Cancer. 2007 Jul 25;7:136
[
17651480.001
]
[Cites]
J Cell Sci. 1989 Jul;93 ( Pt 3):491-500
[
2606940.001
]
[Cites]
Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62
[
12209125.001
]
[Cites]
Gynecol Oncol. 2008 Mar;108(3):591-7
[
18177927.001
]
[Cites]
BMC Cancer. 2008 Apr 24;8:119
[
18435859.001
]
[Cites]
Annu Rev Pathol. 2006;1:119-50
[
18039110.001
]
[Cites]
Nat Rev Cancer. 2007 May;7(5):389-97
[
17446858.001
]
[Cites]
J Biol Chem. 2004 Dec 17;279(51):53272-81
[
15489221.001
]
[Cites]
Traffic. 2007 Dec;8(12):1815-28
[
17892529.001
]
[Cites]
Cell Biol Toxicol. 1998 Jun;14(3):175-90
[
9689491.001
]
[Cites]
Breast Cancer Res. 2003;5(3):130-5
[
12793893.001
]
[Cites]
In Vitro Cell Dev Biol Anim. 2004 Jan-Feb;40(1-2):14-21
[
15180438.001
]
[Cites]
Cell Tissue Res. 2008 Jun;332(3):489-98
[
18386065.001
]
[Cites]
Cell Biol Int. 1999;23(3):157-61
[
10562436.001
]
[Cites]
In Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33
[
12513120.001
]
[Cites]
BMC Cancer. 2006 Apr 07;6:86
[
16603054.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82
[
1359541.001
]
(PMID = 19533258.001).
[ISSN]
1543-706X
[Journal-full-title]
In vitro cellular & developmental biology. Animal
[ISO-abbreviation]
In Vitro Cell. Dev. Biol. Anim.
[Language]
eng
[Grant]
Austria / Austrian Science Fund FWF / / W 1101
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Cytokines; 0 / Cytostatic Agents; 0 / Interferon Regulatory Factor-1; 0 / STAT1 Transcription Factor; 0 / Socs1 protein, mouse; 0 / Stat1 protein, mouse; 0 / Suppressor of Cytokine Signaling 1 Protein; 0 / Suppressor of Cytokine Signaling Proteins; 80168379AG / Doxorubicin; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
20.
Leve F, de Souza W, Morgado-Díaz JA:
A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in epithelial cancer cells.
J Pharmacol Exp Ther
; 2008 Dec;327(3):777-88
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in
epithelial
cancer cells.
Disassembly of the apical junctional complex (AJC) together with actin cytoskeleton alterations are among the initial events for the development of
epithelial
cancer.
Thus, our findings demonstrate a central role of a regulatory cascade that integrates PKA and Rho-family GTPases in the AJC disassembly and actin organization in
tumor
epithelial
cells.
[MeSH-major]
Adenocarcinoma / pathology. Cell Adhesion. Cyclic AMP-Dependent Protein Kinases / metabolism. Cytoskeleton / metabolism.
Epithelial
Cells / ultrastructure. Signal Transduction. rho GTP-Binding Proteins / metabolism
[MeSH-minor]
Actins / metabolism. Caco-2 Cells. Colonic
Neoplasms
/ pathology. Humans. Intercellular Junctions / metabolism
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18791066.001).
[ISSN]
1521-0103
[Journal-full-title]
The Journal of pharmacology and experimental therapeutics
[ISO-abbreviation]
J. Pharmacol. Exp. Ther.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Actins; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
21.
Akihara Y, Shimoyama Y, Kawasako K, Komine M, Hirayama K, Kagawa Y, Omachi T, Matsuda K, Okamoto M, Kadosawa T, Taniyama H:
Immunohistochemical evaluation of canine ovarian tumors.
J Vet Med Sci
; 2007 Jul;69(7):703-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunohistochemical evaluation of canine ovarian
tumors
.
Canine ovarian
tumors
(
epithelial
tumor
, sex-cord stromal
tumor
, germ cell
tumor
) classifying into 9 histological types were examined immunohistochemically using placental alkaline phosphatase (PLAP), cytokeratin7 (CK7), desmin, S100, AE1/AE3, inhibin alpha, vimentin, and alfa feto-protein (AFP).
The papillary and tubular types observed in
epithelial
tumors
were immunoreactive for desmin and AE1/AE3.
The solid type, nest type, cord type, palisade type, cystic type and spindle type, which were observed in sex-cord stromal
tumors
, showed a positive immunoreaction for S100 but little or no positive immunoreaction for inhibin alpha with an exception of positive result in the palisade type.
Most of the sex-cord stromal
tumors
were AE1/AE3-positive except for the palisade type.
In the cobblestone type observed in germ cell
tumors
, only vimentin and AFP were positive.
The present study elucidated the detailed histological and immunohistochemical characteristics of canine ovarian
tumors
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17675800.001).
[ISSN]
0916-7250
[Journal-full-title]
The Journal of veterinary medical science
[ISO-abbreviation]
J. Vet. Med. Sci.
[Language]
ENG
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
22.
Parikh AH, Khan SH, Wright JD Jr, Oh KT:
Systemic non-Hodgkin's lymphoma simulating primary intraocular lymphoma.
Am J Ophthalmol
; 2005 Mar;139(3):573-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Diagnostic enucleation and histopathologic studies revealed findings consistent with primary intraocular lymphoma including intraretinal, subretinal, and subretinal pigment
epithelial
tumor
cells without involvement of the choroid.
[MeSH-major]
Eye
Neoplasms
/ diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Retinal
Neoplasms
/ diagnosis. Vitreous Body / pathology
MedlinePlus Health Information.
consumer health - Eye Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15767087.001).
[ISSN]
0002-9394
[Journal-full-title]
American journal of ophthalmology
[ISO-abbreviation]
Am. J. Ophthalmol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
23.
Downs LS Jr, Lima PH, Bliss RL, Blomquist CH:
Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
J Soc Gynecol Investig
; 2005 Oct;12(7):539-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian
neoplasms
, and
epithelial
ovarian cancer.
OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in
tumor
metastasis and invasion.
It has been suggested that both enzymes play a role the progression of
epithelial
ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
Tissue specimens were divided into four groups: normal ovary, benign
neoplasm
, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
CONCLUSIONS: CB activity is associated with invasive ovarian
neoplasm
.
[MeSH-major]
Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian
Neoplasms
/ enzymology. Ovary / enzymology
[MeSH-minor]
Female. Humans. Isoenzymes.
Tumor
Cells, Cultured
Genetic Alliance.
consumer health - Ovarian cancer
.
Genetic Alliance.
consumer health - Ovarian epithelial cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16202931.001).
[ISSN]
1556-7117
[Journal-full-title]
Journal of the Society for Gynecologic Investigation
[ISO-abbreviation]
J. Soc. Gynecol. Investig.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
24.
Samaila MO:
Malignant tumours of childhood in Zaria.
Afr J Paediatr Surg
; 2009 Jan-Jun;6(1):19-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant
tumours
of childhood in Zaria.
BACKGROUND: The increased prevalence of hitherto uncommon
tumours
in children in our geographic setting formed the basis for this study.
MATERIALS AND METHODS: An eight year (2000-2007) consecutive analysis of malignant
tumours
in children ages 0 to 15 years in a referral University laboratory.
Tumours
were characterised histologically into tissues of origin and categorised into three age groups; <1 year, 1-5 years and 6-15 years.
RESULT: 189 children with malignant
tumours
were analysed.
Tumours
of mesenchymal origin were the commonest (115: 60.8%) while
epithelial
tumours
including germ cell
tumours
accounted for 74 (39.2%) cases.
The age group 1-5 years had the highest
epithelial
tumours
while age group 6-15 years had the most
tumours
with 102 (54%) cases overall.
The five commonest
tumours
over-all were rhabdomyosarcoma, Burkitt lymphoma, retinoblastoma, non-Hodgkin's lymphoma and nephroblastoma.
Germ cell
tumours
affected the ovary predominantly and two of the endodermal sinus
tumour
cases were seen in the testis of an eighteen month child and sacrococcygeum of a 5 year old girl, respectively.
The vascular
tumours
included epithelioid haemangioendothelioma, haemangioblastoma and Dabska
tumour
and they accounted for (5.8%) of all
tumours
seen.
The commonest sites of occurrence of these
tumours
were the oculo-orbital, jaw, head and neck regions with 82 cases (43.4%) while lymph nodes were involved in 31 (16.4%) cases.
CONCLUSION: The distribution and occurrence of malignant
tumours
in children is age related.
Lymphomas were the commonest
tumours
overall while retinoblastoma and Burkitt lymphoma were the commonest
tumours
affecting children below 5 years and 6-10 years old, respectively, in our centre.
The head region and lymph nodes were the sites of predilection for majority of these
tumours
.
[MeSH-major]
Lymphoma / epidemiology.
Neoplasms
/ epidemiology.
Neoplasms
/ pathology. Retinal
Neoplasms
/ epidemiology. Retinoblastoma / epidemiology
MedlinePlus Health Information.
consumer health - Cancer in Children
.
MedlinePlus Health Information.
consumer health - Lymphoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19661660.001).
[ISSN]
0974-5998
[Journal-full-title]
African journal of paediatric surgery : AJPS
[ISO-abbreviation]
Afr J Paediatr Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Nigeria
25.
Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA:
Muc4/MUC4 functions and regulation in cancer.
Future Oncol
; 2009 Dec;5(10):1631-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The membrane mucin MUC4 (human) is abundantly expressed in many epithelia, where it is proposed to play a protective role, and is overexpressed in some
epithelial
tumors
.
The roles of MUC4 in
tumors
suggest that it may be valuable as
a tumor
marker or target for therapy.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
FASEB J. 2008 Apr;22(4):966-81
[
18024835.001
]
[Cites]
FASEB J. 2008 Aug;22(8):3035-45
[
18492726.001
]
[Cites]
Biochim Biophys Acta. 2008 Oct;1783(10):1728-36
[
18573283.001
]
[Cites]
Br J Cancer. 2009 Jan 27;100(2):344-51
[
19127263.001
]
[Cites]
Exp Cell Res. 2009 Feb 15;315(4):638-48
[
19038249.001
]
[Cites]
Cancer Res. 2009 Apr 1;69(7):2845-52
[
19293191.001
]
[Cites]
Crit Rev Oncog. 2008;14(2-3):177-96
[
19409062.001
]
[Cites]
J Cell Biochem. 2009 Jul 1;107(4):797-802
[
19388004.001
]
[Cites]
J Biol Chem. 2003 May 30;278(22):20338-44
[
12668667.001
]
[Cites]
J Biol Chem. 2003 Aug 8;278(32):30142-7
[
12748185.001
]
[Cites]
J Biol Chem. 2003 Sep 19;278(38):36942-52
[
12855694.001
]
[Cites]
Biochem J. 2004 Feb 1;377(Pt 3):701-8
[
14583090.001
]
[Cites]
Cancer Res. 2004 Jan 15;64(2):622-30
[
14744777.001
]
[Cites]
Hepatology. 2004 Jan;39(1):220-9
[
14752841.001
]
[Cites]
Mod Pathol. 2004 Feb;17(2):150-7
[
14657954.001
]
[Cites]
Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32
[
15284539.001
]
[Cites]
Oncogene. 2004 Jul 29;23(34):5729-38
[
15184872.001
]
[Cites]
Inflammation. 2004 Apr;28(2):67-76
[
15379212.001
]
[Cites]
Nat Cell Biol. 2001 Sep;3(9):785-92
[
11533657.001
]
[Cites]
Cancer. 2001 Oct 15;92(8):2148-57
[
11596032.001
]
[Cites]
Curr Biol. 2001 Nov 13;11(22):1739-48
[
11719215.001
]
[Cites]
Am J Respir Cell Mol Biol. 2002 Apr;26(4):447-52
[
11919081.001
]
[Cites]
Am J Clin Pathol. 2002 May;117(5):791-6
[
12090430.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 2002;71:149-85
[
12102554.001
]
[Cites]
Int J Cancer. 2002 Jun 20;99(6):783-91
[
12115478.001
]
[Cites]
Eur J Biochem. 2002 Aug;269(15):3637-44
[
12153560.001
]
[Cites]
Cell Microbiol. 2002 Aug;4(8):515-29
[
12174086.001
]
[Cites]
J Biol Chem. 2002 Aug 30;277(35):32258-67
[
12077147.001
]
[Cites]
Oncogene. 2002 Oct 24;21(49):7524-32
[
12386815.001
]
[Cites]
Biochem J. 2002 Nov 15;368(Pt 1):41-8
[
12186632.001
]
[Cites]
Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L671-9
[
12495942.001
]
[Cites]
Mol Cell. 2003 Feb;11(2):495-505
[
12620236.001
]
[Cites]
Nature. 2003 Mar 20;422(6929):322-6
[
12646923.001
]
[Cites]
Biochem Pharmacol. 2003 May 1;65(9):1419-25
[
12732353.001
]
[Cites]
Cancer Res. 1999 May 1;59(9):2229-36
[
10232613.001
]
[Cites]
Br J Cancer. 2004 Nov 1;91(9):1633-8
[
15494719.001
]
[Cites]
J Biol Chem. 1980 Jan 25;255(2):783-90
[
7356644.001
]
[Cites]
J Biol Chem. 1980 Dec 25;255(24):12051-9
[
7440586.001
]
[Cites]
J Biol Chem. 1984 Apr 25;259(8):4866-77
[
6715325.001
]
[Cites]
Biochem J. 1990 Jan 1;265(1):121-9
[
2302161.001
]
[Cites]
J Biol Chem. 1990 May 25;265(15):8505-10
[
2111320.001
]
[Cites]
Biochem Biophys Res Commun. 1991 Mar 15;175(2):414-22
[
1673336.001
]
[Cites]
J Biol Chem. 1992 Aug 15;267(23):16341-6
[
1379596.001
]
[Cites]
J Biol Chem. 1994 Apr 22;269(16):11950-5
[
8163496.001
]
[Cites]
Cell. 1994 Jul 15;78(1):5-8
[
8033211.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6
[
8058768.001
]
[Cites]
J Biol Chem. 1997 Dec 26;272(52):33245-54
[
9407114.001
]
[Cites]
Biochem J. 1998 Mar 1;330 ( Pt 2):737-44
[
9480884.001
]
[Cites]
Biochem J. 1998 Oct 15;335 ( Pt 2):457-63
[
9761747.001
]
[Cites]
Clin Cancer Res. 1998 Nov;4(11):2669-76
[
9829729.001
]
[Cites]
J Biol Chem. 1998 Dec 25;273(52):35228-37
[
9857062.001
]
[Cites]
J Biol Chem. 1999 Feb 26;274(9):5263-6
[
10026131.001
]
[Cites]
Biochem J. 1999 Mar 1;338 ( Pt 2):325-33
[
10024507.001
]
[Cites]
Nat Med. 2000 Apr;6(4):443-6
[
10742152.001
]
[Cites]
J Biol Chem. 2000 Jun 9;275(23):17800-7
[
10837499.001
]
[Cites]
Int J Cancer. 2000 Aug 15;87(4):480-6
[
10918186.001
]
[Cites]
Oncogene. 2000 Sep 7;19(38):4354-61
[
10980611.001
]
[Cites]
J Cell Physiol. 2000 Nov;185(2):310-6
[
11025453.001
]
[Cites]
J Biol Chem. 2000 Oct 27;275(43):33929-36
[
10938282.001
]
[Cites]
Biochem J. 2000 Jul 15;349(Pt 2):641-9
[
10880365.001
]
[Cites]
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
[
11252954.001
]
[Cites]
J Biol Chem. 2001 Jun 15;276(24):21885-94
[
11283019.001
]
[Cites]
J Biol Chem. 2001 Aug 17;276(33):30923-33
[
11418607.001
]
[Cites]
Biochem J. 2005 Feb 15;386(Pt 1):35-45
[
15461591.001
]
[Cites]
Cancer Res. 2005 Jan 15;65(2):473-82
[
15695389.001
]
[Cites]
J Clin Pathol. 2005 Aug;58(8):845-52
[
16049287.001
]
[Cites]
Oncogene. 2005 Sep 8;24(40):6143-54
[
16007204.001
]
[Cites]
Mod Pathol. 2005 Oct;18(10):1295-304
[
15976813.001
]
[Cites]
Respir Res. 2006;7:39
[
16551361.001
]
[Cites]
Biosci Rep. 2006 Feb;26(1):55-67
[
16779668.001
]
[Cites]
Mol Biol Cell. 2006 Jul;17(7):2931-41
[
16624867.001
]
[Cites]
J Biol Chem. 2006 Jul 14;281(28):19310-9
[
16690615.001
]
[Cites]
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64
[
16857800.001
]
[Cites]
Mod Pathol. 2006 Oct;19(10):1386-94
[
16880776.001
]
[Cites]
J Biol Chem. 2006 Sep 29;281(39):29411-20
[
16891313.001
]
[Cites]
Oncogene. 2007 Jan 4;26(1):30-41
[
16799633.001
]
[Cites]
Lung Cancer. 2007 Feb;55(2):195-203
[
17126950.001
]
[Cites]
Cancer Res. 2007 Jan 15;67(2):433-6
[
17234748.001
]
[Cites]
Biochem J. 2007 Feb 15;402(1):81-91
[
17037983.001
]
[Cites]
Arch Pathol Lab Med. 2007 Apr;131(4):593-8
[
17425390.001
]
[Cites]
J Biol Chem. 2007 Aug 3;282(31):22638-50
[
17553805.001
]
[Cites]
Annu Rev Physiol. 2008;70:431-57
[
17850209.001
]
(PMID = 20001800.001).
[ISSN]
1744-8301
[Journal-full-title]
Future oncology (London, England)
[ISO-abbreviation]
Future Oncol
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA052498-17; United States / NCI NIH HHS / CA / CA52498; United States / NCI NIH HHS / CA / R01 CA052498-17; United States / NCI NIH HHS / CA / R01 CA052498; United States / NCI NIH HHS / CA / CA052498-16; United States / NCI NIH HHS / CA / R01 CA052498-16
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4
[Number-of-references]
86
[Other-IDs]
NLM/ NIHMS171897; NLM/ PMC2825673
26.
Maestá I, Michelin OC, Traiman P, Hokama P, Rudge MV:
Primary non-gestational choriocarcinoma of the uterine cervix: a case report.
Gynecol Oncol
; 2005 Jul;98(1):146-50
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pelvic examination realized under anesthetic revealed
a tumor
mass occupying the uterine cervix.
CONCLUSION: Primary non-gestational uterine cervical choriocarcinoma may arise from germ cell
tumor
or
epithelial
tissue.
[MeSH-major]
Choriocarcinoma, Non-gestational / pathology. Uterine Cervical
Neoplasms
/ pathology
Genetic Alliance.
consumer health - Choriocarcinoma
.
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
COS Scholar Universe.
author profiles
.
International Agency for Research on Cancer - Screening Group.
diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15925400.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
27.
Korst RJ, Kansler AL, Christos PJ, Mandal S:
Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis.
Ann Thorac Surg
; 2009 May;87(5):1641-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adjuvant radiotherapy for thymic
epithelial
tumors
: a systematic review and meta-analysis.
Adjuvant radiotherapy after complete resection of localized, invasive thymic
epithelial
tumors
is considered by many to be the standard of care, despite little supporting literature.
Analysis of data from 592 patients with completely resected stage II or III thymic
epithelial
tumors
, however, revealed no statistically significant reduction in recurrence after adjuvant radiotherapy (odds ratio 1.05; 95% confidence interval: 0.63 to 1.75; p = 0.840).
[MeSH-major]
Thymus
Neoplasms
/ radiotherapy
[MeSH-minor]
Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Humans.
Neoplasm
Invasiveness.
Neoplasm
Staging. Radiotherapy, Adjuvant / methods. Secondary Prevention
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
COS Scholar Universe.
author profiles
.
PubMed Health.
DARE review
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19379938.001).
[ISSN]
1552-6259
[Journal-full-title]
The Annals of thoracic surgery
[ISO-abbreviation]
Ann. Thorac. Surg.
[Language]
eng
[Publication-type]
Journal Article; Meta-Analysis; Review
[Publication-country]
Netherlands
[Number-of-references]
42
28.
Pachmann K, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U:
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
J Cancer Res Clin Oncol
; 2008 Jan;134(1):59-65
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating
epithelial
tumor
cells (CETC) for monitoring of adjuvant therapy in breast cancer.
Circulating
epithelial
tumor
cells (CETC) were quantified before and after each second cycle of the therapy regimen, between the anthracycline and the taxane block of the regimen and in some cases repeatedly during CMF treatment.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast
Neoplasms
/ blood. Breast
Neoplasms
/ drug therapy.
Epithelial
Cells / pathology.
Neoplasm
Recurrence, Local / diagnosis. Neoplastic Cells, Circulating / pathology
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
Hazardous Substances Data Bank.
CYCLOPHOSPHAMIDE
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
EPIRUBICIN
.
Hazardous Substances Data Bank.
METHOTREXATE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Breast. 2007 Apr;16(2):211-8
[
17291754.001
]
[Cites]
Clin Chem Lab Med. 2001 Sep;39(9):811-7
[
11601678.001
]
[Cites]
BMJ. 2005 Jan 29;330(7485):205-6
[
15677633.001
]
[Cites]
Clin Cancer Res. 2001 Dec;7(12):4102-8
[
11751508.001
]
[Cites]
Lancet. 1999 Jul 17;354(9174):197-202
[
10421301.001
]
[Cites]
Breast Cancer Res Treat. 2003 Dec;82(3):199-206
[
14703067.001
]
[Cites]
Cancer Res. 1999 Aug 1;59(15):3776-82
[
10446995.001
]
[Cites]
Cancer. 2005 Mar 1;103(5):884-91
[
15666325.001
]
[Cites]
Nat Med. 2005 Aug;11(8):824-5
[
16079872.001
]
[Cites]
Ann Oncol. 2003 Jun;14(6):849-55
[
12796021.001
]
[Cites]
Crit Rev Oncol Hematol. 2005 Sep;55(3):167-75
[
16039867.001
]
[Cites]
N Engl J Med. 2005 Aug 25;353(8):793-802
[
16120859.001
]
[Cites]
Exp Hematol. 2004 Oct;32(10):891-904
[
15504544.001
]
[Cites]
BMJ. 2005 Jan 29;330(7485):217
[
15649903.001
]
[Cites]
N Engl J Med. 2004 Aug 19;351(8):781-91
[
15317891.001
]
[Cites]
World J Surg Oncol. 2005 Mar 31;3(1):18
[
15801980.001
]
[Cites]
Eur J Surg Oncol. 2002 Sep;28(6):615-9
[
12359196.001
]
[Cites]
Clin Cancer Res. 2005 Aug 1;11(15):5657; author reply 5657-8
[
16061886.001
]
[Cites]
Clin Cancer Res. 2004 Feb 15;10(4):1392-400
[
14977842.001
]
[Cites]
Anticancer Res. 2004 Nov-Dec;24(6):4211-6
[
15736474.001
]
[Cites]
Clin Cancer Res. 2005 May 15;11(10):3678-85
[
15897564.001
]
[Cites]
Breast Cancer Res. 2005;7(6):R975-9
[
16280045.001
]
[Cites]
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003372
[
15846660.001
]
[Cites]
MMW Fortschr Med. 2002 Oct 10;144(41):37-9
[
12474359.001
]
[Cites]
Clin Cancer Res. 2004 Dec 15;10(24):8152-62
[
15623589.001
]
(PMID = 17611779.001).
[ISSN]
1432-1335
[Journal-full-title]
Journal of cancer research and clinical oncology
[ISO-abbreviation]
J. Cancer Res. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Bridged-Ring Compounds; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1605-68-1 / taxane; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
29.
Xu D, Liu D, Zhang Z, Zhang Y, Li Y, Liu X, Jia Q, Zheng L, Song G:
Gamma Knife surgery in the management of orbital tumors.
J Neurosurg
; 2010 Dec;113 Suppl:34-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Gamma Knife surgery in the management of orbital
tumors
.
OBJECT: The authors evaluated the results they obtained using Gamma Knife surgery (GKS) in patients with orbital
tumors
.
METHODS: This is a retrospective clinical evaluation of 202 patients with orbital
tumors
who were treated with GKS between September 1995 and October 2008.
There were 84 meningiomas, 38
epithelial
tumors
of the lacrimal gland, 23 schwannomas, 18 malignant choroidal melanomas, 12 optic nerve gliomas, 11 orbital metastases, 10 pseudotumors of the orbit, 3 retinoblastomas, and 3 cases of fibromatosis.
The
tumor
margin dose ranged from 10 to 40 Gy.
RESULTS: At a median follow-up period of 34.5 ± 14.7 months (range 12-114 months),
tumor
shrinkage was observed in 118 patients (58.4%) and stable
tumor
size in 71 patients (35.1%).
Regularly scheduled neuroimaging studies demonstrated evidence of
tumor
progression in only 13 patients (6.4%): 9 of these patients underwent repeated GKS and 4 received surgical treatment.
CONCLUSIONS: Gamma Knife surgery provides an effective management strategy in patients with orbital
tumors
; it achieves excellent preservation of neurological function and is associated with few treatment-related complications.
[MeSH-major]
Meningioma / surgery. Neurilemmoma / surgery. Optic Nerve Glioma / surgery. Orbital
Neoplasms
/ surgery. Radiosurgery / instrumentation
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Meningeal
Neoplasms
/ surgery. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21121785.001).
[ISSN]
1933-0693
[Journal-full-title]
Journal of neurosurgery
[ISO-abbreviation]
J. Neurosurg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
30.
Richardsen E, Uglehus RD, Due J, Busch C, Busund LT:
COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67.
Cancer Epidemiol
; 2010 Jun;34(3):316-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Ki67 was included as a measure of growth fraction of
tumor
cells.
METHODS: Digital video analysis images from
tumor
cell areas and
tumor
stromal areas were analyzed on formalin fixed, paraffin-embedded and immunohistochemical stained cancer specimens from 59 patients: 32 patients with metastases and 27 patients without clinical, biochemical, or radiological evidence of metastases within 10 years after diagnosis.
RESULTS: In primary cancers in the metastatic group, COX-2, TGF-beta and Ki67 were stronger expressed in
epithelial
tumor
cell and
tumor
stromal areas compared with non-metastatic cancers (for all markers, p<0.0001).
High intensity of COX-2 staining in
tumor
areas was strongly associated with death from prostate cancer in univariate analyses (hazard ratio [HR] 95% CI, 4.0 (1.1-14.5)).
[MeSH-major]
Cyclooxygenase 2 / metabolism. Interleukin-10 / metabolism. Ki-67 Antigen / metabolism. Prostatic
Neoplasms
/ metabolism. Transforming Growth Factor beta / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Carcinoma / metabolism. Carcinoma / mortality. Carcinoma / pathology. Humans. Liver
Neoplasms
/ metabolism. Liver
Neoplasms
/ secondary. Lymphatic Metastasis. Male. Middle Aged.
Neoplasm
Metastasis. Rectal
Neoplasms
/ metabolism. Rectal
Neoplasms
/ secondary. Urinary Bladder
Neoplasms
/ metabolism. Urinary Bladder
Neoplasms
/ secondary
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
(PMID = 20409773.001).
[ISSN]
1877-783X
[Journal-full-title]
Cancer epidemiology
[ISO-abbreviation]
Cancer Epidemiol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Ki-67 Antigen; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; EC 1.14.99.1 / Cyclooxygenase 2
31.
Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, Teillac P, Calvo F, Janin A, Dosquet C:
VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
Cancer
; 2008 Jan 15;112(2):433-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
VEGF and VEGFR-1 are coexpressed by
epithelial
and stromal cells of renal cell carcinoma.
BACKGROUND:
Tumor
angiogenesis is a dynamic process that plays a major role in cancer progression.
METHODS: Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in
tumor
tissue samples from surgical specimens of 65 patients with clear cell RCC.
At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral
epithelial
as stromal cells and in corresponding normal tissue compartments.
In laser-microdissected
epithelial
cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively).
There was no differential VEGFR-2 expression in
epithelial
or in stromal cells of tumoral or nontumoral kidney.
By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC
tumor
epithelial
and stromal cells.
CONCLUSIONS: Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in
epithelial
and stromal cells of RCC.
[MeSH-major]
Carcinoma, Renal Cell / chemistry. Kidney
Neoplasms
/ chemistry. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-1 / analysis
[MeSH-minor]
Adult. Aged. Aged, 80 and over.
Epithelial
Cells / chemistry. Female. Fluorescent Antibody Technique. Humans. Keratins / analysis. Keratins / genetics. Male. Microdissection. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / chemistry. Vascular Endothelial Growth Factor Receptor-2 / analysis. Vascular Endothelial Growth Factor Receptor-2 / genetics
Genetic Alliance.
consumer health - Renal cell carcinoma
.
MedlinePlus Health Information.
consumer health - Kidney Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18041056.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 68238-35-7 / Keratins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
32.
Röcken C, Röhl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP:
The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.
Cancer Epidemiol Biomarkers Prev
; 2007 Jun;16(6):1206-12
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Local expression of AT1R, AT2R, and angiotensin-converting enzyme (ACE) was investigated by immunohistochemistry in
tumor
and corresponding nontumor specimens obtained from 100 patients with gastric cancer, and compared with the ACE insertion/deletion gene polymorphism.
AT1R and AT2R were found in the
tumor
epithelial
cells of 26 (26%) and 95 (95%) patients, respectively.
In intestinal type gastric cancer, its expression correlated with the N category (P = 0.009) and the International Union Against Cancer
tumor
stage (P = 0.024).
AT1R+ intestinal type gastric cancers had a larger number of lymph node metastases (P = 0.026), a higher International Union Against Cancer
tumor
stage (P = 0.032), and a shorter survival time (P = 0.009) than AT1R-
tumors
.
When the ACE genotype was included, the relative risk of having lymph node metastases increased considerably in AT1R+
tumors
being heterozygous or homozygous for the ACE D allele (odds ratio, 19.00; 95% confidence interval, 1.45-248.24).
[MeSH-major]
Adenocarcinoma / pathology. Angiotensin II / metabolism. Genetic Predisposition to Disease. Peptidyl-Dipeptidase A / genetics. Receptors, Angiotensin / metabolism. Stomach
Neoplasms
/ pathology
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17548686.001).
[ISSN]
1055-9965
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Angiotensin; 11128-99-7 / Angiotensin II; EC 3.4.15.1 / Peptidyl-Dipeptidase A
33.
Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK:
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
Clin Cancer Res
; 2006 Mar 15;12(6):1707-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We sought to determine the role of
epithelial
(
tumor
cell-derived) and stromal (host-derived) expression of MMPs in predicting the clinical outcome of patients with
epithelial
ovarian cancer (EOC).
EXPERIMENTAL DESIGN: MMP-2, MMP-9, and membrane type 1 (MT1)-MMP expression was evaluated using immunohistochemistry in 90 invasive EOCs, and samples were scored for
epithelial
and stromal staining.
RESULTS: High expression of MMP-2, MMP-9, and MT1-MMP in
tumor
epithelium was detected in 54%, 97%, and 100% of cases, and in stromal compartments, in 38%, 70%, and 38% of cases, respectively.
Kaplan-Meier analysis showed that high
epithelial
and stromal expression of MMP-2, MMP-9, and MT1-MMP were each significantly associated with shorter disease-specific survival (DSS; P < 0.01).
On tree-structured survival analysis, patients with strong
epithelial
MT1-MMP expression had the shortest DSS, whereas patients with moderate
epithelial
MT1-MMP and low stromal MMP-9 expression had the longest DSS (P < 0.01).
On multivariate analysis, high stromal expression of MMP-9 (P = 0.01) and MT1-MMP (P = 0.04), strong
epithelial
MT1-MMP (P = 0.01) and high stage (P = 0.04) were independent predictors of poor DSS.
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Breast Cancer Res Treat. 2000 Sep;63(2):105-15
[
11097087.001
]
[Cites]
Clin Exp Metastasis. 1999;17(10):799-808
[
11089877.001
]
[Cites]
Eur J Cancer. 2001 Nov;37(16):2040-9
[
11597382.001
]
[Cites]
Trends Cell Biol. 2001 Nov;11(11):S37-43
[
11684441.001
]
[Cites]
Gynecol Oncol. 2002 Jan;84(1):126-34
[
11748988.001
]
[Cites]
Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45
[
11988310.001
]
[Cites]
Nat Rev Cancer. 2002 Mar;2(3):161-74
[
11990853.001
]
[Cites]
J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42
[
12165638.001
]
[Cites]
Surgery. 2002 Aug;132(2):220-5
[
12219015.001
]
[Cites]
Clin Cancer Res. 2002 Sep;8(9):2924-32
[
12231537.001
]
[Cites]
Eur J Gynaecol Oncol. 2003;24(5):417-20
[
14584660.001
]
[Cites]
Gynecol Oncol. 2004 Feb;92(2):559-67
[
14766248.001
]
[Cites]
Mol Cancer Res. 2004 Feb;2(2):73-80
[
14985463.001
]
[Cites]
J Biol Chem. 2004 Apr 2;279(14):13564-74
[
14729679.001
]
[Cites]
Am J Obstet Gynecol. 2004 Apr;190(4):899-909
[
15118611.001
]
[Cites]
Clin Cancer Res. 2004 Oct 1;10(19):6512-21
[
15475438.001
]
[Cites]
Lab Invest. 1983 Dec;49(6):636-49
[
6317982.001
]
[Cites]
FASEB J. 1990 Apr 1;4(6):1577-90
[
2180767.001
]
[Cites]
Cell. 1991 Jan 25;64(2):327-36
[
1703045.001
]
[Cites]
Biometrics. 1992 Jun;48(2):411-25
[
1637970.001
]
[Cites]
Breast Cancer Res Treat. 1993;24(3):185-93
[
8435474.001
]
[Cites]
Lab Invest. 1993 Sep;69(3):312-21
[
8377473.001
]
[Cites]
Int J Cancer. 1994 Feb 15;56(4):500-5
[
8112886.001
]
[Cites]
J Cell Sci. 1994 Feb;107 ( Pt 2):477-86
[
8207074.001
]
[Cites]
Int J Cancer. 1994 Jul 1;58(1):50-6
[
8014015.001
]
[Cites]
J Histochem Cytochem. 1994 Jul;42(7):945-51
[
8014478.001
]
[Cites]
J Biol Chem. 1995 Mar 10;270(10):5331-8
[
7890645.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730-4
[
7708715.001
]
[Cites]
Int J Cancer. 1996 Jan 3;65(1):57-62
[
8543396.001
]
[Cites]
Int J Cancer. 1996 Feb 20;69(1):9-16
[
8600068.001
]
[Cites]
J Biochem. 1996 Feb;119(2):209-15
[
8882706.001
]
[Cites]
J Clin Oncol. 1996 Nov;14(11):2968-75
[
8918494.001
]
[Cites]
Invasion Metastasis. 1996;16(3):150-9
[
9186550.001
]
[Cites]
Cancer. 1997 Oct 15;80(8):1457-63
[
9338470.001
]
[Cites]
Cell. 1997 Nov 14;91(4):439-42
[
9390552.001
]
[Cites]
Hum Pathol. 1998 Feb;29(2):155-65
[
9490275.001
]
[Cites]
Int J Oncol. 1998 Mar;12(3):569-76
[
9472094.001
]
[Cites]
Br J Cancer. 1999 May;80(3-4):315-21
[
10408832.001
]
[Cites]
J Biol Chem. 1999 Jul 30;274(31):21491-4
[
10419448.001
]
[Cites]
Gynecol Oncol. 1999 Oct;75(1):91-8
[
10502432.001
]
[Cites]
Gynecol Oncol. 2004 Dec;95(3):437-48
[
15581944.001
]
[Cites]
CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
[
15661684.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3193-9
[
15833850.001
]
[Cites]
Cancer Res. 2005 Aug 1;65(15):6910-8
[
16061675.001
]
[Cites]
J Pathol. 1999 Nov;189(3):300-8
[
10547590.001
]
[Cites]
Gynecol Oncol. 2000 Jun;77(3):369-76
[
10831344.001
]
[Cites]
Int J Oncol. 2000 Oct;17(4):673-81
[
10995877.001
]
[Cites]
Cell. 2000 Oct 27;103(3):481-90
[
11081634.001
]
[Cites]
Am J Clin Pathol. 2001 Apr;115(4):517-24
[
11293899.001
]
(PMID = 16551853.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA109298; United States / NCI NIH HHS / CA / 1P50CA83639; United States / NCI NIH HHS / CA / R01 CA110793; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA11079301; United States / NCI NIH HHS / CA / CA10929801
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
[Other-IDs]
NLM/ NIHMS310734; NLM/ PMC3202606
34.
Navarro BG, Parada AC, Alvarez P, Leon A, Santana E, Bada A, Figueredo R, Iznaga-Escobar N, Perez R:
Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats.
Exp Toxicol Pathol
; 2005 Mar;56(4-5):313-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This receptor is over-expressed in the majority of
tumors
of
epithelial
origin, including glioblastomas.
188Rhenium (188Re) constitutes an ideal radionuclide for imagining and radioimmunotherapy, and its toxicity is known, nevertheless, it is unknown if 188Os, as 188Re's daughter, has any local or systemic toxicity effect when it is administered intracerebrally for treating intracranial
tumors
.
Hazardous Substances Data Bank.
OSMIUM, ELEMENTAL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15816360.001).
[ISSN]
0940-2993
[Journal-full-title]
Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
[ISO-abbreviation]
Exp. Toxicol. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Radioisotopes; 2E7M255OPY / Osmium; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
35.
Agoston AT, Liang CW, Richkind KE, Fletcher JA, Vargas SO:
Trisomy 18 is a consistent cytogenetic feature in pilomatricoma.
Mod Pathol
; 2010 Aug;23(8):1147-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Pilomatricoma, also known as 'calcifying
epithelioma
of Malherbe', is a common skin adnexal
tumor
that mimics hair growth.
This aberration was corroborated by interphase fluorescence in situ hybridization, using a chromosome 18 pericentromeric probe, in the basaloid
epithelial
component of 7 of 11 pilomatricomas, including the index case.
Trisomy 18 was present in a small subset of cells, suggesting a role in pilomatricoma progression, rather than in
tumor
initiation.
We conclude that trisomy 18 is a consistent feature in pilomatricoma, suggesting that genes carried on this chromosome, such as that for the antiapoptotic oncoprotein BCL2, may have a role in the growth and differentiation of this benign self-limited
tumor
.
[MeSH-major]
Chromosomes, Human, Pair 18. Hair Diseases / genetics. Pilomatrixoma / genetics. Skin
Neoplasms
/ genetics. Trisomy
Genetic Alliance.
consumer health - Trisomy 18
.
MedlinePlus Health Information.
consumer health - Hair Problems
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20495544.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
36.
Lim KT, Cosgrave N, Hill AD, Young LS:
Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.
Breast Cancer Res
; 2006;8(3):R33
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Increased Raf phosphorylation was also observed in primary human breast cultures derived from ER-positive and ER-negative breast
tumours
.
AT1 receptor was found to be expressed in the cell membrane of breast
tumour
epithelial
cells.
[MeSH-major]
Breast
Neoplasms
/ physiopathology. Receptor, Angiotensin, Type 1 / physiology. Receptors, Estrogen / physiology
[MeSH-minor]
Cell Proliferation. Cell Survival. Cyclic AMP / metabolism. Female. Humans. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation. RNA, Small Interfering. Signal Transduction.
Tumor
Cells, Cultured
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Mol Endocrinol. 2000 Oct;14(10):1649-60
[
11043579.001
]
[Cites]
Circ Res. 2000 Nov 24;87(11):E44-52
[
11090554.001
]
[Cites]
Endocrinology. 2000 Dec;141(12):4503-11
[
11108261.001
]
[Cites]
Mol Endocrinol. 2002 Jan;16(1):70-84
[
11773440.001
]
[Cites]
Mol Endocrinol. 2002 Jan;16(1):100-15
[
11773442.001
]
[Cites]
J Steroid Biochem Mol Biol. 2002 Feb;80(2):231-8
[
11897506.001
]
[Cites]
J Biol Chem. 2003 Jan 24;278(4):2701-12
[
12421825.001
]
[Cites]
J Cell Physiol. 2003 Aug;196(2):370-7
[
12811831.001
]
[Cites]
J Biol Chem. 2004 Jun 25;279(26):27008-16
[
15090535.001
]
[Cites]
Br J Cancer. 2004 Nov 1;91(9):1687-93
[
15477868.001
]
[Cites]
J Clin Endocrinol Metab. 1990 Aug;71(2):398-404
[
2166070.001
]
[Cites]
Endocrinology. 1992 Sep;131(3):1305-12
[
1505465.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21
[
8078914.001
]
[Cites]
Nature. 1995 May 18;375(6528):247-50
[
7746328.001
]
[Cites]
Hypertension. 1996 Mar;27(3 Pt 2):476-80
[
8613189.001
]
[Cites]
EMBO J. 1996 Mar 15;15(6):1292-300
[
8635462.001
]
[Cites]
Eur J Endocrinol. 1996 Sep;135(3):367-73
[
8890730.001
]
[Cites]
J Biol Chem. 1997 May 2;272(18):11902-7
[
9115251.001
]
[Cites]
Br J Cancer. 1997;75(9):1279-83
[
9155046.001
]
[Cites]
Biochem Biophys Res Commun. 1997 Jun 9;235(1):99-102
[
9196043.001
]
[Cites]
Endocrinology. 1997 Sep;138(9):4030-3
[
9275096.001
]
[Cites]
Mol Endocrinol. 1999 Feb;13(2):307-19
[
9973260.001
]
[Cites]
Endocrinology. 1999 Mar;140(3):1385-91
[
10067866.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4686-91
[
10200323.001
]
[Cites]
Biochem Biophys Res Commun. 1999 Sep 16;263(1):257-62
[
10486286.001
]
[Cites]
Mol Endocrinol. 2004 Dec;18(12):2854-65
[
15231873.001
]
[Cites]
Mol Endocrinol. 2005 Feb;19(2):277-89
[
15486047.001
]
[Cites]
Steroids. 2005 May-Jun;70(5-7):361-3
[
15862818.001
]
[Cites]
Mol Endocrinol. 2005 Aug;19(8):1951-9
[
15705661.001
]
[Cites]
J Cell Physiol. 2000 Jul;184(1):27-36
[
10825231.001
]
[Cites]
Mol Pharmacol. 2000 Sep;58(3):608-13
[
10953055.001
]
[Cites]
Circ Res. 2000 Oct 13;87(8):677-82
[
11029403.001
]
(PMID = 16805920.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Small Interfering; 0 / Receptor, Angiotensin, Type 1; 0 / Receptors, Estrogen; E0399OZS9N / Cyclic AMP; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
[Other-IDs]
NLM/ PMC1557727
37.
Horinouchi H, Asakura K, Kimura Y, Takeuchi K, Kawamura M, Watanabe M, Eguchi K, Kobayashi K:
[Prognosis of surgically treated thymic epithelial tumors].
Nihon Geka Gakkai Zasshi
; 2006 Nov;107(6):262-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Prognosis of surgically treated thymic
epithelial
tumors
].
This study was performed to clarify the prognosis of patients with surgically treated thymic
epithelial
tumors
.
Pathologic review was done according to the WHO classification of
tumors
of the thymus.
Patients characteristics were: 76 male and 55 fimale; average age 53 (range 20-80) years;
tumor
stage was stage I in 42, stage II in 43, stage III in 23, stage IVa in 15, stage IVb in 1, and thymic carcinoma (squamous cell carcinoma) in 7 based on Masaoka's staging.
The prognosis of patients with thymic
epithelial
tumors
after resection is thought to be determined by histologic classification and clinical invasiveness.
[MeSH-major]
Carcinoma / surgery. Thymus
Neoplasms
/ surgery
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged.
Neoplasm
Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. World Health Organization
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17147284.001).
[ISSN]
0301-4894
[Journal-full-title]
Nihon Geka Gakkai zasshi
[ISO-abbreviation]
Nihon Geka Gakkai Zasshi
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
38.
Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D:
Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.
J Histochem Cytochem
; 2010 Nov;58(11):1015-23
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of serum amyloid a in human ovarian
epithelial
tumors
: implication for a role in ovarian tumorigenesis.
Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian
tumors
has not been described.
Here, we investigated the expression of SAA in human benign and malignant ovarian
epithelial
tumors
.
Expression was increased gradually as
epithelial
cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
[MeSH-major]
Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian
Neoplasms
/ genetics. Ovarian
Neoplasms
/ pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line,
Tumor
. Female. Humans. Middle Aged.
Neoplasm
Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 1983 Nov;43(11):5379-89
[
6604576.001
]
[Cites]
Ann Intern Med. 1979 Sep;91(3):383-90
[
289303.001
]
[Cites]
Scand J Immunol. 1984 Mar;19(3):193-8
[
6200925.001
]
[Cites]
Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5
[
2039494.001
]
[Cites]
DNA Cell Biol. 1991 Nov;10(9):651-61
[
1755958.001
]
[Cites]
J Biol Chem. 1992 Feb 25;267(6):3862-7
[
1740433.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90
[
8159722.001
]
[Cites]
Genomics. 1994 Jan 15;19(2):228-35
[
8188253.001
]
[Cites]
J Exp Med. 1994 Jul 1;180(1):203-9
[
7516407.001
]
[Cites]
Am J Pathol. 1994 Sep;145(3):650-60
[
8080047.001
]
[Cites]
J Immunol. 1995 Aug 1;155(3):1184-90
[
7636186.001
]
[Cites]
Lab Invest. 1998 May;78(5):535-9
[
9605178.001
]
[Cites]
J Histochem Cytochem. 1998 Dec;46(12):1377-84
[
9815279.001
]
[Cites]
J Rheumatol. 1999 Apr;26(4):785-90
[
10229397.001
]
[Cites]
N Engl J Med. 2004 Dec 9;351(24):2519-29
[
15590954.001
]
[Cites]
Eur J Immunol. 2005 Mar;35(3):718-26
[
15724247.001
]
[Cites]
Biochem Biophys Res Commun. 2005 May 13;330(3):989-98
[
15809093.001
]
[Cites]
Proteomics. 2005 Sep;5(14):3790-7
[
16121334.001
]
[Cites]
Int J Oncol. 2005 Nov;27(5):1361-9
[
16211233.001
]
[Cites]
J Histochem Cytochem. 2006 Jan;54(1):63-73
[
16116035.001
]
[Cites]
Arthritis Rheum. 2006 Jan;54(1):105-14
[
16385502.001
]
[Cites]
Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21
[
16297528.001
]
[Cites]
J Immunol. 2006 Oct 15;177(8):5585-94
[
17015746.001
]
[Cites]
Biomed Environ Sci. 2007 Feb;20(1):33-40
[
17458139.001
]
[Cites]
J Clin Oncol. 2008 Feb 20;26(6):995-1005
[
18195328.001
]
[Cites]
Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73
[
18237545.001
]
[Cites]
FEBS Lett. 2008 Mar 5;582(5):579-85
[
18243142.001
]
[Cites]
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95
[
18028381.001
]
[Cites]
J Clin Oncol. 2009 May 1;27(13):2199-208
[
19307507.001
]
[Cites]
Br J Cancer. 2009 Jul 21;101(2):335-41
[
19536090.001
]
[Cites]
Cancer. 2010 Feb 15;116(4):843-51
[
20041483.001
]
[Cites]
J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88
[
20082099.001
]
[Cites]
Eur Urol. 2010 May;57(5):859-66
[
19747761.001
]
[Cites]
J Clin Pathol. 1986 Jul;39(7):794-7
[
3734116.001
]
[Cites]
Curr Opin Hematol. 2000 Jan;7(1):64-9
[
10608507.001
]
[Cites]
Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8
[
10679217.001
]
[Cites]
Int J Cancer. 2001 May 15;92(4):497-502
[
11304683.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1224-9
[
11830469.001
]
[Cites]
Am J Pathol. 2002 Apr;160(4):1223-8
[
11943707.001
]
[Cites]
J Histochem Cytochem. 1984 Mar;32(3):322-8
[
6363521.001
]
(PMID = 20713982.001).
[ISSN]
1551-5044
[Journal-full-title]
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
[ISO-abbreviation]
J. Histochem. Cytochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
[Other-IDs]
NLM/ PMC2958134
39.
Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A:
Feasibility of the sentinel node biopsy in anal cancer.
Q J Nucl Med Mol Imaging
; 2009 Feb;53(1):3-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
AIM: Anal cancer is a rare
neoplasm
.
RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular
epithelioma
associated with areas of Bowen's disease.
[MeSH-major]
Anus
Neoplasms
/ diagnosis. Sentinel Lymph Node Biopsy
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged.
Neoplasm
Staging. Recurrence
Genetic Alliance.
consumer health - Anal Cancer
.
MedlinePlus Health Information.
consumer health - Anal Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18337684.001).
[ISSN]
1824-4785
[Journal-full-title]
The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
[ISO-abbreviation]
Q J Nucl Med Mol Imaging
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Italy
40.
Xu J, Zhang S, You C, Wang X, Zhou Q:
Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma.
Surg Neurol
; 2006;66 Suppl 1:S30-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Craniopharyngioma is histologically a benign
epithelial
tumor
located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP
tumor
.
CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the
tumor
, which may be explained by the minimal blood circulation in the craniopharyngioma.
Adamantine
epithelioma
showed more tendency to recur than SP.
[MeSH-major]
Craniopharyngioma / blood supply. Craniopharyngioma / metabolism.
Neoplasm
Recurrence, Local / etiology. Pituitary
Neoplasms
/ blood supply. Pituitary
Neoplasms
/ metabolism. Vascular Endothelial Growth Factor A / metabolism
Genetic Alliance.
consumer health - Craniopharyngioma
.
MedlinePlus Health Information.
consumer health - Pituitary Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16904996.001).
[ISSN]
0090-3019
[Journal-full-title]
Surgical neurology
[ISO-abbreviation]
Surg Neurol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Vascular Endothelial Growth Factor A
41.
Yang J, Moses MA:
Lipocalin 2: a multifaceted modulator of human cancer.
Cell Cycle
; 2009 Aug;8(15):2347-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Lcn2 has been shown to induce the
epithelial
to mesenchymal transition (EMT) in breast cancer cells and to promote breast
tumor
invasion.
The potential roles of Lcn2 in
epithelial
tumors
as well as leukemia are also reviewed and discussed here.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
IRON, ELEMENTAL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cell. 2005 Dec 29;123(7):1293-305
[
16377569.001
]
[Cites]
Biochem J. 2005 Oct 15;391(Pt 2):441-8
[
16060857.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
[
16493418.001
]
[Cites]
Int J Cancer. 2006 May 15;118(10):2490-7
[
16381001.001
]
[Cites]
Mol Cell Proteomics. 2006 Aug;5(8):1471-83
[
16733264.001
]
[Cites]
Int J Cancer. 2007 Jun 1;120(11):2426-34
[
17294443.001
]
[Cites]
J Clin Pathol. 2007 May;60(5):555-61
[
17412867.001
]
[Cites]
Breast Cancer Res Treat. 2008 Apr;108(3):389-97
[
17554627.001
]
[Cites]
J Clin Invest. 2008 Apr;118(4):1468-78
[
18317594.001
]
[Cites]
J Proteome Res. 2008 Apr;7(4):1481-9
[
18311905.001
]
[Cites]
Br J Cancer. 2008 May 6;98(9):1540-7
[
18392050.001
]
[Cites]
Leuk Lymphoma. 2008 May;49(5):984-8
[
18464118.001
]
[Cites]
Cancer Res. 2008 Aug 1;68(15):6100-8
[
18676832.001
]
[Cites]
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14058-63
[
18768801.001
]
[Cites]
Oncogene. 2008 Oct 16;27(47):6110-9
[
18663364.001
]
[Cites]
Clin Cancer Res. 2008 Oct 15;14(20):6440-8
[
18927283.001
]
[Cites]
Int J Cancer. 2008 Dec 15;123(12):2856-64
[
18798264.001
]
[Cites]
J Exp Clin Cancer Res. 2008;27:83
[
19077278.001
]
[Cites]
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8
[
19237579.001
]
[Cites]
J Immunol. 2009 Apr 15;182(8):4947-56
[
19342674.001
]
[Cites]
EMBO J. 2009 Apr 8;28(7):866-76
[
19229297.001
]
[Cites]
J Histochem Cytochem. 2009 May;57(5):513-21
[
19188485.001
]
[Cites]
PLoS Genet. 2009 Apr;5(4):e1000460
[
19390610.001
]
[Cites]
Lab Invest. 2009 May;89(5):531-48
[
19308044.001
]
[Cites]
Biochim Biophys Acta. 2000 Oct 18;1482(1-2):9-24
[
11058743.001
]
[Cites]
Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307
[
11058770.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9265-70
[
11459932.001
]
[Cites]
Science. 2001 Aug 3;293(5531):829-34
[
11486081.001
]
[Cites]
Cancer Res. 2001 Aug 15;61(16):5979-84
[
11507038.001
]
[Cites]
J Biol Chem. 2001 Oct 5;276(40):37258-65
[
11486009.001
]
[Cites]
Cancer Res. 2001 Nov 1;61(21):7792-7
[
11691794.001
]
[Cites]
JAMA. 2002 Apr 17;287(15):1972-81
[
11960540.001
]
[Cites]
Cancer Res. 2002 May 15;62(10):2890-6
[
12019169.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4352-63
[
12154040.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1033-43
[
12453412.001
]
[Cites]
Mol Cell. 2002 Nov;10(5):1045-56
[
12453413.001
]
[Cites]
Cell. 2003 Apr 18;113(2):207-19
[
12705869.001
]
[Cites]
Int J Oncol. 2003 Sep;23(3):681-91
[
12888904.001
]
[Cites]
Cancer Res. 2003 Dec 15;63(24):8614-22
[
14695172.001
]
[Cites]
Int J Cancer. 2004 Oct 20;112(1):14-25
[
15305371.001
]
[Cites]
Int J Cancer. 2004 Oct 20;112(1):100-12
[
15305381.001
]
[Cites]
J Proteome Res. 2004 Sep-Oct;3(5):1042-55
[
15473694.001
]
[Cites]
FEBS Lett. 1992 Dec 21;314(3):386-8
[
1281792.001
]
[Cites]
J Biol Chem. 1993 May 15;268(14):10425-32
[
7683678.001
]
[Cites]
Gut. 1996 Mar;38(3):414-20
[
8675096.001
]
[Cites]
Biochem J. 1996 Aug 15;318 ( Pt 1):1-14
[
8761444.001
]
[Cites]
J Dent Res. 1996 Aug;75(8):1553-63
[
8906123.001
]
[Cites]
Genomics. 1997 Oct 1;45(1):17-23
[
9339356.001
]
[Cites]
Cancer Lett. 1998 Jan 9;122(1-2):209-14
[
9464512.001
]
[Cites]
Int J Cancer. 1998 Dec 18;79(6):565-72
[
9842963.001
]
[Cites]
Histochem J. 1999 Jul;31(7):433-41
[
10475571.001
]
[Cites]
Nature. 2004 Dec 16;432(7019):917-21
[
15531878.001
]
[Cites]
FEBS Lett. 2005 Jan 31;579(3):773-7
[
15670845.001
]
[Cites]
J Clin Invest. 2005 Mar;115(3):610-21
[
15711640.001
]
[Cites]
J Biol Chem. 2005 Apr 8;280(14):13641-7
[
15691834.001
]
[Cites]
Oncogene. 2005 May 5;24(20):3246-56
[
15735695.001
]
[Cites]
Clin Cancer Res. 2005 Aug 1;11(15):5390-5
[
16061852.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1834-9
[
16446425.001
]
(PMID = 19571677.001).
[ISSN]
1551-4005
[Journal-full-title]
Cell cycle (Georgetown, Tex.)
[ISO-abbreviation]
Cell Cycle
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA118764-05; United States / NCI NIH HHS / CA / R01 CA118764; United States / NCI NIH HHS / CA / R01 CA118764-05
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Acute-Phase Proteins; 0 / Estrogen Receptor alpha; 0 / LCN2 protein, human; 0 / Ligands; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; E1UOL152H7 / Iron; EC 3.4.24.35 / Matrix Metalloproteinase 9
[Other-IDs]
NLM/ NIHMS278018; NLM/ PMC3381736
42.
Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI:
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Breast Cancer Res
; 2007;9(4):R50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In clinical tissue all samples demonstrated cytoplasmic
tumour
epithelial
HRGbeta1 protein staining, with expression correlating with EGFR positivity and activation of both AKT and ERK1/2.
This may have implications for the effectiveness of anti-EGFR therapies in breast cancer as HRGbeta1 is enriched in many EGFR-positive breast
tumours
.
[MeSH-major]
Antineoplastic Agents, Hormonal / pharmacology. Breast
Neoplasms
/ drug therapy. Drug Resistance,
Neoplasm
. Neuregulin-1 / pharmacology. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. Tamoxifen / pharmacology
[MeSH-minor]
Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Blotting, Western. Cell Line,
Tumor
/ drug effects. Cell Line,
Tumor
/ metabolism. Cell Proliferation. Dimerization. Female. Humans. Immunoprecipitation. Mitogen-Activated Protein Kinases / metabolism.
Neoplasm
Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / metabolism. Signal Transduction. Trastuzumab
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
TAMOXIFEN
.
Hazardous Substances Data Bank.
Trastuzumab
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2001 Jul 20;95(4):247-54
[
11400118.001
]
[Cites]
Semin Oncol. 2006 Aug;33(4):369-85
[
16890793.001
]
[Cites]
Cancer Res. 2001 Dec 15;61(24):8887-95
[
11751413.001
]
[Cites]
Cancer Res. 2002 Jan 1;62(1):200-7
[
11782378.001
]
[Cites]
Ann Oncol. 2002 Jan;13(1):65-72
[
11863114.001
]
[Cites]
Cancer Res. 2002 Jun 1;62(11):3151-8
[
12036928.001
]
[Cites]
Oncologist. 2002;7 Suppl 4:2-8
[
12202782.001
]
[Cites]
Cancer Res. 2002 Oct 15;62(20):5749-54
[
12384534.001
]
[Cites]
Mol Cancer Res. 2003 Jan;1(3):165-75
[
12556556.001
]
[Cites]
Endocrinology. 2003 Mar;144(3):1032-44
[
12586780.001
]
[Cites]
Clin Cancer Res. 2003 Apr;9(4):1274-83
[
12684395.001
]
[Cites]
Oncogene. 2003 May 8;22(18):2812-22
[
12743604.001
]
[Cites]
Clin Cancer Res. 2003 Oct 1;9(12):4340-6
[
14555504.001
]
[Cites]
J Pathol. 2004 Jun;203(2):672-80
[
15141382.001
]
[Cites]
Breast Cancer Res Treat. 2004 Sep;87(2):167-80
[
15377841.001
]
[Cites]
Clin Exp Metastasis. 2004;21(3):201-12
[
15387370.001
]
[Cites]
Mol Cell Biol. 1994 Jun;14(6):3550-8
[
7515147.001
]
[Cites]
Breast Cancer Res Treat. 1994 Jan;29(1):117-25
[
7912565.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6
[
8058768.001
]
[Cites]
Int J Cancer. 1994 Dec 1;59(5):619-28
[
7960234.001
]
[Cites]
Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232
[
7612182.001
]
[Cites]
Cancer Res. 1996 Mar 15;56(6):1457-65
[
8640840.001
]
[Cites]
Mol Cell Biol. 1996 Oct;16(10):5276-87
[
8816440.001
]
[Cites]
EMBO J. 1997 Apr 1;16(7):1647-55
[
9130710.001
]
[Cites]
Breast Cancer Res Treat. 1997 Aug;45(1):75-80
[
9285119.001
]
[Cites]
Biochem J. 1998 Aug 1;333 ( Pt 3):757-63
[
9677338.001
]
[Cites]
J Biol Chem. 1998 Oct 23;273(43):28238-46
[
9774445.001
]
[Cites]
Oncogene. 1998 Oct 15;17(15):1949-57
[
9788438.001
]
[Cites]
Cancer Res. 1999 Apr 1;59(7):1620-5
[
10197638.001
]
[Cites]
J Cell Sci. 1999 Sep;112 Pt 18:3081-90
[
10462524.001
]
[Cites]
Endocr Relat Cancer. 2004 Dec;11(4):793-814
[
15613453.001
]
[Cites]
Clin Cancer Res. 2005 Jan 1;11(1):397-405
[
15671571.001
]
[Cites]
J Clin Oncol. 2005 Apr 10;23(11):2445-59
[
15753456.001
]
[Cites]
Clin Cancer Res. 1999 Oct;5(10):2877-83
[
10537356.001
]
[Cites]
Oncogene. 1999 Oct 28;18(44):6050-62
[
10557094.001
]
[Cites]
EMBO J. 2000 Jul 3;19(13):3159-67
[
10880430.001
]
[Cites]
Int J Cancer. 2000 Aug 15;87(4):487-98
[
10918187.001
]
[Cites]
Int J Oncol. 2000 Oct;17(4):629-41
[
10995872.001
]
[Cites]
Cell. 2000 Oct 13;103(2):211-25
[
11057895.001
]
[Cites]
Breast Cancer Res. 2005;7(4):R570-9
[
15987464.001
]
[Cites]
Clin Exp Metastasis. 2004;21(8):665-84
[
16035612.001
]
[Cites]
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S173-82
[
16113094.001
]
[Cites]
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111
[
16113104.001
]
[Cites]
Endocrinology. 2005 Nov;146(11):4609-18
[
16037379.001
]
[Cites]
Cancer Res. 2006 Feb 1;66(3):1418-26
[
16452197.001
]
[Cites]
Cancer Res. 2006 Feb 1;66(3):1640-7
[
16452223.001
]
[Cites]
Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45
[
16531062.001
]
[Cites]
Future Oncol. 2005 Apr;1(2):221-34
[
16555994.001
]
[Cites]
Future Oncol. 2005 Aug;1(4):461-6
[
16556022.001
]
[Cites]
Breast Cancer Res Treat. 2006 Mar;96(2):131-46
[
16261397.001
]
[Cites]
Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15
[
11597399.001
]
(PMID = 17686159.001).
[ISSN]
1465-542X
[Journal-full-title]
Breast cancer research : BCR
[ISO-abbreviation]
Breast Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Hormonal; 0 / Neuregulin-1; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 094ZI81Y45 / Tamoxifen; 155646-83-6 / heregulin beta1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; P188ANX8CK / Trastuzumab; S65743JHBS / gefitinib
[Other-IDs]
NLM/ PMC2206726
43.
Newman S, Edwards PA:
High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers.
Genome Med
; 2010;2(3):19
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
High-throughput analysis of chromosome translocations and other genome rearrangements in
epithelial
cancers.
Genes that are broken or fused by structural changes to the genome are an important class of mutation in the leukemias and sarcomas but have been largely overlooked in the common
epithelial
cancers.
This reveals more clearly than before the extent to which many cancer genomes are rearranged and how much these rearrangements contribute to the mutational burden of
epithelial
tumors
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Science. 2005 Oct 28;310(5748):644-8
[
16254181.001
]
[Cites]
Nature. 2007 Mar 8;446(7132):153-8
[
17344846.001
]
[Cites]
Nat Rev Cancer. 2007 Apr;7(4):233-45
[
17361217.001
]
[Cites]
Nature. 2007 Aug 2;448(7153):561-6
[
17625570.001
]
[Cites]
Science. 2007 Sep 14;317(5844):1500
[
17872428.001
]
[Cites]
Science. 2007 Nov 16;318(5853):1108-13
[
17932254.001
]
[Cites]
Nature. 2009 Dec 24;462(7276):1005-10
[
20033038.001
]
[Cites]
Nat Genet. 2008 Jun;40(6):722-9
[
18438408.001
]
[Cites]
Cancer Res. 2008 Nov 1;68(21):8673-7
[
18974108.001
]
[Cites]
Genome Res. 2009 Feb;19(2):167-77
[
19056696.001
]
[Cites]
Nature. 2009 Apr 9;458(7239):719-24
[
19360079.001
]
[Cites]
J Pathol. 2010 Jan;220(2):244-54
[
19921709.001
]
[Cites]
Oncogene. 2008 May 22;27(23):3345-59
[
18084325.001
]
(PMID = 20236477.001).
[ISSN]
1756-994X
[Journal-full-title]
Genome medicine
[ISO-abbreviation]
Genome Med
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Other-IDs]
NLM/ PMC2873797
44.
Prensner JR, Chinnaiyan AM:
Oncogenic gene fusions in epithelial carcinomas.
Curr Opin Genet Dev
; 2009 Feb;19(1):82-91
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Oncogenic gene fusions in
epithelial
carcinomas.
New discoveries regarding recurrent chromosomal aberrations in
epithelial
tumors
have challenged the view that gene fusions play a minor role in these cancers.
This work has generated new insights into the molecular subtypes of
tumors
and highlighted important advances in bioinformatics, sequencing, and microarray technology as tools for gene fusion discovery.
Nevertheless, the majority of chromosomal abnormalities in
epithelial
cancers remain uncharacterized, underscoring the limitations of our knowledge of carcinogenesis and the requirement for further research.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
SciCrunch.
KEGG: Data: Disease Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cytogenet Genome Res. 2007;118(2-4):157-65
[
18000366.001
]
[Cites]
Cell. 2007 Dec 14;131(6):1190-203
[
18083107.001
]
[Cites]
Oncogene. 2008 Jan 10;27(3):253-63
[
17637754.001
]
[Cites]
Neoplasia. 2008 Mar;10(3):298-302
[
18320074.001
]
[Cites]
PLoS Comput Biol. 2008 Apr;4(4):e1000051
[
18404202.001
]
[Cites]
Mod Pathol. 2008 May;21 Suppl 2:S37-43
[
18437172.001
]
[Cites]
Nat Genet. 2008 Jun;40(6):685-6
[
18509307.001
]
[Cites]
Clin Cancer Res. 2008 Jun 1;14(11):3380-5
[
18519767.001
]
[Cites]
Clin Cancer Res. 2008 Jun 1;14(11):3395-400
[
18519769.001
]
[Cites]
J Natl Cancer Inst. 2008 Jun 4;100(11):815-25
[
18505969.001
]
[Cites]
Cancer Res. 2008 Jul 1;68(13):4971-6
[
18593892.001
]
[Cites]
Clin Cancer Res. 2008 Jul 1;14(13):4275-83
[
18594010.001
]
[Cites]
Genome Res. 2008 Jul;18(7):1143-9
[
18326688.001
]
[Cites]
Science. 2008 Aug 15;321(5891):956-60
[
18599741.001
]
[Cites]
Mod Pathol. 2008 Dec;21(12):1451-60
[
18500259.001
]
[Cites]
Neoplasia. 2008 Feb;10(2):177-88
[
18283340.001
]
[Cites]
Nat Rev Cancer. 2004 Mar;4(3):177-83
[
14993899.001
]
[Cites]
Nat Genet. 2004 Apr;36(4):331-4
[
15054488.001
]
[Cites]
Oncogene. 2004 Apr 29;23(20):3634-41
[
15077183.001
]
[Cites]
Cancer. 2004 Jun 1;100(11):2362-6
[
15160339.001
]
[Cites]
Br J Cancer. 2004 Aug 16;91(4):732-8
[
15238980.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13257-61
[
15326299.001
]
[Cites]
Science. 1990 Feb 16;247(4944):824-30
[
2406902.001
]
[Cites]
Science. 1990 Mar 2;247(4946):1079-82
[
2408149.001
]
[Cites]
Science. 1991 Nov 29;254(5036):1371-4
[
1720570.001
]
[Cites]
Nat Genet. 1997 Feb;15(2):170-4
[
9020842.001
]
[Cites]
Clin Cancer Res. 1998 Jan;4(1):223-8
[
9516975.001
]
[Cites]
Mod Pathol. 2008 Feb;21(2):67-75
[
18065961.001
]
[Cites]
Genes Chromosomes Cancer. 2003 May;37(1):58-71
[
12661006.001
]
[Cites]
Oncogene. 2003 Jul 17;22(29):4578-80
[
12881714.001
]
[Cites]
Genes Chromosomes Cancer. 1998 Oct;23(2):81-99
[
9739011.001
]
[Cites]
J Natl Cancer Inst. 1960 Jul;25:85-109
[
14427847.001
]
[Cites]
J Clin Endocrinol Metab. 2005 Jan;90(1):463-8
[
15483076.001
]
[Cites]
Semin Cancer Biol. 2005 Jun;15(3):224-35
[
15826837.001
]
[Cites]
Clin Lab Med. 2005 Jun;25(2):363-78
[
15848741.001
]
[Cites]
Genes Chromosomes Cancer. 2005 Aug;43(4):350-66
[
15880352.001
]
[Cites]
Science. 2005 Oct 28;310(5748):644-8
[
16254181.001
]
[Cites]
Endocrinology. 2006 Jan;147(1):367-76
[
16179407.001
]
[Cites]
J Clin Endocrinol Metab. 2006 Jan;91(1):213-20
[
16219715.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Science. 2000 Aug 25;289(5483):1357-60
[
10958784.001
]
[Cites]
N Engl J Med. 2001 Apr 5;344(14):1031-7
[
11287972.001
]
[Cites]
Nature. 2001 May 17;411(6835):355-65
[
11357143.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13808-13
[
11717438.001
]
[Cites]
Am J Pathol. 2001 Dec;159(6):1987-92
[
11733348.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82
[
11930005.001
]
[Cites]
Cancer Cell. 2002 Nov;2(5):367-76
[
12450792.001
]
[Cites]
Cancer Res. 2003 Jan 15;63(2):304-7
[
12543779.001
]
[Cites]
Nat Genet. 2003 Feb;33(2):208-13
[
12539049.001
]
[Cites]
Genes Chromosomes Cancer. 2006 Jul;45(7):717-9
[
16575875.001
]
[Cites]
Neoplasia. 2006 Jun;8(6):465-9
[
16820092.001
]
[Cites]
Cancer Res. 2006 Sep 1;66(17):8337-41
[
16951139.001
]
[Cites]
Nat Immunol. 2006 Oct;7(10):1082-91
[
16936731.001
]
[Cites]
Science. 2006 Sep 29;313(5795):1929-35
[
17008526.001
]
[Cites]
Neoplasia. 2006 Oct;8(10):826-32
[
17032499.001
]
[Cites]
Oncogene. 2007 Jan 11;26(2):277-83
[
16832349.001
]
[Cites]
Cancer Res. 2007 Feb 1;67(3):919-29
[
17283122.001
]
[Cites]
Neoplasia. 2007 Feb;9(2):166-80
[
17356713.001
]
[Cites]
Am J Surg Pathol. 2007 Jun;31(6):882-8
[
17527075.001
]
[Cites]
Neoplasia. 2007 May;9(5):443-54
[
17534450.001
]
[Cites]
Oncogene. 2007 Jul 5;26(31):4596-9
[
17237811.001
]
[Cites]
Nature. 2007 Aug 2;448(7153):561-6
[
17625570.001
]
[Cites]
Nature. 2007 Aug 2;448(7153):595-9
[
17671502.001
]
[Cites]
Clin Cancer Res. 2007 Sep 1;13(17):5103-8
[
17785564.001
]
[Cites]
Cancer Res. 2007 Sep 1;67(17):7991-5
[
17804708.001
]
[Cites]
J Cell Biochem. 2007 Oct 1;102(2):320-31
[
17722107.001
]
[Cites]
J Clin Pathol. 2007 Nov;60(11):1238-43
[
17259299.001
]
(PMID = 19233641.001).
[ISSN]
1879-0380
[Journal-full-title]
Current opinion in genetics & development
[ISO-abbreviation]
Curr. Opin. Genet. Dev.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / R01 CA132874; United States / NCI NIH HHS / CA / CA132874-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / R01 CA132874-01A1; United States / NCI NIH HHS / CA / CA069568-110020; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Oncogene Proteins, Fusion
[Number-of-references]
69
[Other-IDs]
NLM/ NIHMS102222; NLM/ PMC2676581
45.
Mays MC:
Basaloid epithelial tumors of dogs and cats.
Vet Clin Pathol
; 2010 Jun;39(2):133; author reply 133-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basaloid
epithelial
tumors
of dogs and cats.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Vet Clin Pathol. 2010 Mar;39(1):96-8
[
19645743.001
]
(PMID = 20624263.001).
[ISSN]
1939-165X
[Journal-full-title]
Veterinary clinical pathology
[ISO-abbreviation]
Vet Clin Pathol
[Language]
ENG
[Publication-type]
Comment; Letter
[Publication-country]
United States
46.
Zhu Y, Nilsson M, Sundfeldt K:
Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro.
Endocrinology
; 2010 Nov;151(11):5497-505
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of
epithelial
to mesenchymal transition (EMT) in vitro.
Ovarian surface epithelium (OSE) is the most conceivable cell origin of
epithelial
ovarian carcinomas.
Unlike many other
epithelial
tumors
, the precancerous lesion acquires expression of
epithelial
markers, e.g.
E-cadherin and claudins, suggesting that OSE cells undergo mesenchymal to
epithelial
transition (MET) during transformation.
Recent findings indicate that TGF-β1, a prototypic stimulus of
epithelial
to mesenchymal transition (EMT), i.e. reverse to MET, is produced at significant amounts in the intact ovary.
In the present study, we therefore investigated whether TGF-β1 changes the OSE phenotype accordingly, focusing on
epithelial
junction proteins and transcriptional EMT regulators quantified by real-time RT-PCR and Western blotting in cultured normal human OSE.
Early OSE passages were found to paradoxically express
de
novo E-cadherin and also establish tight junctions exhibiting claudin-1 (but not claudin-3 and -4) and occludin.
Stimulation with TGF-β1 (100 ng/ml) for 3-5 d down-regulated all these
epithelial
markers including Crumbs3 and also prevented the formation of an
epithelial
barrier This was accompanied by sustained expression of Snail and N-cadherin and transient expression of Slug, whereas Zeb1 (zinc finger E-box binding homeobox 1) and Twist mRNA levels were not significantly changed.
In conclusion, TGF-β1 enforces the mesenchymal phenotype of OSE cells in vitro by an EMT-like process, leading to an altered molecular composition of the
epithelial
junction complex that partly coincides with the expression pattern of the native OSE.
This suggests a potential role of TGF-β1-induced EMT in OSE under physiological conditions and possibly also in
epithelial
ovarian tumorigenesis.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Endocrinology. 2010 Nov;151(11):5092-4
[
20962057.001
]
(PMID = 20844000.001).
[ISSN]
1945-7170
[Journal-full-title]
Endocrinology
[ISO-abbreviation]
Endocrinology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / CLDN1 protein, human; 0 / CRB3 protein, human; 0 / Cadherins; 0 / Claudin-1; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / OCLN protein, human; 0 / Occludin; 0 / Transforming Growth Factor beta1
47.
Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G:
Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
Clin Cancer Res
; 2008 Nov 15;14(22):7430-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic significance of
epithelial
-mesenchymal and mesenchymal-
epithelial
transition protein expression in non-small cell lung cancer.
PURPOSE: In carcinomas, invasive
tumor
growth is accompanied by desmoplastic stroma reaction and facilitated by
epithelial
-mesenchymal transition (EMT) of cancer cells.
We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-
epithelial
transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
EXPERIMENTAL DESIGN:
Tumor
of 533 patients with surgically resected NSCLC was used for analysis of stromal and
epithelial
protein expression by immunohistochemistry (EMT-MET proteins) and Elastica van Gieson histochemical staining (collagen and elastin).
High expression of periostin in either stroma or
tumor
epithelia, independently scored by two pathologists, correlated with male gender, higher stage, higher pT category, and larger
tumor
size, and in only stroma with
tumor
relapse.
High expression of versican in either stroma or epithelia as well as of stromal collagen had fewer but concordant associations with advanced
tumor
and periostin, respectively.
CONCLUSIONS: Because up-regulation is frequently observed in the stromal and
epithelial
tumor
compartment, EMT-MET indicator proteins may be integrated in progression models of NSCLC.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung
Neoplasms
/ metabolism. Vimentin / biosynthesis
[MeSH-minor]
Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis.
Epithelial
Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis
Genetic Alliance.
consumer health - Lung Cancer
.
Genetic Alliance.
consumer health - Non-small cell lung cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19010860.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
48.
Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y:
Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma.
Clin Cancer Res
; 2005 Apr 1;11(7):2597-605
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The expression of fascin in
epithelial neoplasms
has been described only recently, and the role of fascin in esophageal squamous cell carcinoma (ESCC) is still unknown.
RESULTS: In immunohistochemical study, the intensity of fascin expression was usually increased in the
tumor
compared with that in normal epithelium.
The fascin immunoreactive rate was associated with extent of the
tumor
(P = 0.002) and lymph node metastasis (P = 0.003).
[MeSH-major]
Carcinoma, Squamous Cell / pathology. Carrier Proteins / genetics. Esophageal
Neoplasms
/ pathology. Microfilament Proteins / genetics
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line,
Tumor
. Cell Movement. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Transfection
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15814639.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 146808-54-0 / fascin
49.
Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG:
Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis.
J Immunol
; 2005 Jan 1;174(1):41-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, CD154 treatment of carcinoma cells expressing proteasome-dependent but TAP-independent Ags from the EBV-encoded BRLF1 and BMLF1 failed to increase
tumor
cell lysis by specific CTLs.
Taken together, these observations demonstrate the functional expression of CD40 in
epithelial
tumors
of the cervix and support the clinical exploitation of the CD40 pathway for the treatment of cervical cancer through its multiple effects on
tumor
cell growth, apoptosis, and immune recognition.
[MeSH-major]
Antigens, CD40 / metabolism. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. T-Lymphocytes, Cytotoxic / immunology. Uterine Cervical
Neoplasms
/ immunology. Uterine Cervical
Neoplasms
/ metabolism
[MeSH-minor]
Antigen Presentation / drug effects. Antigen Presentation / immunology. CD40 Ligand / metabolism. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial
Neoplasia
/ immunology. Cervical Intraepithelial
Neoplasia
/ metabolism. Female. Flow Cytometry. HeLa Cells. Humans. Immunoblotting. Immunohistochemistry. Mitogen-Activated Protein Kinase Kinases / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. NF-kappa B / drug effects. NF-kappa B / metabolism. Papillomavirus Infections. Proteasome Endopeptidase Complex / drug effects. Proteasome Endopeptidase Complex / immunology. Signal Transduction / drug effects. Signal Transduction / immunology
MedlinePlus Health Information.
consumer health - Cervical Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15611226.001).
[ISSN]
0022-1767
[Journal-full-title]
Journal of immunology (Baltimore, Md. : 1950)
[ISO-abbreviation]
J. Immunol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD40; 0 / NF-kappa B; 147205-72-9 / CD40 Ligand; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
50.
Tapia B, Ahrens W, Kenney B, Touloukian R, Reyes-Múgica M:
Acinar cell carcinoma versus solid pseudopapillary tumor of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature.
Pediatr Dev Pathol
; 2008 Sep-Oct;11(5):384-90
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Acinar cell carcinoma versus solid pseudopapillary
tumor
of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature.
Primary
epithelial
tumors
of the pancreas are extremely uncommon in children, and among these, acinar cell carcinoma (ACC) is the most rare.
Despite its rarity, ACC should be kept in the differential diagnosis of pediatric pancreatic exocrine
tumors
.
We also provide a comparison with an example of solid pseudopapillary
tumor
, another relatively infrequent
epithelial
tumor
of the pancreas in the young.
We review the relevant literature addressing the clinical and pathologic features of ACC and its distinction from other pancreatic
neoplasms
.
[MeSH-major]
Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Pancreatic Cyst / pathology. Pancreatic
Neoplasms
/ diagnosis. Pancreatic
Neoplasms
/ pathology
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19006424.001).
[ISSN]
1093-5266
[Journal-full-title]
Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
[ISO-abbreviation]
Pediatr. Dev. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Comparative Study; Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
[Number-of-references]
37
51.
Motokura T, Nakamura Y, Sato H:
Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
BMC Cancer
; 2007;7:217
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Aberrant overexpression of an
epithelial
marker, 14-3-3sigma, in a subset of hematological malignancies.
BACKGROUND: 14-3-3sigma is a p53-mediated cell-cycle inhibitor in
epithelial
cells.
The expression of 14-3-3sigma is frequently altered in cancers of
epithelial
origin associated with altered DNA methylation.
Since its involvement in a non-
epithelial
tumor
is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies.
In contrast to
epithelial
tumors
, methylation status of the 14-3-3sigma gene was not associated with expression in hematological malignancies.
The expression levels of 14-3-3sigma, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with
tumor
growth.
CONCLUSION: 14-3-3sigma, an
epithelial
cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies.
This is the first report of aberrant 14-3-3sigma expression in non-
epithelial
tumors
in vivo.
Since the significance of 14-3-3sigma overexpression is unknown even in
epithelial
tumors
such as pancreatic cancers, further analysis of regulation and function of the 14-3-3sigma gene in non-
epithelial
as well as
epithelial
tumors
is warranted.
[MeSH-major]
Biomarkers,
Tumor
/ biosynthesis. Exonucleases / biosynthesis. Hematologic
Neoplasms
/ genetics.
Neoplasm
Proteins / biosynthesis
[MeSH-minor]
14-3-3 Proteins. ADP-Ribosylation Factors / genetics. Base Sequence. Blotting, Western. Cell Cycle. DNA Methylation. Exoribonucleases. Gene Expression Regulation, Neoplastic / genetics. Genes, p16. Humans. Polymorphism, Single-Stranded Conformational / genetics. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction.
Tumor
Cells, Cultured.
Tumor
Suppressor Protein p53 / genetics. Up-Regulation
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Leukemia. 1999 Nov;13(11):1760-9
[
10557050.001
]
[Cites]
Neurosci Res. 2006 Sep;56(1):61-72
[
16797759.001
]
[Cites]
J Cell Biol. 2000 May 29;149(5):1117-30
[
10831615.001
]
[Cites]
Oncogene. 2000 Nov 2;19(46):5298-302
[
11077447.001
]
[Cites]
Oncogene. 2001 Jun 7;20(26):3348-53
[
11423985.001
]
[Cites]
J Biol Chem. 2001 Nov 30;276(48):45201-6
[
11574543.001
]
[Cites]
Blood. 2002 Feb 15;99(4):1411-8
[
11830494.001
]
[Cites]
Cancer Res. 2002 Apr 1;62(7):2072-6
[
11929827.001
]
[Cites]
Oncogene. 2002 Apr 4;21(15):2418-24
[
11948426.001
]
[Cites]
Nature. 2002 Jun 20;417(6891):871-5
[
12075357.001
]
[Cites]
Oncogene. 2002 May 2;21(19):3043-9
[
12082535.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):165-9
[
12582028.001
]
[Cites]
Am J Pathol. 2003 Apr;162(4):1151-62
[
12651607.001
]
[Cites]
Cancer Lett. 2003 Oct 28;200(2):161-6
[
14568170.001
]
[Cites]
Nat Rev Cancer. 2003 Dec;3(12):931-43
[
14737123.001
]
[Cites]
Biochem J. 2004 Jul 15;381(Pt 2):329-42
[
15167810.001
]
[Cites]
Carcinogenesis. 2004 Sep;25(9):1575-85
[
15073049.001
]
[Cites]
Anal Biochem. 1988 Apr;170(1):203-8
[
3389511.001
]
[Cites]
Cell Growth Differ. 1992 Aug;3(8):507-13
[
1390337.001
]
[Cites]
Lab Invest. 1993 Mar;68(3):361-6
[
8450652.001
]
[Cites]
Cell. 1995 Dec 15;83(6):993-1000
[
8521522.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
[
8790415.001
]
[Cites]
Blood. 1997 Feb 1;89(3):965-74
[
9028328.001
]
[Cites]
Cell. 1997 Nov 28;91(5):649-59
[
9393858.001
]
[Cites]
Leukemia. 1998 Jun;12(6):845-59
[
9639410.001
]
[Cites]
Leuk Res. 1998 May;22(5):413-20
[
9652727.001
]
[Cites]
Mol Cell. 1997 Dec;1(1):3-11
[
9659898.001
]
[Cites]
Nature. 1999 Oct 7;401(6753):616-20
[
10524633.001
]
[Cites]
Amino Acids. 2005 Mar;28(2):199-205
[
15723242.001
]
[Cites]
Pathol Int. 2005 Nov;55(11):707-15
[
16271083.001
]
[Cites]
Int J Cancer. 2006 May 15;118(10):2448-54
[
16353156.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3248-55
[
16540677.001
]
[Cites]
Cancer Lett. 2006 May 8;236(1):105-14
[
15979784.001
]
[Cites]
Semin Cancer Biol. 2006 Jun;16(3):162-72
[
16678438.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54
[
10811911.001
]
(PMID = 18036248.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 3.6.5.2 / ADP-Ribosylation Factors
[Other-IDs]
NLM/ PMC2222637
52.
Mega S, Oguri M, Kawasaki R, Hazama K, Iwai K, Kondo S:
Large-cell neuroendocrine carcinoma in the thymus.
Gen Thorac Cardiovasc Surg
; 2008 Nov;56(11):566-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Large-cell neuroendocrine carcinoma in the thymus is a rare cancer that is more aggressive and leads to a poorer prognosis than other thymic
epithelial
tumors
.
[MeSH-major]
Carcinoma, Neuroendocrine. Thymus
Neoplasms
[MeSH-minor]
Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging.
Neoplasm
Recurrence, Local.
Neoplasm
Staging. Radiotherapy Dosage. Thymectomy. Thymus Gland / pathology. Time Factors. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Jpn J Thorac Cardiovasc Surg. 2006 Jun;54(6):256-9
[
16813109.001
]
[Cites]
Semin Diagn Pathol. 1991 Feb;8(1):35-51
[
1646476.001
]
[Cites]
Chest. 2003 Jul;124(1):141-6
[
12853516.001
]
[Cites]
Histopathology. 1997 Sep;31(3):274-6
[
9354899.001
]
[Cites]
Cancer. 2002 Jun 15;94(12):3115-9
[
12115342.001
]
[Cites]
Cancer. 1981 Dec 1;48(11):2485-92
[
7296496.001
]
[Cites]
Am J Surg Pathol. 1991 Jun;15(6):529-53
[
1709558.001
]
[Cites]
Am J Clin Pathol. 2000 Jul;114(1):100-10
[
10884805.001
]
(PMID = 19002759.001).
[ISSN]
1863-6705
[Journal-full-title]
General thoracic and cardiovascular surgery
[ISO-abbreviation]
Gen Thorac Cardiovasc Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Japan
53.
Okumura M, Shiono H, Inoue M, Tanaka H, Yoon HE, Nakagawa K, Matsumura A, Ohta M, Iuchi K, Matsuda H:
Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system.
J Surg Oncol
; 2007 Jan 1;95(1):40-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Outcome of surgical treatment for recurrent thymic
epithelial
tumors
with reference to world health organization histologic classification system.
BACKGROUND AND OBJECTIVES: The aim of this study was to clarify the significance of surgical treatment for recurrent thymic
epithelial
tumors
with reference to the World Health Organization (WHO) histological classification system.
PATIENTS: Among 67 patients with
tumor
recurrence, 22 underwent a re-resection.
There were 1 patient with a type AB
tumor
, 5 with type B1
tumors
, 10 with type B2
tumors
, 5 with type B3
tumors
, and 1 with a carcinoma.
The average intervals from the initial resection to re-resection were 10.3, 7.8, 6.0, 2.4, and 2.6 years for patients with type AB, B1, B2, B3
tumors
, and carcinoma, respectively.
The patient with a type AB
tumor
was alive at 2.4 years after re-resection, 12.7 years after the initial resection.
The 5-year survival rates following re-resection in the patients with type B1, B2, and B3
tumors
were 100, 56, and 60, respectively.
The patient with a carcinoma died as a result of the
tumor
2 years after re-resection.
CONCLUSION: WHO histological classification indicates the outcome of surgical treatment for recurrent thymic
epithelial
tumors
.
[MeSH-major]
Neoplasm
Recurrence, Local / surgery. Thymoma / classification. Thymoma / surgery. Thymus
Neoplasms
/ classification. Thymus
Neoplasms
/ surgery
[MeSH-minor]
Adult. Aged. Humans. Middle Aged.
Neoplasm
Staging. Reoperation. Survival Rate. Treatment Outcome. World Health Organization
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17192865.001).
[ISSN]
0022-4790
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
54.
Sumida A, Yanai H, Tanioka Y, Sakaguchi E, Yutoku K:
Stenosis of gastric body as a rare complication after endoscopic submucosal dissection for multiple gastric epithelial tumors.
J Gastrointest Cancer
; 2008;39(1-4):34-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Stenosis of gastric body as a rare complication after endoscopic submucosal dissection for multiple gastric
epithelial
tumors
.
[MeSH-major]
Gastric Mucosa / surgery. Gastric Outlet Obstruction / etiology. Gastroscopy.
Neoplasms
, Glandular and
Epithelial
/ surgery. Postoperative Complications / etiology. Stomach
Neoplasms
/ surgery
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gastrointest Endosc. 2004 Nov;60(5):771-7
[
15557953.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):237-41
[
16921303.001
]
[Cites]
J Gastroenterol. 2006 Oct;41(10):929-42
[
17096062.001
]
[Cites]
Gastrointest Endosc. 2008 May;67(6):979-83
[
18440388.001
]
(PMID = 19294537.001).
[ISSN]
1941-6628
[Journal-full-title]
Journal of gastrointestinal cancer
[ISO-abbreviation]
J Gastrointest Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
55.
Hart WR:
Borderline epithelial tumors of the ovary.
Mod Pathol
; 2005 Feb;18 Suppl 2:S33-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Borderline
epithelial
tumors
of the ovary.
The concept and terminology of borderline
epithelial
tumors
of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian
tumors
.
Typically, borderline
tumors
are noninvasive
neoplasms
that have nuclear abnormalities and mitotic activity intermediate between benign and malignant
tumors
of similar cell type.
Borderline
tumors
of all surface
epithelial
cell types have been studied.
The most common and best understood are serous borderline
tumors
and mucinous borderline
tumors
of intestinal type, which are the subject of this review.
Some of the most challenging issues for serous
tumors
include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal
tumor
implants, especially invasive implants; and, the prognostic significance of micropapillary
tumors
.
The mucinous borderline
tumors
of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline
tumors
and pertinent information on their treatment and prognosis.
[MeSH-major]
Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian
Neoplasms
/ pathology
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15761465.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
93
56.
Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I:
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
Cancer Chemother Pharmacol
; 2010 May;66(1):53-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid
tumors
of
epithelial
origin.
This study sought to determine the maximum tolerated dose (MTD) of erlotinib administered as a single 30-min infusion in patients with advanced solid
tumors
and absolute bioavailability of erlotinib tablets at matched doses.
[MeSH-major]
Neoplasms
, Glandular and
Epithelial
/ drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
[MeSH-minor]
Administration, Oral. Adolescent. Adult. Aged. Biological Availability. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged.
Neoplasm
Metastasis
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19956953.001).
[ISSN]
1432-0843
[Journal-full-title]
Cancer chemotherapy and pharmacology
[ISO-abbreviation]
Cancer Chemother. Pharmacol.
[Language]
eng
[Publication-type]
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
57.
Singer SR, Mupparapu M, Philipone E:
Cone beam computed tomography findings in a case of plexiform ameloblastoma.
Quintessence Int
; 2009 Sep;40(8):627-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Ameloblastoma is a fairly common and highly aggressive odontogenic
tumor
of
epithelial
origin.
[MeSH-major]
Ameloblastoma / radiography. Mandibular
Neoplasms
/ radiography. Odontogenic
Tumors
/ radiography
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19639086.001).
[ISSN]
1936-7163
[Journal-full-title]
Quintessence international (Berlin, Germany : 1985)
[ISO-abbreviation]
Quintessence Int
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
58.
Magnata Filho LA, Bordallo MA, Pessoa CH, Corbo R, Bulzico DA, Dias FL, Machado AL, Soares AB, Ferman S:
Thyroid spindle epithelial tumor with thymus-like differentiation (SETTLE): case report and review.
Arq Bras Endocrinol Metabol
; 2010 Oct;54(7):657-62
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Thyroid spindle
epithelial
tumor
with thymus-like differentiation (SETTLE): case report and review.
Spindle
epithelial
tumor
with thymus-like element (SETTLE) is a rare malignant
neoplasm
of the thyroid, occurring predominantly in children, adolescents, and young adults.
Microscopic exam revealed a nodular, highly cellular
neoplasm
displayed in the classic biphasic pattern, with mixture of prominent spindle cell component and a minor glandular component lined by mucinous or respiratory-type epithelium.
[MeSH-major]
Carcinoma / pathology.
Neoplasms
, Glandular and
Epithelial
/ pathology. Thymus Gland / pathology. Thyroid
Neoplasms
/ pathology
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21085772.001).
[ISSN]
1677-9487
[Journal-full-title]
Arquivos brasileiros de endocrinologia e metabologia
[ISO-abbreviation]
Arq Bras Endocrinol Metabol
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Brazil
59.
Höinghaus R, von Wasielewski R, Hewicker-Trautwein M, Freund M, Mischke R:
Immunocytological detection of lymph node metastases in dogs with malignant epithelial tumours.
J Comp Pathol
; 2007 Jul;137(1):1-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immunocytological detection of lymph node metastases in dogs with malignant
epithelial
tumours
.
Cytological touch imprints of 161 lymph nodes from 72 dogs, as well as 50 fine needle aspirates from 23 dogs, with malignant
epithelial
tumours
were included in the study.
In addition, lymph node touch imprints from dogs with primary
tumours
that reacted positively with the specific anticytokeratins CK7 (n=104) and CK20 (n=20) were also labelled with CK7 and CK20.
The immunocytological detection of lymph node metastases with the broad spectrum anti-cytokeratin AE1/AE3 in imprint smears resulted in a significant increase in sensitivity (0.99 vs 0.88 [conventional stain]) and in negative predictive
value
(0.99 vs 0.85) (P<0.01; t-test).
Specificity (0.93 vs 0.88) and positive predictive
value
(0.95 vs 0.90) did not differ significantly between the two techniques.
Immunolabelling with KL1 was associated with lower sensitivity and negative predictive
value
, indicating lack of cross-reactivity of this antibody with canine
epithelial
cells.
The study indicated the
value
of immunocytological labelling for the detection of metastases in cytological specimens of canine lymph node preparations.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17543325.001).
[ISSN]
0021-9975
[Journal-full-title]
Journal of comparative pathology
[ISO-abbreviation]
J. Comp. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antibodies; 0 / Keratin-20; 0 / Keratin-7
60.
Yaris N, Nas Y, Cobanoglu U, Yavuz MN:
Thymic carcinoma in children.
Pediatr Blood Cancer
; 2006 Aug;47(2):224-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Thymic
epithelial neoplasms
consist of thymomas, thymic carcinoids, and thymic carcinomas.
Carcinomas are malignant
tumors
of the thymus characterized by obvious cytological anaplasia.
They constitute only 4%-14% of thymic
epithelial
neoplams.
[MeSH-major]
Thymoma. Thymus
Neoplasms
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16007580.001).
[ISSN]
1545-5009
[Journal-full-title]
Pediatric blood & cancer
[ISO-abbreviation]
Pediatr Blood Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
23
61.
Kim JY, Kim HO, Kim JS, Moon DH, Kim YH, Kim DK, Park SI, Park YS, Ryu JS:
(18)F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial Tumors.
Nucl Med Mol Imaging
; 2010 Sep;44(3):177-84
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
(18)F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic
Epithelial
Tumors
.
PURPOSE: This study was performed to assess the usefulness of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) or PET/computed tomography (CT) for distinguishing thymic
epithelial
tumors
according to World Health Organization (WHO) classifications.
METHODS: We analyzed a total of 45 patients (range, 29-75 years of age; mean, 55 years) with pathologically confirmed thymic
epithelial
tumors
who underwent pretreatment (18)F-FDG PET or PET/CT between November 2003 and October 2009.
The size, visual grading of uptake
value
, peak standardized uptake
value
(SUVpeak), uptake pattern, and contour of each
tumor
, and associated findings on PET or PET/CT, were analyzed relative to the three simplified WHO subgroups: less-invasive thymomas (types A and AB), more-invasive thymomas (types B1, B2, and B3) and thymic carcinomas.
The visual grading scale (p < 0.000), uptake pattern (p = 0.001), and contour (p < 0.000) of the
tumors
differed significantly among the three simplified subgroups.
Pre-treatment evaluation with (18)F-FDG PET or PET/CT might be helpful in differentiating subgroups of thymic
epithelial
tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 24899947.001).
[ISSN]
1869-3474
[Journal-full-title]
Nuclear medicine and molecular imaging
[ISO-abbreviation]
Nucl Med Mol Imaging
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Other-IDs]
NLM/ PMC4042935
[Keywords]
NOTNLM ; 18F-fluorodeoxyglucose / PET / Thymic carcinoma / Thymoma / Thymus
62.
Muangnoi P, Lu M, Lee J, Thepouyporn A, Mirzayans R, Le XC, Weinfeld M, Changbumrung S:
Cytotoxicity, apoptosis and DNA damage induced by Alpinia galanga rhizome extract.
Planta Med
; 2007 Jul;73(8):748-54
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This study was conducted to analyze the capacity of galangal extract to induce cytotoxicity and DNA damage in six different human cell lines including normal and p53-inactive fibroblasts, normal
epithelial
and
tumour
mammary cells and a lung adenocarcinoma cell line.
There was no evidence for preferential cytotoxicity of
tumour
cells, but there was an indication that p53-active cell lines may be more sensitive than their p53-inactive counterparts.
[MeSH-minor]
Breast / cytology. Cell Line,
Tumor
/ drug effects.
Epithelial
Cells / drug effects. Fibroblasts / drug effects. Humans. Rhizome
MedlinePlus Health Information.
consumer health - Herbal Medicine
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17611930.001).
[ISSN]
0032-0943
[Journal-full-title]
Planta medica
[ISO-abbreviation]
Planta Med.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
63.
Irazoqui FJ, Sendra VG, Lardone RD, Nores GA:
Immune response to Thomsen-Friedenreich disaccharide and glycan engineering.
Immunol Cell Biol
; 2005 Aug;83(4):405-12
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Epithelial
tumour
cells typically show overexpression of the uncovered Gal(beta)1-3GalNAc(alpha)-O-Ser/Thr (Core 1) structure, known as the T antigen or the Thomsen-Friedenreich antigen, the oligosaccharide chain of which is called the Thomsen-Friedenreich disaccharide (TFD).
[MeSH-major]
Antigens,
Tumor
-Associated, Carbohydrate / chemistry. Antigens,
Tumor
-Associated, Carbohydrate / immunology. Disaccharides / chemistry. Disaccharides / immunology. Drug Design. Polysaccharides / chemistry. Polysaccharides / immunology
[MeSH-minor]
Animals. Carbohydrate Conformation.
Neoplasms
/ chemistry.
Neoplasms
/ immunology
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16033536.001).
[ISSN]
0818-9641
[Journal-full-title]
Immunology and cell biology
[ISO-abbreviation]
Immunol. Cell Biol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Australia
[Chemical-registry-number]
0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Disaccharides; 0 / Polysaccharides; 3554-90-3 / Thomsen-Friedenreich antigen
64.
Baron V, Adamson ED, Calogero A, Ragona G, Mercola D:
The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.
Cancer Gene Ther
; 2006 Feb;13(2):115-24
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The transcription factor Egr1 is a direct regulator of multiple
tumor
suppressors including TGFbeta1, PTEN, p53, and fibronectin.
Recent studies are reviewed indicating that the transcription factor early growth response-1 (Egr1) is a direct regulator of multiple
tumor
suppressors including TGFbeta1, PTEN, p53, and fibronectin.
It is suggested that these defects in the suppressor network allow for the unopposed induction of TGFbeta1 and fibronectin, which favor transformation and survival of prostate
tumor
epithelial
cells, and explain the role of Egr1 in prostate cancer.
MedlinePlus Health Information.
consumer health - Genes and Gene Therapy
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Carcinogenesis. 1994 Aug;15(8):1667-74
[
8055649.001
]
[Cites]
Mol Endocrinol. 1994 May;8(5):595-602
[
8058069.001
]
[Cites]
Oncogene. 1995 Feb 2;10(3):467-75
[
7845671.001
]
[Cites]
J Biol Chem. 1995 Dec 1;270(48):28623-8
[
7499379.001
]
[Cites]
Hereditas. 1995;122(3):239-43
[
8537239.001
]
[Cites]
Semin Oncol. 1999 Aug;26(4):382-98
[
10482181.001
]
[Cites]
J Cell Biochem. 2005 Jan 1;94(1):117-25
[
15517593.001
]
[Cites]
Cancer Res. 2004 Dec 15;64(24):9002-11
[
15604265.001
]
[Cites]
Cancer Gene Ther. 2005 Jul;12(7):655-62
[
15818381.001
]
[Cites]
Cancer Res. 2005 Jun 15;65(12):5133-43
[
15958557.001
]
[Cites]
Curr Opin Cell Biol. 2001 Oct;13(5):555-62
[
11544023.001
]
[Cites]
Mol Cell. 2001 Aug;8(2):317-25
[
11545734.001
]
[Cites]
Clin Cancer Res. 2001 Sep;7(9):2788-96
[
11555594.001
]
[Cites]
Cancer Biochem Biophys. 1995 Nov;15(2):107-10
[
8590435.001
]
[Cites]
Methods Mol Biol. 2000;142:55-65
[
10806613.001
]
[Cites]
Mol Cell Biol. 2000 Jul;20(14):5261-8
[
10866682.001
]
[Cites]
J Biol Chem. 2000 Jul 7;275(27):20315-23
[
10783396.001
]
[Cites]
Biotechniques. 2000 Jul;29(1):162-9
[
10907091.001
]
[Cites]
J Biol Chem. 2000 Aug 11;275(32):24565-74
[
10835423.001
]
[Cites]
Exp Cell Res. 2000 Aug 25;259(1):149-57
[
10942587.001
]
[Cites]
Clin Cancer Res. 2000 Sep;6(9):3522-9
[
10999739.001
]
[Cites]
Cancer Genet Cytogenet. 1995 Mar;80(1):47-54
[
7697632.001
]
[Cites]
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9
[
7777546.001
]
[Cites]
Oncogene. 1995 Oct 5;11(7):1261-9
[
7478546.001
]
[Cites]
J Urol. 1996 Mar;155(3):975-81
[
8583621.001
]
[Cites]
Science. 1996 Aug 30;273(5279):1219-21
[
8703054.001
]
[Cites]
Cancer Res. 1996 Oct 1;56(19):4541-6
[
8813154.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11831-6
[
8876223.001
]
[Cites]
J Biol Chem. 1996 Nov 15;271(46):29231-7
[
8910582.001
]
[Cites]
Crit Rev Oncog. 1996;7(1-2):101-25
[
9109500.001
]
[Cites]
Int J Cancer. 1997 Jul 3;72(1):102-9
[
9212230.001
]
[Cites]
J Biol Chem. 1997 Aug 8;272(32):20131-8
[
9242687.001
]
[Cites]
Cancer Gene Ther. 1998 Jan-Feb;5(1):3-28
[
9476963.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50
[
9560261.001
]
[Cites]
Cancer Res. 1998 Jun 1;58(11):2461-8
[
9622090.001
]
[Cites]
Am J Respir Cell Mol Biol. 1998 Jun;18(6):823-33
[
9618387.001
]
[Cites]
J Biol Chem. 1999 Feb 12;274(7):4400-11
[
9933644.001
]
[Cites]
EMBO J. 1999 Mar 1;18(5):1345-56
[
10064600.001
]
[Cites]
Cytokine. 1999 Feb;11(2):157-62
[
10089138.001
]
[Cites]
Cell Death Differ. 1998 Jan;5(1):96-106
[
10200450.001
]
[Cites]
Adv Cancer Res. 1999;76:1-20
[
10218097.001
]
[Cites]
J Pathol. 1999 Jan;187(1):82-90
[
10341708.001
]
[Cites]
Int Immunol. 1999 Jun;11(6):871-9
[
10360960.001
]
[Cites]
Cancer Metastasis Rev. 2001;20(3-4):173-93
[
12085961.001
]
[Cites]
Anticancer Res. 2002 May-Jun;22(3):1433-44
[
12168820.001
]
[Cites]
Trends Biochem Sci. 2002 Sep;27(9):462-7
[
12217521.001
]
[Cites]
Exp Mol Pathol. 2002 Oct;73(2):142-53
[
12231217.001
]
[Cites]
J Cell Biochem. 2003 Jan 1;88(1):138-43
[
12461783.001
]
[Cites]
Biochem J. 2003 Mar 15;370(Pt 3):1019-25
[
12457461.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3233-8
[
12629205.001
]
[Cites]
Cell Struct Funct. 2003 Feb;28(1):11-21
[
12655146.001
]
[Cites]
J Biol Chem. 2003 Apr 4;278(14):11802-10
[
12556466.001
]
[Cites]
Oncogene. 2003 Jul 3;22(27):4194-204
[
12833142.001
]
[Cites]
Biochem J. 2003 Aug 1;373(Pt 3):739-46
[
12755686.001
]
[Cites]
Oncogene. 2003 Aug 14;22(34):5325-37
[
12917634.001
]
[Cites]
Can J Urol. 2003 Aug;10(4):1924-33
[
14503938.001
]
[Cites]
Oncogene. 2003 Nov 13;22(51):8246-54
[
14614448.001
]
[Cites]
FASEB J. 2003 Dec;17(15):2316-8
[
14525948.001
]
[Cites]
J Biol Chem. 2003 Dec 12;278(50):50422-7
[
14517213.001
]
[Cites]
Ann N Y Acad Sci. 2003 Dec;1002:197-216
[
14751836.001
]
[Cites]
Mol Cancer Res. 2004 Jul;2(7):371-86
[
15280445.001
]
[Cites]
J Exp Med. 2004 Aug 2;200(3):377-89
[
15289506.001
]
[Cites]
Dev Biol. 2004 Sep 15;273(2):175-84
[
15328005.001
]
[Cites]
Mol Cancer Ther. 2004 Sep;3(9):1167-75
[
15367711.001
]
[Cites]
Endocrinology. 2004 Oct;145(10):4660-6
[
15231710.001
]
[Cites]
Adv Exp Med Biol. 1992;324:107-14
[
1492611.001
]
[Cites]
J Cell Biochem Suppl. 1992;16H:99-105
[
1289680.001
]
[Cites]
Science. 1993 Apr 23;260(5107):536-9
[
8475385.001
]
[Cites]
Genes Dev. 1994 Jan;8(1):9-22
[
8288131.001
]
[Cites]
Biochem Biophys Res Commun. 1994 May 16;200(3):1271-6
[
8185575.001
]
[Cites]
Cell. 1994 Jul 15;78(1):59-66
[
8033212.001
]
[Cites]
Oncogene. 1999 Jun 17;18(24):3633-42
[
10380885.001
]
[Cites]
Histochem Cell Biol. 1999 Jul;112(1):51-61
[
10461812.001
]
[Cites]
J Am Soc Nephrol. 1999 Sep;10(9):1891-9
[
10477140.001
]
[Cites]
Development. 1999 Nov;126(22):5061-71
[
10529423.001
]
[Cites]
DNA Res. 1999 Oct 29;6(5):347-51
[
10574463.001
]
[Cites]
J Clin Invest. 2000 Mar;105(5):653-62
[
10712437.001
]
[Cites]
J Biol Chem. 2000 Dec 8;275(49):38524-31
[
10984481.001
]
[Cites]
Nat Med. 2001 Jan;7(1):101-7
[
11135623.001
]
[Cites]
Int J Oncol. 2001 Apr;18(4):863-70
[
11251186.001
]
[Cites]
Hum Pathol. 2001 Sep;32(9):935-9
[
11567222.001
]
[Cites]
Acta Oncol. 2001;40(6):735-8
[
11765068.001
]
[Cites]
Nat Cell Biol. 2001 Dec;3(12):1124-8
[
11781575.001
]
[Cites]
J Biol Chem. 2002 Feb 15;277(7):5484-9
[
11729185.001
]
[Cites]
Gene Ther. 2002 Apr;9(8):495-502
[
11948374.001
]
(PMID = 16138117.001).
[ISSN]
0929-1903
[Journal-full-title]
Cancer gene therapy
[ISO-abbreviation]
Cancer Gene Ther.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA102688-05; United States / NCI NIH HHS / CA / R01 CA102688; United States / NCI NIH HHS / CA / R01 CA084107-05; United States / NCI NIH HHS / CA / U01 CA084998-05; United States / NCI NIH HHS / CA / U01 CA084998; United States / NCI NIH HHS / CA / CA067888-17; United States / NCI NIH HHS / CA / CA084998-05; United States / NCI NIH HHS / CA / R01 CA102688-05; United States / PHS HHS / / R01 67888; United States / NCI NIH HHS / CA / 1R01 CA102688; United States / NCI NIH HHS / CA / UO1 CA084998; United States / NCI NIH HHS / CA / CA084107-05; United States / NCI NIH HHS / CA / R01 CA084107; United States / NCI NIH HHS / CA / R01 CA067888-17
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
[Publication-country]
England
[Chemical-registry-number]
0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Fibronectins; 0 / Plasminogen Activator Inhibitor 1; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
[Number-of-references]
93
[Other-IDs]
NLM/ NIHMS56346; NLM/ PMC2455793
65.
Fujishiro M:
Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms.
World J Gastroenterol
; 2008 Jul 21;14(27):4289-95
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal
neoplasms
.
This technique is applied for the endoscopic treatment of
epithelial neoplasms
in the gastrointestinal tract from the pharynx to the rectum.
Furthermore, some carcinoids and submucosal
tumors
in the gastrointestinal tract are treated by ESD.
In this review, practical guidelines of ESD for the gastrointestinal
neoplasms
are discussed based on the evidence found in the literature.
[MeSH-major]
Endoscopy / methods. Gastric Mucosa / pathology. Gastroenterology / methods. Gastrointestinal
Neoplasms
/ diagnosis. Gastrointestinal
Neoplasms
/ pathology. Medical Oncology / methods
[MeSH-minor]
Algorithms. Carcinoid
Tumor
/ diagnosis. Decision Support Techniques. Endoscopes, Gastrointestinal. Humans. Lymphatic Metastasis.
Neoplasm
Metastasis
MedlinePlus Health Information.
consumer health - Endoscopy
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Gut. 2006 Nov;55(11):1592-7
[
16682427.001
]
[Cites]
Endoscopy. 2006 Oct;38(10):1024-8
[
17058168.001
]
[Cites]
Gastrointest Endosc. 2004 Nov;60(5):703-10
[
15557945.001
]
[Cites]
Gut. 2005 Feb;54(2):187-92
[
15647178.001
]
[Cites]
Cancer. 2000 Mar 15;88(6):1285-93
[
10717608.001
]
[Cites]
Gastrointest Endosc. 2000 Jun;51(6):697-700
[
10840302.001
]
[Cites]
Gastrointest Endosc. 2000 Sep;52(3):328-32
[
10968845.001
]
[Cites]
Gastrointest Endosc. 2001 Jul;54(1):62-6
[
11427843.001
]
[Cites]
Endoscopy. 2001 Jun;33(6):501-6
[
11437043.001
]
[Cites]
Gastrointest Endosc. 2001 Dec;54(6):682-8
[
11726842.001
]
[Cites]
Dig Liver Dis. 2002 Feb;34(2):137-40
[
11926558.001
]
[Cites]
J Gastrointest Surg. 2001 Nov-Dec;5(6):588-93
[
12086896.001
]
[Cites]
Endoscopy. 2003 Mar;35(3):203-6
[
12584637.001
]
[Cites]
Gastrointest Endosc. 2003 Apr;57(4):583-7
[
12665777.001
]
[Cites]
Gastrointest Endosc. 2003 Jun;57(7):854-9
[
12776032.001
]
[Cites]
J Clin Gastroenterol. 2003 Nov-Dec;37(5):381-6
[
14564184.001
]
[Cites]
Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43
[
14652541.001
]
[Cites]
Gastric Cancer. 2003;6(4):255-61
[
14716521.001
]
[Cites]
Gastric Cancer. 2003;6(4):262-6
[
14716522.001
]
[Cites]
Endoscopy. 2004 Mar;36(3):202-5
[
14986216.001
]
[Cites]
Hepatogastroenterology. 2004 Jan-Feb;51(55):269-72
[
15011883.001
]
[Cites]
Endoscopy. 2004 Apr;36(4):306-12
[
15057679.001
]
[Cites]
Gastric Cancer. 2005;8(1):42-6
[
15747174.001
]
[Cites]
Gastroenterology. 2005 May;128(6):1717-51
[
15887161.001
]
[Cites]
Anticancer Res. 2005 Sep-Oct;25(5):3513-6
[
16101171.001
]
[Cites]
Am J Surg. 2005 Sep;190(3):496-503
[
16105543.001
]
[Cites]
Endoscopy. 2005 Sep;37(9):879-920
[
16116544.001
]
[Cites]
World J Gastroenterol. 2005 Aug 28;11(32):5061-3
[
16124067.001
]
[Cites]
Gastrointest Endosc. 2006 Jan;63(1):16-21
[
16377310.001
]
[Cites]
Gastrointest Endosc. 2006 Dec;64(6):877-83
[
17140890.001
]
[Cites]
Gastrointest Endosc. 2007 Jan;65(1):3-10
[
17185072.001
]
[Cites]
Endoscopy. 2007 Jan;39(1):30-5
[
17252457.001
]
[Cites]
Dig Liver Dis. 2007 Jun;39(6):566-71
[
17382610.001
]
[Cites]
Endoscopy. 2007 May;39(5):423-7
[
17354181.001
]
[Cites]
Endoscopy. 2007 May;39(5):418-22
[
17516348.001
]
[Cites]
Gut. 2007 Jun;56(6):863-8
[
17213340.001
]
[Cites]
Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645
[
17466600.001
]
[Cites]
Gastrointest Endosc. 2007 Jul;66(1):100-7
[
17591481.001
]
[Cites]
World J Gastroenterol. 2007 Jun 28;13(24):3311-5
[
17659669.001
]
[Cites]
World J Gastroenterol. 2007 Jun 28;13(24):3316-22
[
17659670.001
]
[Cites]
World J Gastroenterol. 2007 Jul 21;13(27):3657-61
[
17659722.001
]
[Cites]
Dig Dis Sci. 2007 Oct;52(10):2796-9
[
17394064.001
]
[Cites]
Gastrointest Endosc. 2007 Nov;66(5):966-73
[
17524403.001
]
[Cites]
Br J Surg. 2007 Dec;94(12):1536-42
[
17948864.001
]
[Cites]
World J Gastroenterol. 2008 May 21;14(19):2962-7
[
18494043.001
]
[Cites]
Surg Endosc. 2008 Jul;22(7):1729-35
[
18074180.001
]
[Cites]
Am J Gastroenterol. 2004 Jul;99(7):1226-32
[
15233658.001
]
[Cites]
J Gastroenterol. 2004 Jun;39(6):534-43
[
15235870.001
]
[Cites]
World J Gastroenterol. 2004 Aug 15;10(16):2461-3
[
15285046.001
]
[Cites]
Endoscopy. 2004 Sep;36(9):782-7
[
15326573.001
]
[Cites]
Endoscopy. 2004 Sep;36(9):788-801
[
15326574.001
]
[Cites]
Am Surg. 1991 Jul;57(7):434-7
[
2058850.001
]
[Cites]
J Clin Gastroenterol. 1995 Mar;20(2):168-71; discussion 71-2
[
7769204.001
]
[Cites]
Digestion. 1995;56(6):455-62
[
8536814.001
]
[Cites]
World J Surg. 1996 Feb;20(2):183-8
[
8661815.001
]
[Cites]
Dis Colon Rectum. 1996 Nov;39(11):1308-14
[
8918445.001
]
[Cites]
Surgery. 1998 Apr;123(4):432-9
[
9551070.001
]
[Cites]
Gastrointest Endosc. 2006 Feb;63(2):243-9
[
16427929.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8
[
16527698.001
]
[Cites]
Gastrointest Endosc. 2006 May;63(6):776-82
[
16650537.001
]
[Cites]
Endoscopy. 2006 Apr;38(4):391-4
[
16680640.001
]
[Cites]
Clin Gastroenterol Hepatol. 2006 Jun;4(6):688-94
[
16713746.001
]
[Cites]
Endoscopy. 2006 May;38(5):493-7
[
16767585.001
]
[Cites]
World J Gastroenterol. 2006 Jul 7;12(25):4026-8
[
16810752.001
]
[Cites]
Gastrointest Endosc. 2006 Aug;64(2):255-9; discussion 260-2
[
16860078.001
]
[Cites]
World J Gastroenterol. 2006 Aug 28;12(32):5108-12
[
16937520.001
]
(PMID = 18666315.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
China
[Number-of-references]
69
[Other-IDs]
NLM/ PMC2731178
66.
Vera J, García MD, Marigil M, Abascal M, Lopez JI, Ligorred L:
Biphasic synovial sarcoma of the abdominal wall.
Virchows Arch
; 2006 Sep;449(3):367-72
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Synovial sarcoma arising in the abdominal wall is a rare
tumor
.
The
tumor
was first thought to be a sarcoma arising from the omentum or mesentery.
During surgery, a large
tumor
was found attached to the inner surface of the abdominal wall and compressing the gastrointestinal tract.
On microscopic examination the
tumor
corresponded to a biphasic synovial sarcoma immunoreactive for cytokeratins (AE1/AE3, 7 and 19),
epithelial
membrane antigen and carcinoembryonic antigen in the
epithelial
tumor
cells, for E-cadherin especially in their glandular structure, vimentin, CD99, and CD56 in the spindle cell component and for bcl-2 protein.
The
tumor
recurred at the same site, and clinical course progressed to death 3 months after the initial diagnosis.
[MeSH-major]
Abdominal
Neoplasms
/ pathology. Abdominal Wall / pathology. Carcinosarcoma / pathology. Sarcoma, Synovial / pathology
[MeSH-minor]
Adult. Antigens, CD / analysis. Antigens, CD56 / analysis. Antigens, CD99. Biomarkers,
Tumor
/ analysis. Cadherins / analysis. Carcinoembryonic Antigen / analysis. Cell Adhesion Molecules / analysis. Fatal Outcome. Humans. Keratins / analysis. Male.
Neoplasm
Recurrence, Local. Tomography, X-Ray Computed. Vimentin / analysis
Genetic Alliance.
consumer health - Synovial sarcoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Surg Pathol. 2005 May;29(5):569-78
[
15832079.001
]
[Cites]
Hum Pathol. 1995 May;26(5):474-80
[
7750931.001
]
[Cites]
Int J Cancer. 1997 Sep 17;72(6):995-1002
[
9378564.001
]
[Cites]
Am J Surg Pathol. 1998 Jun;22(6):673-82
[
9630174.001
]
[Cites]
Arch Pathol Lab Med. 1995 Nov;119(11):1080-2
[
7487412.001
]
[Cites]
Hum Pathol. 1984 Jul;15(7):615-21
[
6204918.001
]
[Cites]
Mod Pathol. 1996 Jul;9(7):738-41
[
8832556.001
]
[Cites]
Pathol Int. 1997 Sep;47(9):637-41
[
9311017.001
]
[Cites]
J Pathol. 2000 Nov;192(3):342-50
[
11054718.001
]
[Cites]
Br J Cancer. 2001 Aug 3;85(3):405-11
[
11487273.001
]
[Cites]
Am J Surg Pathol. 2002 Nov;26(11):1434-40
[
12409719.001
]
[Cites]
Cancer. 1993 Jul 15;72(2):469-77
[
8391380.001
]
[Cites]
Hum Mol Genet. 1995 Jun;4(6):1097-9
[
7655467.001
]
[Cites]
Lancet. 1997 Dec 6;350(9092):1679-80
[
9400520.001
]
[Cites]
Acta Pathol Jpn. 1983 Jan;33(1):23-36
[
6301209.001
]
[Cites]
Am J Surg Pathol. 1996 Jan;20(1):36-45
[
8540607.001
]
[Cites]
Orbit. 2003 Dec;22(4):299-303
[
14685906.001
]
[Cites]
Mod Pathol. 1998 Jan;11(1):65-71
[
9556426.001
]
[Cites]
Cancer. 1965 May;18:613-27
[
14278894.001
]
[Cites]
Ann Surg. 1968 Nov;168(5):928-30
[
4300893.001
]
[Cites]
Hum Pathol. 1986 Oct;17(10):996-1008
[
2428727.001
]
[Cites]
Ann Diagn Pathol. 1998 Dec;2(6):401-21
[
9930576.001
]
[Cites]
Surgery. 1950 Dec;28(6):1047-84
[
14787842.001
]
[Cites]
Histopathology. 2004 Sep;45(3):245-53
[
15330802.001
]
[Cites]
Genes Chromosomes Cancer. 1991 Sep;3(5):338-45
[
1665704.001
]
[Cites]
Cancer. 1975 Apr;35(4):1243-53
[
163680.001
]
[Cites]
Br J Cancer. 1970 Sep;24(3):471-4
[
4319939.001
]
[Cites]
Cancer. 1989 Jun 1;63(11):2182-5
[
2541885.001
]
[Cites]
Cancer. 1993 Jul 15;72(2):478-85
[
8100481.001
]
[Cites]
Am J Clin Pathol. 1982 Jun;77(6):686-91
[
6283877.001
]
[Cites]
Virchows Arch A Pathol Anat Histol. 1980;388(3):349-60
[
6254240.001
]
[Cites]
Histopathology. 1998 Dec;33(6):508-13
[
9870144.001
]
[Cites]
Mod Pathol. 1992 Jul;5(4):357-62
[
1379714.001
]
[Cites]
Am J Surg Pathol. 2000 Aug;24(8):1087-96
[
10935649.001
]
[Cites]
Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):379-402
[
1721748.001
]
[Cites]
Cancer. 1987 May 15;59(10):1810-4
[
3828949.001
]
[Cites]
J Surg Oncol. 1981;18(4):335-44
[
6275210.001
]
[Cites]
J Pathol. 1985 Sep;147(1):49-57
[
2995626.001
]
[Cites]
Cancer. 1973 May;31(5):1247-55
[
4705164.001
]
[Cites]
Am J Surg Pathol. 1999 Feb;23 (2):220-6
[
9989850.001
]
[Cites]
Am J Clin Oncol. 2005 Jun;28(3):323-4
[
15923809.001
]
(PMID = 16855839.001).
[ISSN]
0945-6317
[Journal-full-title]
Virchows Archiv : an international journal of pathology
[ISO-abbreviation]
Virchows Arch.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD99; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cadherins; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / Vimentin; 68238-35-7 / Keratins
67.
Jindal S, Vij V, Singhal D, Chaudhary A:
Squamous cell carcinoma of stomach.
Trop Gastroenterol
; 2006 Apr-Jun;27(2):91-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Gastric squamous cell carcinoma is a rare
epithelial
tumour
.
[MeSH-major]
Carcinoma, Squamous Cell / diagnosis. Stomach
Neoplasms
/ diagnosis
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
Genetic Alliance.
consumer health - Stomach carcinoma
.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17089621.001).
[ISSN]
0250-636X
[Journal-full-title]
Tropical gastroenterology : official journal of the Digestive Diseases Foundation
[ISO-abbreviation]
Trop Gastroenterol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
68.
Johnson KA, Brown PH:
Drug development for cancer chemoprevention: focus on molecular targets.
Semin Oncol
; 2010 Aug;37(4):345-58
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A review of solid
tumor
targets provides a manageable list of factors that are critical to cancer cell survival.
As such, these targets represent factors that are not only clinically relevant but also may play a critical role in early
tumor
development prior to the evolution of frank invasive malignancy.
Among solid
tumors
, the treatment of breast cancer with targeted drugs has a long record benchmarked by the initial US Food and Drug Administation (FDA) approval of tamoxifen for metastatic breast cancer treatment in 1977.
The focus of this review is the pharmacologic manipulation of targets within
epithelial
tumor
cells and the implication of those targets for intervening to suppress and eliminate premalignant cells in human tissue.
One of these is the refinement of early phase prevention trials to identify drug targets in
epithelial
cells that are at demonstrated risk of evolving into cancer cells, ie, cells from a developmental niche in cancer ontogeny.
To the extent that this approach can be developed, it will allow for cancer risk reduction in a way that is analogous to the measurement of
tumor
response to treatment.
In addition to drug targets located in
epithelial
tumor
cells, another list of malignancy-associated targets could be generated by considering targets in
tumor
-associated stromal and endothelial cells (eg, fibroblast growth factor [FGF], vascular endothelial growth factor [VEGF]), as well as targets related to a systemic reservoir of circulating cells that can be recruited to carcinogenic influence by inflammatory factors such as nuclear factor (NF)kappaB.
The complementarities of target-related processes within
tumors
cells, in the
tumor
microenvironment, and beyond suggests that there is great potential for multi-targeted approaches that may be more effective than single agents and also less prone to resistance.
As long as multiple agents can be used in combination for optimal effect with acceptable toxicity, the co-targeting of the
epithelial
cell compartment along with other compartments of oncogenic activity is expected to expand the dimensions of targeted prevention and enhance the overall opportunity to eliminate precancer or cells at risk of eventually transitioning to invasive cancer.
[MeSH-major]
Anticarcinogenic Agents / therapeutic use. Drug Delivery Systems. Drug Design.
Neoplasms
/ drug therapy
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010. Published by Elsevier Inc.
(PMID = 20816505.001).
[ISSN]
1532-8708
[Journal-full-title]
Seminars in oncology
[ISO-abbreviation]
Semin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Anticarcinogenic Agents
[Number-of-references]
112
69.
Jakab C, Halász J, Szász AM, Kiss A, Schaff Z, Rusvai M, Gálfi P, Kulka J:
Expression of claudin-1, -2, -3, -4, -5 and -7 proteins in benign and malignant canine mammary gland epithelial tumours.
J Comp Pathol
; 2008 Nov;139(4):238-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of claudin-1, -2, -3, -4, -5 and -7 proteins in benign and malignant canine mammary gland
epithelial
tumours
.
Claudins are tight junction proteins expressed by
epithelial
and endothelial cells.
These results suggest that loss or reduction of expression of claudin-1, -2, -5 and -7 may lead to cellular disorientation, detachment and invasion in canine mammary
neoplasia
.
[MeSH-major]
Carcinoma / metabolism. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary
Neoplasms
, Animal / metabolism. Membrane Proteins / biosynthesis
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18848337.001).
[ISSN]
0021-9975
[Journal-full-title]
Journal of comparative pathology
[ISO-abbreviation]
J. Comp. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Membrane Proteins
70.
Pino V, Ramsauer VP, Salas P, Carothers Carraway CA, Carraway KL:
Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition.
J Biol Chem
; 2006 Sep 29;281(39):29411-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary
epithelial
and
tumor
cells: role in reversal of contact inhibition.
An analysis of the effects of Muc4 expression on ERK phosphorylation in mammary
tumor
and
epithelial
cells, which exhibit both adhesion-dependent growth and contact inhibition of growth, showed that the effects are density dependent, with opposing effects on proliferating cells and contact-inhibited cells.
Muc4-induced abrogation of contact inhibition may be an important mechanism by which
tumors
progress from an early, more benign state to invasiveness.
[MeSH-major]
Breast
Neoplasms
/ metabolism.
Epithelial
Cells / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Mucins / physiology
[MeSH-minor]
Cadherins / metabolism. Cell Line,
Tumor
. Cell Proliferation. Enzyme Activation. Humans. Models, Biological. Mucin-4. Proto-Oncogene Proteins c-raf / metabolism. Receptor, ErbB-2 / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16891313.001).
[ISSN]
0021-9258
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA 74072; United States / NCI NIH HHS / CA / CA52498
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Cadherins; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
71.
Gould VE, Schmitt M, Vinokurova S, Reddy VB, Bitterman P, Alonso A, Gattuso P:
Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder.
Cancer Lett
; 2010 Jun 28;292(2):171-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Inverted papillomas of the urinary bladder are
epithelial
tumors
considered to be of benign nature.
We conclude that HPV does not play an indispensable role in the development of urinary bladder inverted papillomas and that overexpression of p16(Ink4a) does not correlate with HPV infection in these
tumors
.
[MeSH-major]
Alphapapillomavirus / isolation & purification. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Papilloma / metabolism. Papilloma / virology. Urinary Bladder
Neoplasms
/ metabolism. Urinary Bladder
Neoplasms
/ virology
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
(PMID = 20036459.001).
[ISSN]
1872-7980
[Journal-full-title]
Cancer letters
[ISO-abbreviation]
Cancer Lett.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Ireland
[Chemical-registry-number]
0 / Cyclin-Dependent Kinase Inhibitor p16
72.
Yan YG, Zhao G, Ma JP, Cai SR, Zhan WH:
Effects of different Helicobacter pylori culture filtrates on growth of gastric epithelial cells.
World J Gastroenterol
; 2008 Jun 21;14(23):3745-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Effects of different Helicobacter pylori culture filtrates on growth of gastric
epithelial
cells.
AIM: To study the effects of different Helicobacter pylori (H pylori) culture filtrates on growth of gastric
epithelial
cells.
Gastric
epithelial
cells were treated with the filtrates, and cell growth was determined by growth curve and flow cytometry.
DNA damage of gastric
epithelial
cells was measured by single-cell microgel electrophoresis.
RESULTS: Gastric
epithelial
cells proliferated actively when treated by CagA-gene-positive broth culture filtrates, and colony formation reached 40%.
CONCLUSION: CagA-positive filtrates enhance the changes in morphology and growth characteristics of human gastric
epithelial
tumor
cells.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
World J Gastroenterol. 2004 Aug 1;10(15):2232-40
[
15259072.001
]
[Cites]
J Clin Microbiol. 2004 Jun;42(6):2508-17
[
15184428.001
]
[Cites]
Exp Cell Res. 1988 Mar;175(1):184-91
[
3345800.001
]
[Cites]
N Engl J Med. 1991 Oct 17;325(16):1132-6
[
1891021.001
]
[Cites]
IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241
[
7715068.001
]
[Cites]
Mutat Res. 1996 Jun 12;363(2):89-96
[
8676929.001
]
[Cites]
Digestion. 1996;57(5):299-304
[
8886572.001
]
[Cites]
Am J Pathol. 1997 Sep;151(3):821-9
[
9284831.001
]
[Cites]
Cancer Sci. 2004 Dec;95(12):977-83
[
15596047.001
]
[Cites]
Int J Mol Med. 2005 Oct;16(4):741-5
[
16142414.001
]
[Cites]
Korean J Gastroenterol. 2005 Sep;46(3):159-65
[
16179834.001
]
[Cites]
J Exp Clin Cancer Res. 2005 Sep;24(3):337-45
[
16270519.001
]
[Cites]
Lancet. 1993 May 29;341(8857):1359-62
[
8098787.001
]
[Cites]
Cancer Res. 2007 May 15;67(10):4709-15
[
17510398.001
]
[Cites]
J Pathol. 2007 Oct;213(2):140-51
[
17724739.001
]
[Cites]
Cytogenet Genome Res. 2007;118(2-4):277-83
[
18000381.001
]
[Cites]
Best Pract Res Clin Gastroenterol. 2007;21(6):921-45
[
18070696.001
]
[Cites]
Gastroenterology. 2008 Jan;134(1):306-23
[
18166359.001
]
[Cites]
J Dig Dis. 2008 Feb;9(1):20-6
[
18251790.001
]
[Cites]
Acta Gastroenterol Latinoam. 2007 Dec;37(4):238-45
[
18254262.001
]
[Cites]
J Clin Gastroenterol. 2008 Mar;42(3):279-83
[
18223496.001
]
[Cites]
Gastroenterology. 2001 Oct;121(4):784-91
[
11606491.001
]
[Cites]
J Biol Chem. 2002 Mar 1;277(9):6775-8
[
11788577.001
]
[Cites]
Mol Microbiol. 2002 Feb;43(4):971-80
[
11929545.001
]
[Cites]
Mol Cell. 2002 Oct;10(4):745-55
[
12419219.001
]
[Cites]
J Biol Chem. 2003 Feb 7;278(6):3664-70
[
12446738.001
]
[Cites]
J Cell Biol. 2003 Apr 28;161(2):249-55
[
12719469.001
]
[Cites]
Gastroenterology. 2003 Dec;125(6):1636-44
[
14724815.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):631-7
[
15066929.001
]
[Cites]
J Gastroenterol. 2004;39(2):97-103
[
15069615.001
]
[Cites]
Gastroenterology. 2004 Aug;127(2):514-23
[
15300584.001
]
(PMID = 18595143.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Culture Media, Conditioned; 0 / cagA protein, Helicobacter pylori
[Other-IDs]
NLM/ PMC2719239
73.
Schmalhofer O, Brabletz S, Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer.
Cancer Metastasis Rev
; 2009 Jun;28(1-2):151-66
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The embryonic program '
epithelial
-mesenchymal transition' (EMT) is activated during
tumor
invasion in disseminating cancer cells.
In addition to an accumulation of cancer stem cells, nuclear beta-catenin induces a gene expression pattern favoring
tumor
invasion, and mounting evidence indicates multiple reciprocal interactions of E-cadherin and beta-catenin with EMT-inducing transcriptional repressors to stabilize an invasive mesenchymal phenotype of
epithelial
tumor
cells.
[MeSH-major]
Cadherins / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism.
Neoplasms
/ metabolism.
Neoplasms
/ pathology. Transcription Factors / metabolism. beta Catenin / metabolism
[MeSH-minor]
Animals. Cell Adhesion. Disease Progression. Epithelium / metabolism. Humans. Mesoderm / metabolism. Models, Biological.
Neoplasm
Invasiveness.
Neoplasm
Metastasis. Transcription, Genetic
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19153669.001).
[ISSN]
1573-7233
[Journal-full-title]
Cancer metastasis reviews
[ISO-abbreviation]
Cancer Metastasis Rev.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Cadherins; 0 / Homeodomain Proteins; 0 / Transcription Factors; 0 / ZEB1 protein, human; 0 / beta Catenin
[Number-of-references]
205
74.
Pinzani P, Mazzini C, Salvianti F, Massi D, Grifoni R, Paoletti C, Ucci F, Molinara E, Orlando C, Pazzagli M, Neri B:
Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression.
Melanoma Res
; 2010 Aug;20(4):303-10
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating
tumor
cells and
tumor
progression.
Results were correlated with clinical data and, in a subgroup of patients, with the number of circulating
tumor
cells (CTC) assessed using isolation by size of
epithelial
tumor
cells (ISET).
A significant correlation was found between mRNA tyrosinase levels and
tumor
dimension (P<0.01), disease-free and overall survival (P<0.05).
Tyrosinase assay by qRT-PCR is a noninvasive method for the detection of
tumor
progression in uveal melanoma patients.
[MeSH-major]
Melanoma / genetics. Monophenol Monooxygenase / genetics. Neoplastic Cells, Circulating / pathology. RNA, Messenger / blood. Uveal
Neoplasms
/ genetics
[MeSH-minor]
Aged. Aged, 80 and over. Cell Line,
Tumor
. Disease Progression. Disease-Free Survival. Female. Gene Expression. Humans. Longitudinal Studies. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Uveal melanoma
.
MedlinePlus Health Information.
consumer health - Melanoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20442676.001).
[ISSN]
1473-5636
[Journal-full-title]
Melanoma research
[ISO-abbreviation]
Melanoma Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
75.
González-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, Yoshida N, Kikuchi K, Ide F, Sakashita H, Kusama K:
Enhanced expression of podoplanin in ameloblastomas.
J Oral Pathol Med
; 2010 Jan;39(1):103-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In addition, we examined the localization of the
epithelial
marker E-cadherin and the mesenchymal marker vimentin to clarify whether AMs show
epithelial
-mesenchymal transition (EMT).
RESULTS: Immunohistochemical reactivity for podoplanin was detected in the cell membrane and cytoplasm of most odontogenic
tumor
epithelial
cells in AMs.
Immunoreactivity for E-cadherin was weak or negative in keratinizing cells of acanthomatous AMs, suggesting terminal differentiation of the
tumor
cells.
CONCLUSION: Expression of podoplanin in AMs is considered to be associated with neoplastic odontogenic tissues; this molecule might play a role in the collective cell migration of
tumor
nests in AMs.
[MeSH-minor]
Cadherins / analysis. Cell Differentiation. Cell Membrane / ultrastructure. Cell Movement. Cytoplasm / ultrastructure. Dentigerous Cyst / pathology.
Epithelial
Cells / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Intercellular Junctions / pathology.
Neoplasm
Invasiveness.
Neoplasm
Recurrence, Local / pathology. Stromal Cells / pathology. Vimentin / analysis
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19691459.001).
[ISSN]
1600-0714
[Journal-full-title]
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
[ISO-abbreviation]
J. Oral Pathol. Med.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Cadherins; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / Vimentin
76.
Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD:
Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues.
Clin Cancer Res
; 2009 May 1;15(9):3196-204
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
However, preclinical data implicate glucocorticoids in suppressing chemotherapy-mediated apoptosis in
epithelial
tumors
.
We therefore evaluated anti-apoptotic gene expression in
tumor
samples from patients randomized to dexamethasone or normal saline.
Ovarian and omental
tumor
samples were collected intra-operatively before and after infusion.
At 30 min postinfusion,
tumor
samples from five patients receiving dexamethasone revealed an average SGK1 mRNA induction of 6.1-fold (SEM, +/-2.6) compared with only 1.5-fold (SEM, +/-0.4) in
tumor
samples from five patients receiving normal saline (P = 0.028).
CONCLUSION: Glucocorticoid administration to patients is associated with rapid up-regulation of SGK1 and MKP1 expression in ovarian
tumors
.
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Steroids
.
COS Scholar Universe.
author profiles
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
Hazardous Substances Data Bank.
DEXAMETHASONE
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19383827.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / R01 CA089208; United States / NCI NIH HHS / CA / P30CA014599; United States / NCI NIH HHS / CA / R01CA089208
[Publication-type]
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Glucocorticoids; 0 / Immediate-Early Proteins; 0 / Placebos; 0 / RNA, Messenger; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase; EC 3.1.3.48 / DUSP1 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 1
[Other-IDs]
NLM/ NIHMS733059; NLM/ PMC4707040
77.
Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, Soslow RA:
Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
Am J Surg Pathol
; 2008 Jul;32(7):955-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mixed ovarian
epithelial
carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
This could be due to significant interobserver variation in the diagnosis of CCC and other ovarian surface
epithelial
tumors
containing clear cells.
Thirty-two cases previously diagnosed as CCC, high-grade ovarian serous carcinoma (SC), and mixed surface
epithelial
carcinoma (SEC) with clear cell and serous components were reviewed by 4 gynecologic pathologists blinded to the original diagnoses.
Each case was also assessed using immunohistochemical markers Wilm
tumor
1, estrogen receptor, and p53.
Immunoreactivities of the mixed SECs were similar to those of pure SC, but significantly different from those of pure CCC for Wilm
tumor
1 (P=0.0011 for both components), estrogen receptor (P=0.0003 for clear cell component, P=0.0001 for serous component), and p53 (P=0.0062 for both components).
[MeSH-major]
Adenocarcinoma, Clear Cell / pathology. Cystadenocarcinoma, Serous / pathology.
Neoplasms
, Multiple Primary / pathology. Ovarian
Neoplasms
/ pathology
[MeSH-minor]
Apoptosis. Biomarkers,
Tumor
/ analysis. Female. Humans. Immunohistochemistry. Middle Aged. Mitosis.
Neoplasm
Staging. Observer Variation. Reproducibility of Results
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18460981.001).
[ISSN]
1532-0979
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
78.
Baker SG, Kramer BS:
Paradoxes in carcinogenesis: new opportunities for research directions.
BMC Cancer
; 2007;7:151
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
(1) the presence of large numbers of spatially distinct precancerous lesions at the onset of promotion, (2) the large number of genetic instabilities found in hyperplastic polyps not considered cancer, (3) spontaneous regression, (4) higher incidence of cancer in patients with xeroderma pigmentosa but not in patients with other comparable defects in DNA repair, (5) lower incidence of many cancers except leukemia and testicular cancer in patients with Down's syndrome, (6) cancer developing after normal tissue is transplanted to other parts of the body or next to stroma previously exposed to carcinogens, (7) the lack of
tumors
when
epithelial
cells exposed to a carcinogen were transplanted next to normal stroma, (8) the development of cancers when Millipore filters of various pore sizes were was inserted under the skin of rats, but only if the holes were sufficiently small.
[MeSH-major]
Cell Transformation, Neoplastic / genetics.
Neoplasms
/ etiology. Research / trends
[MeSH-minor]
Animals. Carcinogens / pharmacology. DNA. DNA Repair. Humans. Mutation.
Neoplasm
Regression, Spontaneous. Rats
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14675-7
[
10611270.001
]
[Cites]
Proc Natl Acad Sci U S A. 1976 Feb;73(2):549-53
[
1061157.001
]
[Cites]
Proc Natl Acad Sci U S A. 1986 Dec;83(23):8878-82
[
3466163.001
]
[Cites]
Cancer Res. 1994 Oct 15;54(20):5296-300
[
7923156.001
]
[Cites]
J Cell Biol. 1997 Apr 7;137(1):231-45
[
9105051.001
]
[Cites]
Technol Health Care. 1997 Oct;5(4):331-4
[
9429273.001
]
[Cites]
Cancer Res. 1998 Oct 1;58(19):4314-23
[
9766659.001
]
[Cites]
Cell. 1999 Jul 23;98(2):137-46
[
10428026.001
]
[Cites]
Int J Cancer. 2005 Jan 1;113(1):168-70
[
15386432.001
]
[Cites]
Br Med Bull. 1958 May;14(2):99-101
[
13536368.001
]
[Cites]
Lancet. 1962 Jul 21;2(7247):107-12
[
14484229.001
]
[Cites]
Prog Exp Tumor Res. 1964;5:85-133
[
14317768.001
]
[Cites]
Lancet. 2005 Feb 5-11;365(9458):488-92
[
15705458.001
]
[Cites]
J Biosci. 2005 Feb;30(1):103-18
[
15824446.001
]
[Cites]
Breast Cancer. 2005;12(2):140-4
[
15858446.001
]
[Cites]
Cancer Biol Ther. 2005 Jun;4(6):621-7
[
15970666.001
]
[Cites]
Int J Cancer. 2006 Apr 1;118(7):1769-72
[
16231334.001
]
[Cites]
BMC Bioinformatics. 2006;7:407
[
16959042.001
]
[Cites]
J Mol Histol. 2006 Sep;37(5-7):225-38
[
16855787.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6
[
10611348.001
]
[Cites]
Lancet. 2000 Jan 15;355(9199):165-9
[
10675114.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1254-60
[
10728684.001
]
[Cites]
Mol Carcinog. 2000 Dec;29(4):205-11
[
11170258.001
]
[Cites]
Lancet. 2002 Mar 23;359(9311):1019-25
[
11937181.001
]
[Cites]
Nat Rev Cancer. 2004 Mar;4(3):197-205
[
14993901.001
]
[Cites]
J Cell Sci. 2004 Mar 15;117(Pt 8):1495-502
[
14996910.001
]
[Cites]
Bioessays. 2004 Oct;26(10):1097-107
[
15382143.001
]
[Cites]
J Natl Cancer Inst. 1966 Aug;37(2):145-51
[
5912611.001
]
[Cites]
J Natl Cancer Inst. 1972 Apr;48(4):1251-4
[
5023683.001
]
[Cites]
J Natl Cancer Inst. 1973 Oct;51(4):1275-85
[
4583375.001
]
[Cites]
Nature. 1981 Jan 29;289(5796):353-7
[
6258076.001
]
(PMID = 17683619.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Carcinogens; 9007-49-2 / DNA
[Other-IDs]
NLM/ PMC1993836
79.
Elmslie WJ:
Etiology of epithelioma among the Kashmiris.1866.
Natl Med J India
; 2010 Jan-Feb;23(1):49-50, 48, 54-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Etiology of
epithelioma
among the Kashmiris.1866.
[MeSH-major]
Carcinoma / etiology. Skin
Neoplasms
/ etiology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20839598.001).
[ISSN]
0970-258X
[Journal-full-title]
The National medical journal of India
[ISO-abbreviation]
Natl Med J India
[Language]
eng
[Publication-type]
Biography; Classical Article; Historical Article; Journal Article; Portraits
[Publication-country]
India
[Personal-name-as-subject]
Elmslie WJ
80.
Lai SY, Johnson FM:
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Drug Resist Updat
; 2010 Jun;13(3):67-78
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Although the role of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has been most extensively studied in hematopoietic cells and hematologic malignancies, it is also activated in
epithelial
tumors
, including those originating in the lungs and head and neck.
[MeSH-major]
Antineoplastic Agents / therapeutic use. Head and Neck
Neoplasms
/ metabolism. Janus Kinases / metabolism. Lung
Neoplasms
/ metabolism. STAT Transcription Factors / metabolism. Signal Transduction
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Ltd. All rights reserved.
(PMID = 20471303.001).
[ISSN]
1532-2084
[Journal-full-title]
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
[ISO-abbreviation]
Drug Resist. Updat.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Scotland
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Interleukin-6; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligonucleotides; 0 / Receptors, Cytokine; 0 / STAT Transcription Factors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / Janus Kinases
[Number-of-references]
133
81.
Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR:
Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites.
Biochemistry
; 2008 Jan 22;47(3):1076-86
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A highly consistent trait of
tumor
stromal fibroblasts is the induction of the membrane-bound serine protease fibroblast activation protein-alpha (FAP), which is overexpressed on the surface of reactive stromal fibroblasts present within the stroma of the majority of human
epithelial
tumors
.
In contrast, FAP is not expressed by
tumor
epithelial
cells or by fibroblasts or other cell types in normal tissues.
The proteolytic activity of FAP, therefore, represents a potential pan-
tumor
target that can be exploited for the release of potent cytotoxins from inactive prodrugs consisting of an FAP peptide substrate coupled to a cytotoxin.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
GELATIN
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18095711.001).
[ISSN]
0006-2960
[Journal-full-title]
Biochemistry
[ISO-abbreviation]
Biochemistry
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA006973; United States / NCRR NIH HHS / RR / 1S10-RR14702
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / Fluorescent Dyes; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 9000-70-8 / Gelatin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
[Other-IDs]
NLM/ NIHMS737156; NLM/ PMC4696028
82.
Oliva E, Alvarez T, Young RH:
Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases.
Am J Surg Pathol
; 2005 Feb;29(2):143-56
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Sertoli cell
tumors
of the ovary: a clinicopathologic and immunohistochemical study of 54 cases.
Ovarian Sertoli cell
tumors
are rare, and their
morphologic
spectrum, behavior, and factors influencing the latter are not clearly established.
They may be mimicked by many different
tumors
, some of them more frequent than Sertoli cell
tumors
; immunohistochemistry may aid in this differential, but its role has not been analyzed in a large series.
We studied the clinicopathologic features of 54 Sertoli cell
tumors
, including the immunohistochemical profile of 23 of them.
The
tumors
ranged from 0.8 to 30 cm, with the majority being in the range of 4 to 12 cm.
The predominant microscopic pattern was tubular, seen, albeit often only focally, in all
tumors
; other patterns were cords or trabeculae (28), diffuse (21), pseudopapillary (4), retiform (3), islands or alveolar arrangements (3), and spindled (3).
Delicate septa were occasionally seen and were conspicuous in areas of one
tumor
.
The stroma was abundant in 15
tumors
with marked sclerosis in 4.
The cells usually had pale to occasionally densely eosinophilic cytoplasm, but 6
tumors
were composed of cells with prominent foamy cytoplasm, falling in the category of "lipid-rich" Sertoli cell
tumor
, and one had cells with clear non-foamy cytoplasm.
Forty-four
tumors
were stage I (42 of them were stage Ia and 2 were stage Ic), 1 was stage II, 3 were stage III, and 6 were not adequately staged.
Follow-up was available for 27 patients with stage I
tumors
, and all were alive and well at last follow-up except for 2 patients with stage Ia and 1 with stage Ic disease.
Two of the three clinically malignant stage I
tumors
had moderate to severe cytologic atypia and brisk mitotic activity (>5 or more mitoses/10 high power fields [HPFs]), and one of these had
tumor
cell necrosis.
Among the 10 clinically benign stage I
tumors
with more than 5 years of follow-up, only 3 had >5 mitoses/10 HPFs, but none had more than mild cytologic atypia and none had
tumor
cell necrosis.
Two of the three stage III
tumors
had at least moderate cytologic atypia and brisk mitotic activity.
Immunohistochemical stains showed positivity for AE1/3-Cam5.2 in 15 of 23
tumors
;
Epithelial
membrane antigen (EMA) was negative in all the
tumors
.
Inhibin was positive in 18 of 22
tumors
, calretinin in 10 of 20, CD99 in 19 of 22, vimentin in 17 of 18, smooth muscle actin in 4 of 18, neuron specific enolase in 8 of 16, S-100 in 2 of 20, and chromogranin was negative in all 21 cases studied.
Although Sertoli cell
tumors
usually have a distinctive tubular pattern that facilitates the diagnosis, other patterns may occasionally predominate, causing confusion with various other primary and metastatic ovarian
tumors
.
EMA, inhibin, and chromogranin represent the most helpful triad of immunomarkers serving to exclude two common mimics of Sertoli cell
tumors
(endometrioid carcinoma [inhibin-; EMA+; chromogranin-] and carcinoid
tumor
[inhibin-; EMA+; chromogranin+]).
Although CD99 and calretinin are often expressed in these
tumors
, they are much less specific and not as helpful in the differential diagnosis.
Most Sertoli cell
tumors
are stage I, unilateral, cytologically bland, and clinically benign, but occasional examples are high stage, and about 11% of stage I
tumors
have worrisome histologic features that may portend an adverse outcome.
The
tumors
typically occur in young females, sometimes children who typically present with sexual precocity, and occasional patients have Peutz-Jeghers syndrome.
[MeSH-major]
Ovarian
Neoplasms
/ metabolism. Ovarian
Neoplasms
/ pathology. Sertoli Cell
Tumor
/ metabolism. Sertoli Cell
Tumor
/ pathology
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15644771.001).
[ISSN]
0147-5185
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
83.
Chen DJ, Nirodi CS:
The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage.
Clin Cancer Res
; 2007 Nov 15;13(22 Pt 1):6555-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The epidermal growth factor receptor (EGFR), which is frequently expressed in
tumors
of
epithelial
origin, is an important determinant of
tumor
responses to ionizing radiation.
Elevated EGFR expression and activity frequently correlate with
tumor
resistance to radiotherapy in patients.
EGFR is thought to confer
tumor
resistance to radiation through the activation of survival and cell proliferation pathways.
Targeting the DNA repair function of EGFR may serve as a therapeutic model for sensitizing
tumors
to radiotherapy in patients.
[MeSH-major]
DNA Repair. DNA-Activated Protein Kinase / metabolism.
Neoplasms
/ radiotherapy. Radiation Tolerance. Receptor, Epidermal Growth Factor / metabolism
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18006754.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA 50519; United States / NCI NIH HHS / CA / CA 92584
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
9007-49-2 / DNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / DNA-Activated Protein Kinase
[Number-of-references]
75
84.
Cirillo F:
Neuroendocrine tumors and their association with rare tumors: observation of 4 cases.
Eur Rev Med Pharmacol Sci
; 2010 Jul;14(7):577-88
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Neuroendocrine
tumors
and their association with rare
tumors
: observation of 4 cases.
PURPOSE: Neuroendocrine
tumors
are rare
neoplasms
, with an incidence of about 1/100,000/year.
The association between digestive neuroendocrine
tumors
and
epithelial
tumors
is known, accounting for about 10% of cases, whilst in a very small number of other cases an association with other low incidence
tumors
has been observed.
METHODS: During the past 19 years the Rare Hormonal
Tumors
Group of the Istituti Ospitalieri in Cremona, Italy has observed 300 patients affected by neuroendocrine
tumors
.
We report here on four cases in which there was an unusual association with other rare
neoplasms
.
RESULTS: Overall, four of the 300 observed cases (1.3%) showed an unusual association with rare nonepithelial
neoplasms
:.
(2) Merkel cell
tumor
and squamous cell carcinoma of the skin;.
(3) medullary thyroid carcinoma, yolk sac
tumor
of the testis and gastrointestinal stromal
tumor
(GIST);.
(4) gastric carcinoid and gastrointestinal stromal
tumor
(GIST).
The c-kit expression, typical of GISTs but observed also in other
epithelial
and neuroendocrine
tumors
, not only broadens the possibility to gain insight into the carcinogenesis of these
neoplasms
, but also opens the field to possible new therapeutic opportunities using multitargeted molecules.
The contemporaneous presence of other lesions, such as the Merkel cell
tumor
and the squamous cell carcinoma of the skin can be interpreted as an answer by the cell to the same mutagenic stimulus.
In other cases, where a possible link is not yet found which could explain the synchronism or metachronism of low incidence
neoplasms
, it remains possible that the associations are entirely coincidental.
We await for new instruments which could help us demonstrate the possible relationships between low incidence
neoplasms
.
[MeSH-major]
Neoplasms
/ pathology. Neuroendocrine
Tumors
/ pathology
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20707247.001).
[ISSN]
1128-3602
[Journal-full-title]
European review for medical and pharmacological sciences
[ISO-abbreviation]
Eur Rev Med Pharmacol Sci
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Italy
[Chemical-registry-number]
EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
85.
Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM:
Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
Int J Radiat Oncol Biol Phys
; 2008 Oct 1;72(2):534-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Tumor
xenografts in athymic nude mice were used to assess the in vivo activity of panitumumab alone and combined with radiation.
CONCLUSION: These studies have identified a favorable interaction in the combination of radiation and panitumumab in upper aerodigestive tract
tumor
models, both in vitro and in vivo.
These data suggest that clinical investigations examining the combination of radiation and panitumumab in the treatment of
epithelial
tumors
warrant additional pursuit.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Oral Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiother Oncol. 2005 Feb;74(2):109-15
[
15734198.001
]
[Cites]
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805
[
15701870.001
]
[Cites]
Nat Rev Cancer. 2005 May;5(5):341-54
[
15864276.001
]
[Cites]
J Biol Chem. 2005 Sep 2;280(35):31182-9
[
16000298.001
]
[Cites]
Radiother Oncol. 2005 Aug;76(2):157-61
[
16024112.001
]
[Cites]
N Engl J Med. 2006 Feb 9;354(6):567-78
[
16467544.001
]
[Cites]
J Clin Oncol. 2006 Mar 1;24(7):1072-8
[
16505426.001
]
[Cites]
Clin Lung Cancer. 2006 Jan;7(4):285-7
[
16512986.001
]
[Cites]
Cancer Res. 2006 Mar 15;66(6):3162-8
[
16540667.001
]
[Cites]
Cell Signal. 2006 Oct;18(10):1537-48
[
16713182.001
]
[Cites]
Mol Biol Cell. 2002 Jul;13(7):2233-44
[
12134064.001
]
[Cites]
Cancer Res. 2002 Aug 1;62(15):4300-6
[
12154033.001
]
[Cites]
Oncogene. 2002 Oct 31;21(50):7611-8
[
12400004.001
]
[Cites]
Blood. 2003 Feb 15;101(4):1535-42
[
12393476.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62
[
12679524.001
]
[Cites]
Int J Radiat Biol. 2003 Jul;79(7):581-5
[
14530167.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90
[
14967460.001
]
[Cites]
Radiat Res. 1993 Oct;136(1):65-70
[
8210340.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):813-9
[
8040028.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8
[
8083133.001
]
[Cites]
Radiat Res. 1996 Jan;145(1):81-5
[
8532841.001
]
[Cites]
Oncogene. 1997 Sep 4;15(10):1191-7
[
9294612.001
]
[Cites]
Radiat Oncol Investig. 1997;5(4):180-6
[
9327497.001
]
[Cites]
Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99
[
9366260.001
]
[Cites]
Clin Cancer Res. 1999 Feb;5(2):257-65
[
10037173.001
]
[Cites]
Int J Cancer. 2007 Feb 15;120(4):781-7
[
17096332.001
]
[Cites]
Clin Cancer Res. 2007 Mar 1;13(5):1552-61
[
17332301.001
]
[Cites]
J Clin Oncol. 2007 May 1;25(13):1658-64
[
17470858.001
]
[Cites]
J Clin Oncol. 2007 Aug 20;25(24):3712-8
[
17704420.001
]
[Cites]
Nat Biotechnol. 2007 Oct;25(10):1134-43
[
17921999.001
]
[Cites]
Cancer Res. 1999 Apr 15;59(8):1935-40
[
10213503.001
]
[Cites]
Clin Cancer Res. 1999 Oct;5(10):2884-90
[
10537357.001
]
[Cites]
Radiother Oncol. 1999 Aug;52(2):137-48
[
10577699.001
]
[Cites]
Clin Cancer Res. 2000 Feb;6(2):701-8
[
10690556.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32
[
10760290.001
]
[Cites]
Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
[
10850332.001
]
[Cites]
Oncogene. 2000 May 15;19(21):2489-95
[
10851047.001
]
[Cites]
Clin Cancer Res. 2000 Jun;6(6):2166-74
[
10873065.001
]
[Cites]
Clin Cancer Res. 2000 Nov;6(11):4343-50
[
11106252.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):474-7
[
11567823.001
]
[Cites]
J Biol Chem. 2001 Nov 9;276(45):42462-7
[
11571274.001
]
[Cites]
Cancer Res. 1999 Mar 15;59(6):1236-43
[
10096554.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3328-35
[
15833866.001
]
(PMID = 18793955.001).
[ISSN]
0360-3016
[Journal-full-title]
International journal of radiation oncology, biology, physics
[ISO-abbreviation]
Int. J. Radiat. Oncol. Biol. Phys.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / R01 CA113448-02; United States / NCI NIH HHS / CA / CA113448-04; United States / NCI NIH HHS / CA / R01 CA113448; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / CA113448-01A1; United States / NCI NIH HHS / CA / R01 CA113448-03; United States / NCI NIH HHS / CA / CA009614-12; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / R01 CA113448-05; United States / NCI NIH HHS / CA / CA009614-11; United States / NCI NIH HHS / CA / R01 CA 113448-01; United States / NCI NIH HHS / CA / T32 CA009614-13; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / R01 CA113448-04; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / R01 CA113448-01A1; United States / NCI NIH HHS / CA / CA113448-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Proliferating Cell Nuclear Antigen; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / panitumumab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
[Other-IDs]
NLM/ NIHMS220555; NLM/ PMC2927815
86.
Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF:
Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells.
Mol Cancer Res
; 2005 Jan;3(1):50-61
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Malignant ovarian
epithelial
tumors
have been shown to have decreased inhibin production relative to activin production compared with normal ovarian surface
epithelial
(OSE) cells and nonmalignant ovarian
tumors
.
Inhibin antagonizes the action of activin, and inhibin-deficient mice develop gonadal
tumors
, suggesting that inhibin may be
a tumor
suppressor.
[MeSH-major]
Drug Resistance,
Neoplasm
. Gene Expression Regulation, Neoplastic. Inhibins / pharmacology. Ovarian
Neoplasms
/ drug therapy. Ovarian
Neoplasms
/ pathology
[MeSH-minor]
Activins / metabolism. Animals. Blotting, Western. Cell Line,
Tumor
. Cell Proliferation. Collagen / chemistry. Collagen / metabolism. DNA Primers / chemistry. Drug Combinations.
Epithelial
Cells / metabolism. Female. Humans. In Situ Nick-End Labeling. Inhibin-beta Subunits / metabolism. Laminin / chemistry. Laminin / metabolism. Mice. Mice, Nude.
Neoplasm
Invasiveness.
Neoplasm
Transplantation. Ovary / metabolism. Polysaccharides / metabolism. Proteoglycans / chemistry. Proteoglycans / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Up-Regulation
Genetic Alliance.
consumer health - Ovarian cancer
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15671249.001).
[ISSN]
1541-7786
[Journal-full-title]
Molecular cancer research : MCR
[ISO-abbreviation]
Mol. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA Primers; 0 / Drug Combinations; 0 / Laminin; 0 / Polysaccharides; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / activin A; 104625-48-1 / Activins; 119978-18-6 / matrigel; 57285-09-3 / Inhibins; 9007-34-5 / Collagen; 93443-12-0 / Inhibin-beta Subunits
87.
Rumelt S, Pe'er J, Rubin PA:
The clinicopathological spectrum of benign peripunctal tumours.
Graefes Arch Clin Exp Ophthalmol
; 2005 Feb;243(2):113-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The clinicopathological spectrum of benign peripunctal
tumours
.
PURPOSE: Because of the rarity of peripunctal
tumours
and their clinical classification as conjunctival or eyelid
tumours
, they have gained little attention in the literature.
We conducted a retrospective study to illustrate the different clinical and histopathological spectrum of peripunctal
tumours
seen at two oculoplastics clinics.
METHODS: In a retrospective interventional clinicopathologic case series study, all the charts of patients with peripunctal
tumours
presented at an ophthalmic oncology clinic in Jerusalem, Israel and an oculoplastics clinic in Boston, USA were reviewed.
The
tumours
were classified as
epithelial
and non-
epithelial
tumours
.
The symptoms caused by these
tumours
, their pattern of growth and their management were evaluated.
RESULTS: Fourteen peripunctal
tumours
were identified.
Seven histopathological types of peripunctal
tumours
of
epithelial
, subepithelial or melanocytic origin causing punctal occlusion or displacement were identified.
The
tumours
included compound and junctional naevi, non-pigmented compound naevus,
epithelial
, subepithelial inclusion cysts, verrucous and squamous papilloma, pyogenic granuloma and oncocytoma.
All the
tumours
were benign.
CONCLUSIONS: Peripunctal
tumours
are rare.
The location of peripunctal
tumours
potentially allows their extension from the conjunctival sac into the canaliculus and vice versa.
Therefore, it is best to ascertain free margins when the
tumour
is excised.
[MeSH-major]
Eyelid
Neoplasms
/ pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Fr Ophtalmol. 2002 Jun;25(6):657-60
[
12223957.001
]
[Cites]
Ophthalmology. 1989 Jul;96(7):994-8
[
2771365.001
]
[Cites]
Ophthal Plast Reconstr Surg. 1989;5(4):227-34
[
2487228.001
]
[Cites]
Ophthalmology. 1997 Mar;104(3):479-84
[
9082276.001
]
[Cites]
Am J Ophthalmol. 1993 Sep 15;116(3):385-7
[
8357074.001
]
[Cites]
Sb Lek. 1966 Aug;68(8):274-8
[
5975497.001
]
[Cites]
Ophthal Plast Reconstr Surg. 1994 Sep;10 (3):169-84
[
7947444.001
]
(PMID = 15558295.001).
[ISSN]
0721-832X
[Journal-full-title]
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
[ISO-abbreviation]
Graefes Arch. Clin. Exp. Ophthalmol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
88.
Wharry CE, May MJ:
Raising the price of platinum: inhibition of NFkappaB in human tumor epithelial cells.
Cancer Biol Ther
; 2008 Sep;7(9):1415-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Raising the price of platinum: inhibition of NFkappaB in human
tumor
epithelial
cells.
[MeSH-major]
Antineoplastic Agents / pharmacology. NF-kappa B / antagonists & inhibitors.
Neoplasms
, Glandular and
Epithelial
/ drug therapy. Platinum / pharmacology
[MeSH-minor]
Apoptosis / drug effects. Cell Death / drug effects. Cell Line,
Tumor
. Clinical Trials as Topic. Drug Synergism. Humans. Lymphotoxin-alpha / pharmacology. Models, Biological
Hazardous Substances Data Bank.
PLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Cancer Biol Ther. 2008 Sep;7(9):1407-14
[
18719365.001
]
(PMID = 18953187.001).
[ISSN]
1555-8576
[Journal-full-title]
Cancer biology & therapy
[ISO-abbreviation]
Cancer Biol. Ther.
[Language]
eng
[Publication-type]
Comment; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Lymphotoxin-alpha; 0 / NF-kappa B; 49DFR088MY / Platinum
89.
Zafirellis K, Agrogiannis G, Zachaki A:
Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
APMIS
; 2008 Oct;116(10):912-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Prognostic
value
of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
Tissue sections of primary
tumors
from 132 patients undergoing curative resection for colorectal cancer were immunohistochemically examined for COX-2 expression.
COX-2 immunoreactivity was observed in the cytoplasm of
tumour
epithelial
cells of all colorectal cancer tissues examined.
No significant correlation was found between levels of intensity and extent of COX-2 staining and various clinicopathological characteristics, including age, gender,
tumor
location,
tumor
size,
tumor
grade, depth of invasion, lymph node status and TNM stage.
To analyze the prognostic
value
of intensity and extent of COX-2 staining, the patients were divided into four groups with respect to quartiles (< or =25; >25 to < or =50; >50 to < or =75; and >75).
[MeSH-major]
Biomarkers,
Tumor
/ biosynthesis. Carcinoma / mortality. Colorectal
Neoplasms
/ mortality. Cyclooxygenase 2 / biosynthesis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19132985.001).
[ISSN]
1600-0463
[Journal-full-title]
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
[ISO-abbreviation]
APMIS
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
90.
Krafft C, Steiner G, Beleites C, Salzer R:
Disease recognition by infrared and Raman spectroscopy.
J Biophotonics
; 2009 Feb;2(1-2):13-28
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The selected topics include
tumors
of
epithelial
tissue, brain
tumors
, prion diseases, bone diseases, atherosclerosis, kidney stones and gallstones, skin
tumors
, diabetes and osteoarthritis.
[MeSH-minor]
Algorithms. Animals. Atherosclerosis / diagnosis. Bone Diseases / diagnosis. Brain
Neoplasms
/ diagnosis. Calculi / diagnosis. Diabetes Mellitus / diagnosis. Female. Humans. Male.
Neoplasms
, Glandular and
Epithelial
/ diagnosis. Neurodegenerative Diseases / diagnosis. Osteoarthritis / diagnosis. Skin
Neoplasms
/ diagnosis
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
((c) 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).
(PMID = 19343682.001).
[ISSN]
1864-0648
[Journal-full-title]
Journal of biophotonics
[ISO-abbreviation]
J Biophotonics
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Germany
[Number-of-references]
110
91.
Soini Y:
Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours.
Histopathology
; 2005 May;46(5):551-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of
tumours
.
To evaluate their usefulness as differentiation markers claudins 1, 2, 3, 4, 5 and 7 were studied in 116
epithelial
and 92 non-
epithelial
tumours
.
There were, however,
tumour
type-specific differences in their expression.
In contrast to
epithelial
tumours
, lymphomas did not express claudins and most soft tissue
tumours
and naevocytic lesions were negative or showed weaker, mainly cytoplasmic positivity for some claudins.
Of non-
epithelial
tumours
, claudin 5 was found only in angiosarcomas and benign vascular
tumours
, which also showed reactivity for claudins 2, 3 and 7, but was not expressed in any other soft tissue lesions or lymphomas.
CONCLUSIONS: The results show that claudins 1, 2, 3, 4, 5 and 7 can be used as markers for
epithelial
differentiation and to distinguish
epithelial neoplasms
from lymphomas and selectively also from soft tissue and naevocytic lesions.
Since these claudins show type-specific differential expression in
epithelial
tumours
, they may also be of some
value
in distinguishing different
epithelial
tumours
from each other.
[MeSH-major]
Membrane Proteins / biosynthesis.
Neoplasms
/ pathology. Receptors, Cell Surface / biosynthesis
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15842637.001).
[ISSN]
0309-0167
[Journal-full-title]
Histopathology
[ISO-abbreviation]
Histopathology
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / Receptors, Cell Surface
92.
Weberschock T, Flux K, Gholam P, Hartschuh W, Hartmann M:
[Verrucous tumor of the amputation stump].
Hautarzt
; 2010 Mar;61(3):250-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Verrucous
tumor
of the amputation stump].
[Transliterated title]
Verruköser
Tumor
am Amputationsstumpf.
Epithelioma
cuniculatum (EC) belongs to the category of verrucous carcinomas.
In cases of long-standing processes with formation of exophytic, malodorous
tumors
with jagged edges that do not respond to conventional therapy, consideration should already be given to EC upon visual inspection.
The standard treatment of EC is extensive excision of the
tumor
with micrographic margin control.
[MeSH-major]
Amputation Stumps / pathology. Amputation Stumps / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery. Skin
Neoplasms
/ pathology. Skin
Neoplasms
/ surgery
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Acta Derm Venereol. 1994 May;74(3):231-2
[
7915474.001
]
[Cites]
J Am Acad Dermatol. 1995 Jan;32(1):1-21; quiz 22-4
[
7822496.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8
[
18801141.001
]
[Cites]
Am J Dermatopathol. 2006 Oct;28(5):451-61
[
17012926.001
]
[Cites]
J Foot Ankle Surg. 2001 Jul-Aug;40(4):225-31
[
11924683.001
]
(PMID = 20127299.001).
[ISSN]
1432-1173
[Journal-full-title]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
[ISO-abbreviation]
Hautarzt
[Language]
ger
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Germany
93.
Zeng J, Shi JT, Li B, Sun XL, An YZ, Li LQ, Gao F, Xu JP, Jonas JB:
Epithelial tumors of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients.
Graefes Arch Clin Exp Ophthalmol
; 2010 Sep;248(9):1345-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epithelial
tumors
of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients.
OBJECTIVE: To examine the clinicopathologic characteristics and clinical features of
epithelial
tumors
of lacrimal gland in China.
METHODS: The retrospective case series study included all 298 patients of
epithelial
lacrimal gland
tumors
which had been collected in the ophthalmic pathologic laboratory of the Tongren Hospital Beijing in the study period from 1961 to 2005.
RESULTS: Pleomorphic adenomas were the most common
tumors
(n = 213 (72%)), followed by adenoid cystic carcinoma (n = 58 (20%)), pleomorphic adenocarcinoma (n = 13 (4%)), primary adenocarcinoma (n = 8 (3%)) and other
tumors
(n = 6 (2%)).
A restriction of the eye motility was noted for 61 patients (21%), due to an involvement of the extraocular muscles with the
tumor
and due to
a tumor
-induced displacement of the globe.
Apart from the duration of symptoms, the
tumor
types did not vary significantly in age, gender, and laterality.
CONCLUSIONS: Based on the archives of the Beijing Tongren ophthalmo-pathological laboratory, the most common
epithelial
tumors
of the lacrimal gland in mainland China were pleomorphic adenomas, followed by adenoid cystic carcinoma.
The spectrum and clinical signs of
epithelial
lacrimal gland
tumors
did not differ markedly between Chinese patients and Caucasian patients.
[MeSH-major]
Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Eye
Neoplasms
/ pathology. Lacrimal Apparatus Diseases / pathology
MedlinePlus Health Information.
consumer health - Eye Cancer
.
MedlinePlus Health Information.
consumer health - Tears
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Ophthalmology. 1996 Oct;103(10):1606-12
[
8874433.001
]
[Cites]
Ophthal Plast Reconstr Surg. 2004 Jan;20(1):10-21
[
14752304.001
]
[Cites]
Curr Opin Ophthalmol. 1995 Oct;6(5):78-85
[
10159722.001
]
[Cites]
Ophthalmology. 1993 Dec;100(12):1856-60
[
8259287.001
]
[Cites]
Arch Ophthalmol. 2009 Aug;127(8):1016-28
[
19667339.001
]
[Cites]
Ophthalmology. 2000 Jan;107(1):164-8
[
10647736.001
]
[Cites]
Zhonghua Yan Ke Za Zhi. 1997 Sep;33(5):354-6
[
10451980.001
]
[Cites]
Graefes Arch Clin Exp Ophthalmol. 2003 Nov;241(11):907-13
[
14579116.001
]
[Cites]
Zhonghua Yan Ke Za Zhi. 1997 Mar;33(2):92-5
[
10437008.001
]
[Cites]
Ophthalmology. 1989 Apr;96(4):431-5
[
2726173.001
]
[Cites]
Br J Ophthalmol. 1992 Jul;76(7):395-400
[
1320923.001
]
[Cites]
Eur J Ophthalmol. 2001 Jul-Sep;11(3):301-5
[
11681512.001
]
(PMID = 20354863.001).
[ISSN]
1435-702X
[Journal-full-title]
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
[ISO-abbreviation]
Graefes Arch. Clin. Exp. Ophthalmol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
94.
Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM:
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.
J Exp Clin Cancer Res
; 2009;28:18
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Induction of anti-
tumor
immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.
Peritoneal carcinomatosis (PC) from
epithelial
tumors
is a fatal diagnosis without efficient treatment.
Trifunctional antibodies (trAb) are novel therapeutic approaches leading to a concerted anti-
tumor
activity resulting in
tumor
cell destruction.
In addition, preclinical data in mouse
tumor
models demonstrated the induction of long lasting
tumor
immunity after treatment with trAb.
We describe the induction of anti-
tumor
specific T-lymphocytes after intraperitoneal administration of trAb in patients with PC.9 patients with progressive PC from gastric (n = 6) and ovarian cancer (n = 2), and cancer of unknown primary (n = 1) received 3 escalating doses of trAb after surgery and/or ineffective chemotherapy.
Four weeks after the last trAb application, all patients were restimulated by subdermal injection of trAb + autologous PBMC + irradiated autologous
tumor
cells.
Immunological reactivity was tested by analyzing PBMC for specific
tumor
reactive CD4+/CD8+ T lymphocytes using an IFN-gamma secretion assay.In 5 of 9 patients,
tumor
reactive CD4+/CD8+ T-lymphocytes increased significantly, indicating specific anti-
tumor
immunity.
Follow-up showed a mean survival of 11.8 months (median 8.0 months) after trAb therapy.TrAb are able to induce anti-
tumor
immunity after intraperitoneal application and restimulation.
The induction of long-lasting anti-
tumor
immunity may provide an additional benefit of the intraperitoneal therapy with trAb and should be further elevated in larger clinical trials.
[MeSH-major]
Antibodies, Bispecific / therapeutic use. Antibodies, Monoclonal / therapeutic use. Peritoneal
Neoplasms
/ immunology. Peritoneal
Neoplasms
/ therapy
[MeSH-minor]
Adult. Animals. Disease Progression. Dose-Response Relationship, Immunologic. Epitopes, T-Lymphocyte. Female. Humans. Injections, Intraperitoneal. Male. Mice. Middle Aged. Ovarian
Neoplasms
/ immunology. Ovarian
Neoplasms
/ pathology. Ovarian
Neoplasms
/ therapy. Pilot Projects. Prospective Studies. Stomach
Neoplasms
/ immunology. Stomach
Neoplasms
/ pathology. Stomach
Neoplasms
/ therapy. T-Lymphocytes / immunology
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Br J Cancer. 2000 Jul;83(2):261-6
[
10901380.001
]
[Cites]
Clin Cancer Res. 2007 Jul 1;13(13):3899-905
[
17606723.001
]
[Cites]
Eur J Surg Oncol. 2001 Mar;27(2):125-34
[
11289746.001
]
[Cites]
Br J Cancer. 2001 Jul 20;85(2):152-6
[
11461069.001
]
[Cites]
Blood. 2001 Oct 15;98(8):2526-34
[
11588051.001
]
[Cites]
Semin Oncol. 2001 Dec;28(6 Suppl 18):3-11
[
11774200.001
]
[Cites]
Cancer Immunol Immunother. 2002 Dec;51(11-12):621-9
[
12439607.001
]
[Cites]
Br J Cancer. 2003 Dec 15;89(12):2234-43
[
14676800.001
]
[Cites]
Lancet Oncol. 2004 Apr;5(4):219-28
[
15050953.001
]
[Cites]
J Clin Oncol. 1986 Jul;4(7):1135-47
[
3522820.001
]
[Cites]
Cancer. 2000 Jan 15;88(2):358-63
[
10640968.001
]
[Cites]
Oncology. 2000 Feb;58(2):96-107
[
10705236.001
]
[Cites]
J Clin Oncol. 2000 Jun;18(11):2201-9
[
10829039.001
]
[Cites]
J Clin Oncol. 1989 Aug;7(8):1120-8
[
2569032.001
]
[Cites]
J Pathol. 1990 Nov;162(3):255-60
[
2266463.001
]
[Cites]
J Cell Biol. 1994 Apr;125(2):437-46
[
8163559.001
]
[Cites]
Hepatogastroenterology. 1994 Apr;41(2):124-9
[
8056398.001
]
[Cites]
Ann Surg. 1995 Jan;221(1):29-42
[
7826158.001
]
[Cites]
J Immunol. 1995 Jul 1;155(1):219-25
[
7602098.001
]
[Cites]
Cancer Immunol Immunother. 1995 Jun;40(6):390-6
[
7543021.001
]
[Cites]
Cancer Res. 1995 Oct 1;55(19):4409-15
[
7545540.001
]
[Cites]
J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9
[
7674333.001
]
[Cites]
Cancer. 1997 Mar 1;79(5):884-91
[
9041149.001
]
[Cites]
Immunol Today. 1997 Mar;18(3):127-35
[
9078685.001
]
[Cites]
Cancer. 1999 Feb 1;85(3):529-34
[
10091726.001
]
[Cites]
J Immunol. 1999 Aug 1;163(3):1246-52
[
10415020.001
]
[Cites]
Int J Cancer. 2005 Nov 10;117(3):435-43
[
15906359.001
]
[Cites]
Br J Cancer. 2006 Jan 16;94(1):128-35
[
16404366.001
]
[Cites]
Clin Cancer Res. 2006 May 15;12(10):3085-91
[
16707606.001
]
[Cites]
Gynecol Oncol. 2006 Nov;103(2):483-8
[
16678891.001
]
[Cites]
Br J Surg. 2006 Dec;93(12):1530-5
[
17051604.001
]
[Cites]
J Immunol Methods. 2001 Feb 1;248(1-2):149-65
[
11223076.001
]
(PMID = 19216794.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
Italy
[Chemical-registry-number]
0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Epitopes, T-Lymphocyte; 0 / catumaxomab; 0 / ertumaxomab
[Other-IDs]
NLM/ PMC2644666
95.
Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM:
C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Oncol Rep
; 2007 Jul;18(1):121-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In normal breast tissue, the
epithelial
and fibroblast components were positive for galectin-3 mostly showing nuclear and cytoplasmic reactivity.
At the
tumor
epithelial
component, galectin-3 expression was found in 46.7% of the samples with a predominant cytoplasmic staining.
Tumor
stromal fibroblasts maintained positivity in 70 out of 92 cases (76%).
Epithelial
galectin-3 expression cannot be considered a prognostic factor for patients with T1N0M0 breast cancer, p53 seems to be of minor relevance and c-erbB-2 expression was the best discriminator and may be a marker for aggressive clinical behavior in patients with early stage breast cancer.
[MeSH-major]
Breast
Neoplasms
/ metabolism. Galectin 3 / metabolism.
Neoplasm
Recurrence, Local / metabolism. Receptor, ErbB-2 / metabolism.
Tumor
Suppressor Protein p53 / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Biomarkers,
Tumor
/ metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Middle Aged.
Neoplasm
Staging. Prognosis. Retrospective Studies. Survival Rate
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17549356.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectin 3; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
96.
Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Fujiwara T, Tanaka N, Yokota J:
Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report.
Lung Cancer
; 2007 Jul;57(1):103-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Biphasic pulmonary blastoma is a rare lung
tumor
with
epithelial
and mesenchymal components.
Genetic alterations in this
tumor
are largely unknown, except for the presence of beta-catenin and p53 mutations and the absence of KRAS mutation.
To understand the molecular process of histogenesis of this
tumor
, a whole genome allelic imbalance (AI) scanning using a high-resolution single nucleotide polymorphism array as well as mutational analysis of the p53, EGFR, KRAS and beta-catenin genes were performed against the
epithelial
and mesenchymal components in the primary
tumor
and a metastatic
tumor
in a case of pulmonary blastoma.
AI at chromosome regions 14q24-q32 and 17p11-p13 and beta-catenin mutation were commonly detected in all
tumors
.
On the other hand, AI at chromosome regions 3p11-p14 and 9p21-p24 and p53 mutation were detected only in the mesenchymal component in the primary
tumor
but not in the
epithelial
component in the primary
tumor
and the brain metastasis.
Likewise, AI at chromosome regions 6p24-p25 and 6q14-q27 was detected in the
epithelial
component in the primary
tumor
and the brain metastasis but not in the mesenchymal component in the primary
tumor
.
Furthermore, the genetic alterations detected in the metastatic
tumor
were completely the same as those in the
epithelial
component in the primary
tumor
, indicating that
a tumor
cell(s) in the
epithelial
component in the primary
tumor
selectively metastasized to the brain.
These results indicate that this biphasic
tumor
is of monoclonal origin and the phenotypic heterogeneity of the
tumor
is due to the differences in the accumulated genetic alterations in each component of the
tumor
.
[MeSH-major]
Brain
Neoplasms
/ genetics. Genetic Heterogeneity. Lung
Neoplasms
/ genetics. Pulmonary Blastoma / etiology. Pulmonary Blastoma / genetics
[MeSH-minor]
Allelic Imbalance. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Clone Cells. DNA Mutational Analysis. DNA,
Neoplasm
/ genetics. Female. Genes, p53 / genetics. Humans. Microsatellite Repeats. Middle Aged.
Neoplasm
Metastasis / genetics.
Neoplasm
Metastasis / pathology. Polymorphism, Single Nucleotide. Sequence Analysis, DNA. beta Catenin / genetics
Genetic Alliance.
consumer health - Blastoma
.
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17350138.001).
[ISSN]
0169-5002
[Journal-full-title]
Lung cancer (Amsterdam, Netherlands)
[ISO-abbreviation]
Lung Cancer
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Ireland
[Chemical-registry-number]
0 / DNA, Neoplasm; 0 / beta Catenin
97.
Fehm T, Becker S, Bachmann C, Beck V, Gebauer G, Banys M, Wallwiener D, Solomayer EF:
Detection of disseminated tumor cells in patients with gynecological cancers.
Gynecol Oncol
; 2006 Dec;103(3):942-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of disseminated
tumor
cells in patients with gynecological cancers.
OBJECTIVES: The presence of disseminated
tumor
cells (DTC) in breast cancer patients is associated with poor prognosis.
However, there are limited data about the prevalence and prognostic impact of DTC in patients with gynecological
tumors
.
Presence of DTC was significantly correlated with FIGO (International Federation of Gynecology and Obstetrics)
tumor
stage (p<0.05).
CONCLUSIONS: Disseminated
tumor
cells seem to be a general phenomenon in
epithelial
tumors
even though their clinical impact remains to be evaluated.
The hypothesis that bone marrow is the homing site of disseminated
tumor
cells is further supported by these data since gynecological
tumors
only rarely metastasize to the skeletal system.
[MeSH-major]
Bone Marrow / pathology. Genital
Neoplasms
, Female / pathology.
Neoplasm
Recurrence, Local / pathology. Neoplastic Cells, Circulating
[MeSH-minor]
Endometrial
Neoplasms
/ pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis.
Neoplasm
Staging. Ovarian
Neoplasms
/ pathology. Predictive
Value
of Tests. Prognosis. Uterine Cervical
Neoplasms
/ pathology
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16889820.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
98.
Kelemen LE:
The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander?
Int J Cancer
; 2006 Jul 15;119(2):243-50
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
FRalpha levels are high in specific malignant
tumors
of
epithelial
origin compared to normal cells, and are positively associated with
tumor
stage and grade, raising questions of its role in
tumor
etiology and progression.
It has been suggested that FRalpha might confer a growth advantage to the
tumor
by modulating folate uptake from serum or by generating regulatory signals.
Whether FRalpha in
tumors
decreases in vivo among individuals who are folate sufficient, or whether the
tumor
's machinery sustains FRalpha levels to meet the increased folate demands of the
tumor
, has not been studied.
Consequently, the significance of carrying a FRalpha-positive
tumor
in the era of folic acid fortification and widespread vitamin supplement use in countries such as Canada and the United States is unknown.
Epidemiologic and clinical studies using human
tumor
specimens are lacking and increasingly needed to understand the role of environmental and genetic influences on FOLR1 expression in
tumor
etiology and progression.
MedlinePlus Health Information.
consumer health - Folic Acid
.
Hazardous Substances Data Bank.
FOLIC ACID
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2006 Wiley-Liss, Inc.
(PMID = 16453285.001).
[ISSN]
0020-7136
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R25 CA092049; United States / NCI NIH HHS / CA / R25 CA92049
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / FOLR1 protein, human; 0 / Folate Receptor 1; 0 / Folate Receptors, GPI-Anchored; 0 / Gonadal Steroid Hormones; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid
[Number-of-references]
115
99.
Piga A, Gesuita R, Catalano V, Nortilli R, Cetto G, Cardillo F, Giorgi F, Riva N, Porfiri E, Montironi R, Carle F, Cellerino R:
Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.
Oncology
; 2005;69(2):135-44
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of clinical prognostic factors in patients with unknown primary
tumors
treated with a platinum-based combination.
OBJECTIVE: The aim of this study was to evaluate patient and
tumor
characteristics in 102 patients with unknown primary
tumors
(UPT) prospectively treated with a combination of carboplatin, doxorubicin, and etoposide, to identify clinical variables predictive of response and survival.
At multivariate analysis the number of
tumor
sites, bone/visceral involvement and
epithelial
tumor
markers were significantly predictive of response; presence of pain, serum alkaline phosphatase, carboplatin AUC and response to treatment were significantly associated with survival.
[MeSH-major]
Antineoplastic Combined Chemotherapy Protocols / therapeutic use.
Neoplasms
, Unknown Primary / drug therapy.
Neoplasms
, Unknown Primary / pathology
Hazardous Substances Data Bank.
DOXORUBICIN
.
Hazardous Substances Data Bank.
ETOPOSIDE
.
Hazardous Substances Data Bank.
CARBOPLATIN
.
[Email]
Email this result item
Email the results to the following email address: